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CHAPTER I 
 
INTRODUCTION 
 
 Malignant cells are frequently distinguished by rapid growth coupled with 
an impaired ability to activate cell cycle checkpoints and DNA repair pathways 
(2, 3). Consequently, DNA in cancerous tissues often sustains elevated rates of 
replication and transcription, despite a decreased competence to restore genomic 
integrity following damage. This dual property of high DNA metabolism and 
low genetic stability makes the double helix an attractive target for cancer 
chemotherapy. Indeed, several classes of widely utilized anticancer drugs act by 
damaging DNA, either directly or indirectly (4). 
 Multiple therapeutic strategies are used to damage DNA. Ultimately, these 
strategies block DNA replication or other essential nucleic acid processes, 
generate mutations, create DNA strand breaks, or induce gross chromosomal 
abnormalities. For example, methotrexate, which inhibits dihydrofolate 
reductase, decreases cellular thymine pools and promotes incorporation of 
deoxyuridine into chromosomes (5). The unnatural nucleotide AraC is 
incorporated into the genetic material and impairs replication (6). 
Mechlorethamine (nitrogen mustard) (7) and cisplatin (8) alkylate bases or 
crosslink the two strands of the double helix. Finally, bleomycin (9) or etoposide 
(10) generate DNA strand breaks by a chemical mechanism or by altering the 
activity of topoisomerases, respectively.  
 Some of the most effective anticancer drugs currently in clinical use damage 
DNA by targeting topoisomerases (4). These agents act in an insidious manner 
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and convert topoisomerases from essential enzymes to potent cellular toxins that 
fragment the genome to induce apoptosis (11-17). However, if the level of DNA 
strand breaks induced by topoisomerase II poisons is not lethal, repair of these 
breaks generate chromosomal aberrations that lead to specific types of leukemia 
(11-17). In addition to leukemias resulting from clinical topoisomerase II poisons. 
Epidemiological evidence has linked the exposure to environmental poisons and 
leukemia (bioflavanoids and benzene) (18-23). A common feature in these 
leukemias is the presence of translocations at chromosome band 11q23 (13, 14, 
24-26).  
 Bioflavanoids directly interact with topoisomerase II to enhance double-
stranded breaks in the genetic material (27, 28). Benzene, however, is believed to 
act through a quinone metabolite (benzoquinone) to enhance enzyme-mediated 
DNA cleavage (29-32). Similar to benzene, exposure to other environmental 
toxins or drugs that are metabolized to quinones demonstrate clastogenic activity 
in the liver (33-36). While the mechanism behind this damage is unknown, it is 
reminiscent of the actions of topoisomerase II-poisons. 
 Although type II topoisomerases have proven to be effective cancer 
chemotherapy targets and have been linked to the development of cancer, they 
regulate chromatin structure and are involved in virtually every process of DNA 
metabolism. 
 
DNA Topology and Topoisomerases 
 DNA is essentially an extremely long double-stranded rope in which the two 
strands are interwound about one another (37, 38) (Figure 1). As a result, the  
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Figure 1. Model of DNA compaction inside of a cell nucleus. Stretched end 
to end, the DNA of a human cell measures approximately two meters in 
length and is condensed into a nucleus that is only five to ten microns in 
diameter. In addition to this compaction, DNA is composed of two anti-
parallel inter-wound strands. Adapted from Ref. (38).  
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topological properties of the genetic material profoundly influence virtually 
every major DNA process.  
 DNA is globally underwound (i.e., negatively supercoiled) in all vertebrate 
species (39-42). This underwinding makes it easier to separate complementary 
DNA strands from one another and therefore greatly facilitates replication and 
transcription. Once the replication or transcription machinery begins to travel 
along the DNA template, however, deleterious effects of topology are 
manifested. Since helicases separate, but do not unwind the two strands of the 
double helix, fork progression results in acute overwinding (i.e., positive 
supercoiling) of the DNA ahead of the tracking systems (39, 41-43). In contrast to 
underwinding, overwinding dramatically increases the difficulty of opening the 
double helix. Therefore, the accumulation of positive supercoils represents a 
formidable block to all DNA processes that require strand separation (41, 43-46).  
 The effects of DNA topology are further compounded by the extreme length 
of the double helix. The genetic material from a single human cell, which 
approaches two meters in length, exists in a nucleus that is only five to ten 
microns in diameter. Consequently, the double helix is subjected to the same 
forces and constraints as a room tightly packed from floor to ceiling with rope. 
Nuclear processes such as recombination and replication naturally generate 
knots and tangles in DNA, respectively (47, 48). If knots accumulate in the 
genome, DNA tracking systems are unable to separate the two strands of the 
double helix (39, 42, 43, 47). Moreover, if tangled (i.e., catenated) daughter 
chromosomes are not separated prior to cell division, cells will die of mitotic 
failure (16, 43, 49-51). 
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 The topological state of the double helix is regulated by ubiquitous enzymes 
known as topoisomerases, which act by creating transient breaks in the double 
helix (15, 16, 41, 43, 49-54). In order to maintain genomic integrity during this 
process, topoisomerases form covalent bonds between active site tyrosyl residues 
and the phosphate moieties of newly generated DNA termini (15, 16, 41, 43, 49-
54). These covalent protein-cleaved DNA complexes are referred to as cleavage 
complexes. There are two classes of topoisomerases that are distinguished by the 
number of DNA strands that they cleave during their catalytic cycles.  
 
Type I Topoisomerases 
 Type I topoisomerases act by generating a transient single-stranded break in 
the double helix followed by a single-stranded DNA passage event or controlled 
rotation about the break (51, 54-56) (Figure 2). As a result, these enzymes are able 
to alleviate torsional stress (i.e., remove superhelical twists) in duplex DNA. 
Type I topoisomerases are involved in all DNA processes that involve tracking 
systems and play important roles in maintaining genomic integrity (50, 54, 56, 
57). 
 
Type II Topoisomerases 
Mammalian type II topoisomerases are homodimeric enzymes that interconvert 
different topological forms of DNA by a double-stranded DNA passage 
mechanism (43, 50, 51, 53, 57, 58) (Figure 2). Briefly, these enzymes: 1) bind two 
separate segments of DNA, 2) create a double-stranded break in one of the 
segments, 3) translocate the second DNA segment through the cleaved nucleic 
acid “gate,” 4) rejoin (i.e., ligate) the cleaved DNA, and 5) release the translocated  
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Figure 2. Topological problems associated with DNA metabolism. DNA is 
globally underwound in cells. During replication and transcription helicases 
are used to melt DNA ahead of tracking systems. Since helicases separate, but 
do not unwind the two strands of the double helix, fork progression results in 
acute overwinding (i.e., positive supercoiling) of the DNA ahead of the 
tracking systems. This overwinding, if not resolved, can block the progression 
of the replication or transcriptional machinery. In addition to positive 
supercoiling, precatenanes form behind replication forks. If sister 
chromosomes are not decatedated, cells will die of mitotic failure. Finally, 
nuclear processes such as recombination and naturally generate knots and 
tangles in DNA, respectively.  To resolve these topological problems 
associated with DNA, cells possess enzymes called topoisomerases. 
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segment through a gate generated at a C-terminal interface between the two 
protein subunits (43, 50, 51, 53, 57-59) (Figure 3). The two scissile bonds that are 
cut by type II topoisomerases are staggered and located across the major groove 
from one another (43, 50, 51, 53, 57). Thus, these enzymes generate cleaved DNA 
molecules that contain 4-base single-stranded cohesive ends at their 5’-termini 
(60, 61). During the cleavage event, all known type II topoisomerases covalently 
attach to the newly generated 5’-DNA termini. 
 Type II enzymes require two cofactors in order to carry out the catalytic 
double-stranded DNA passage reaction. First, they need a divalent cation for all 
steps beyond enzyme-DNA binding. Mg(II) appears to be used in vivo (60-63). 
Second, they use the energy of ATP to drive the overall DNA strand passage 
reaction (64-67).  
 As a result of their double-stranded DNA passage reaction, type II enzymes 
are able to remove superhelical twists from DNA and resolve knotted or tangled 
duplex molecules (43, 50, 51, 53, 57). They function in numerous DNA processes 
and are required for recombination, the separation of daughter chromosomes, 
and proper chromosome structure, condensation, and decondensation (43, 50, 51, 
53, 57) (See figure 2). 
 Mammals express two distinct isoforms of the type II enzyme, 
topoisomerase IIα and topoisomerase IIβ (51, 53, 68, 69). These isoforms display a 
high degree (~70%) of amino acid sequence identity and similar enzymological 
characteristics, but differ in their protomer molecular masses (170 vs. 180 kDa, 
respectively) and are encoded by separate genes (15, 16, 43, 51, 53, 68-73).  
 Topoisomerase IIα and topoisomerase IIβ are both nuclear enzymes 
(mammals have no known mitochondrial type II enzymes), but have distinct  
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Figure 3. The catalytic cycle of type II topoisomerases. 1) Topoisomerase II 
binds to DNA, preferably at DNA crossovers and creates two staggered breaks in the 
sugar phosphate backbone of DNA to relax, untangle and decatenate DNA. 2) In order 
to prevent these scissile breaks in the DNA from becoming permanent double-stranded 
breaks, the enzyme covalently attaches to DNA at the active site tyrosine residue in 
the presence of a divalent cation. The covalent enzyme-DNA intermediate is known as 
the cleavage complex. 3) Once a cleavage complex is formed topoisomerase II binds 
ATP and undergoes a conformational change. This change in confirmation allows the 
enzyme to pass an intact strand of DNA through the cleaved DNA strand. 4) After 
topoisomerase II passes the intact DNA strand it religates the cleaved strand and 5) 
hydrolyzes ATP to complete the catalytic cycle and 6) releases the DNA substrate. 
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patterns of expression and cellular functions. Topoisomerase IIα is essential for 
the survival of actively growing cells and its concentration is upregulated 
dramatically during periods of proliferation (74-76). Furthermore, enzyme levels 
increase over the cell cycle and peak in G2/M (76-78). Topoisomerase IIα is 
found at replication forks and remains tightly associated with chromosomes 
during mitosis (50, 79). Thus, it is believed to be the isoform that functions in 
growth-dependent processes, such as DNA replication and chromosome 
segregation (43, 50).  
 In contrast to topoisomerase IIα, topoisomerase IIβ is dispensable at the 
cellular level. However, the β isoform is required for proper neural development 
(80). Expression of topoisomerase IIβ is independent of proliferative status and 
cell cycle, and the enzyme dissociates from chromosomes during mitosis (50, 73, 
76, 81). Topoisomerase IIβ cannot compensate for the loss of topoisomerase IIα in 
mammalian cells, suggesting that these two isoforms do not play redundant roles 
in replicative processes (73, 82, 83). Although the physiological functions of 
topoisomerase IIβ have yet to be defined, recent evidence indicates roles in the 
transcription of hormonally- or developmentally-regulated genes (84, 85).  
 
Topoisomerase-targeted Anticancer Drugs 
 As discussed above, all topoisomerases cleave DNA during their critical 
cellular functions. Although the strand breaks generated by these enzymes are 
transient in nature, they are potentially deleterious to the cell (Figure 4). When a 
nucleic acid tracking system, such as a replication or transcription complex, 
attempts to traverse a topoisomerase-DNA cleavage complex, it converts the  
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Figure 4. Topoisomerases as cellular toxins. Levels of transient DNA 
cleavage complexes generated by topoisomerase I or topoisomerase II are 
increased following exposure to a variety of topoisomerase poisons. These 
cleavage complexes are converted to permanent DNA strand breaks (DSB) as 
a result of collisions with replication or transcription complexes. If checkpoint 
and DNA repair pathways function properly and if levels of DSB do not 
overwhelm the cell, DNA damage is repaired, resulting in cellular recovery. If 
checkpoint or DNA repair pathways function are impaired or if levels of DSB 
overwhelm the cell, apoptotic pathways are initiated, resulting in cell death. 
Finally, in some cases, treatment of cells with topoisomerase II poisons 
induces the formation of stable leukemic translocations involving the MLL 
gene at chromosomal band 11q23. The source of the DNA breaks that initiate 
the translocations is controversial and is postulated to result from DNA 
cleavage mediated by topoisomerase II, apoptotic nucleases (coupled with 
abortive apoptosis), or both. 
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transient enzyme-DNA interaction to a permanent double-stranded break (15, 41, 
50, 53, 57). The resulting strand breaks, as well as the inhibition of essential DNA 
processes, initiate recombination/repair pathways (10, 86-94). If the 
accumulation of breaks overwhelms the cell, they trigger apoptotic pathways 
(11-17). However, if the DNA strand breaks are not able to overwhelm the cell, 
surviving populations may contain chromosomal translocations or other 
aberrations (11-17). 
 Agents that increase levels of topoisomerase-DNA cleavage complexes are 
known as “topoisomerase poisons” because they convert these enzymes to 
potent cellular toxins (10, 15, 16, 95, 96). Topoisomerase poisons work by two 
mutually non-exclusive mechanisms. Some poisons act by inhibiting the ability 
of their topoisomerase target to ligate cleaved DNA intermediates (10, 15, 16, 97). 
Other poisons have little effect on the rate of enzyme-mediated ligation and are 
believed to act primarily by enhancing the forward rate of cleavage complex 
formation (10, 15, 16, 98). The exact mechanism by which this second group of 
drugs increases levels of DNA cleavage is unknown. They may specifically affect 
the forward rate of DNA scission. Alternatively, they may affect the enzyme-
DNA binding equilibrium, as the level of topoisomerase-mediated DNA 
cleavage is proportional to the amount of enzyme bound. Clinically relevant 
topoisomerase-targeted agents appear to act primarily by inhibiting DNA 
ligation (10, 15, 16, 97).  
 A diverse group of natural and synthetic compounds increase the levels of 
topoisomerase-DNA cleavage complexes in vitro and in human cells. Several of 
these agents are in wide clinical use as anticancer therapeutics and represent 
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some of the most successful drugs currently used for the treatment of human 
malignancies.  
 
Topoisomerase I-targeted Drugs 
 Topoisomerase I is the target for an emerging class of drugs based on 
camptothecin, a natural product derived from the bark of the Chinese yew tree, 
Camptotheca acuminata (99). These drugs represent some of the most active new 
agents in the clinic and show promise against malignancies that respond poorly 
to existing therapies, such as non-small cell lung cancer, metastatic ovarian 
cancer, and colorectal cancer (4, 54, 56, 100). Other drugs that target 
topoisomerase I, including the indolocarbazoles (101), the 5,11-
diketoindenoisoquinolines (102), and the phenanthridines (103), currently are 
under clinical development. 
 
 Topoisomerase II-targeted Drugs 
 Topoisomerase II is the target for some of the most successful anticancer 
drugs currently used to treat human malignancies (104). It is estimated that one 
half of all chemotherapy regimens include these agents. Six topoisomerase II-
targeted drugs are approved for use in the United States, with others being used 
worldwide (Figure 5) (104). 
 One of the first topoisomerase II-targeted agents to be developed was 
etoposide, which is derived from podophyllotoxin (10, 105). This natural product 
is found in Podophyllum peltatum, more commonly known as the May apple or 
mandrake plant (10, 105). Podophyllotoxin has been used as a folk remedy for 
over a thousand years (10, 105). It has well-established antimitotic properties,  
 13 
 
O
O
O
R
HO
OH O
O
H3CO
OH
OCH3
H
O
H
O
O
R =
 
H3C
 
S
= Etoposide
= Teniposide
 
OH
OH
O
O
HN(CH2)2NH(CH2)2OH
HN(CH2)2NH(CH2)2OH
 
O
O
H
O
C
OH
OH
O
O
H3C
OH
NH3
+
OH
R2
R1
R1 = R2 =
= Doxorubicin
= Daunorubicin
= Idarubicin
 
CH2OH
 
CH2OH
 
OCH3
 
OCH3
 
H
 
CH3
Mitoxantrone
 
CH3O
NH
N
NHSO2CH3
Amsacrine
Figure 5. Structures of clinically used Topoisomerase II poisons. 
 
 14 
which are related to its potent inhibition of tubulin polymerization (10, 105). 
Although clinical use of podophyllotoxin as an antineoplastic agent was 
prevented by high toxicity, two synthetic analogs, etoposide and teniposide, 
were developed (105). These analogs displayed increased antineoplastic activity 
and decreased toxicity compared to the parent compound. Etoposide was 
approved for clinical use against cancer in the mid-1980’s (10, 105). Surprisingly 
(and in marked contrast to podophyllotoxin), etoposide displays no ability to 
inhibit tubulin polymerization. Rather, it kills cells by acting as a topoisomerase 
II poison (106-108).  
 Etoposide and other drugs, such as doxorubicin, are front-line therapy for a 
variety of systemic cancers and solid tumors, including leukemias, lymphomas, 
sarcomas, and breast, lung, and germline cancers. Every form of cancer that is 
considered to be curable by systemic chemotherapy utilizes drugs that target 
topoisomerase II in treatment regimens (109). 
 While topoisomerase II is believed to be the cytotoxic target of the drugs 
shown in Figure 5, the relative contributions of topoisomerase IIα and 
topoisomerase IIβ to the chemotherapeutic effects of these agents has yet to be 
resolved. Some drugs appear to favor one isoform or the other; however, no truly 
“isoform-specific” agents have been identified. The issue of isoform specificity 
has potential clinical ramifications. For example, since topoisomerase IIβ is 
present in all cell types, it may be responsible for mediating some of the toxic 
side effects of topoisomerase II poisons in non-malignant tissues. Alternatively, 
since topoisomerase IIα and topoisomerase IIβ are involved in different cellular 
processes, it may be that cleavage complexes formed with one or the other 
isoform are more likely to be converted to permanent DNA strand breaks.  
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Other Topoisomerase Poisons 
 In addition to the synthetically derived topoisomerase poisons that are used 
to treat cancer (and antibacterial quinolones that target the prokaryotic type II 
enzymes, DNA gyrase and topoisomerase IV), three other categories of 
topoisomerase poisons have been identified. These include natural products that 
are normal dietary components (bioflavonoids), toxic metabolites of drugs or 
industrial chemicals (quinones), and DNA-damaging agents (Figure 6). Thus far, 
compounds in the first two categories have been found to affect primarily the 
type II enzyme. However, DNA damaging agents increase cleavage mediated by 
both type I and II topoisomerases. 
 
 Bioflavonoids 
 The most prominent natural products with activity against mammalian 
topoisomerases are the bioflavonoids (i.e., phytoestrogens). Bioflavonoids 
represent a diverse group of polyphenolic compounds that are components of 
many fruits, vegetables, and plant leaves (110-113). These compounds affect 
human cells through a variety of pathways; they are strong antioxidants, and 
efficient inhibitors of growth factor receptor tyrosine kinases (110-113). In 
addition, they are potent topoisomerase II poisons. It has been suggested that 
genistein (an isoflavone that is abundant in soy) has chemopreventative 
properties and that ingestion of this compound contributes to the low incidence 
of breast and colorectal cancers observed in the Pacific Rim (110-113). However,  
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as discussed below, there also is evidence associating genistein consumption 
during pregnancy to the development of infant leukemias (18, 20-23). 
 
Quinones 
 Quinones are highly reactive compounds that are often produced in the 
body as a result of detoxification or metabolism pathways. Quinones damage 
cells by generating oxygen radicals and by covalently modifying proteins and (to 
a lesser extent) nucleic acids (32, 114-116). Exposure to benzene [metabolized to 
benzoquinone (see Figure 8)], has been linked to the development of 
malignancies in rodents and the development of leukemia in humans (primarily 
acute myelogenous leukemia and acute non-lymphocytic leukemia) (29, 31, 32). 
Recent studies demonstrate that benzoquinone is a strong topoisomerase II-
poison in vitro and in cultured human cells (1, 117). Benzoquinone requires 
adduction to the enzyme to inhibit function (1, 117). However, the mechanism by 
which quinone adduction enhances enzyme-mediate DNA cleavage is largely 
unknown. In addition to benzoquinone other quinones, including Menadione 
(the quinone known as vitamin K3), also display activity against topoisomerase 
II (118).  
 
DNA Damage 
 Unlike the two categories of topoisomerase II poisons discussed above, DNA 
lesions are potent enhancers of DNA scission mediated by both the type I and II 
enzymes. Topoisomerase I is most sensitive to abasic sites, oxidative lesions, and 
alkylated bases (90). Topoisomerase II prefers lesions that distort the double helix 
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and is particularly sensitive to abasic sites and alkylated bases that contain 
exocyclic rings (119-124). 
 DNA damage increases cleavage at naturally occurring sites of 
topoisomerase I or topoisomerase II action. In all cases, lesions must be located 
proximal to the sites of cleavage in order to act as enzyme poisons. Whereas 
topoisomerase I is generally sensitive to lesions immediately upstream or 
downstream from the scissile bond (90, 125), topoisomerase II requires that 
damage be localized within the four-base stagger that separates the two scissile 
bonds on the opposite strands of the double helix (119-124, 126). 
 Although DNA damage increases levels of topoisomerase I and 
topoisomerase II cleavage complexes, the mechanism by which lesions alter the 
activity of these enzymes differs. DNA damage increases the concentration of 
topoisomerase I-DNA cleavage complexes primarily by inhibiting rates of 
enzyme-mediated DNA ligation (90). In contrast, damage has no obvious effects 
on rates of topoisomerase II-mediated DNA ligation and appears to act primarily 
by enhancing the forward rate of scission (119, 121, 124, 126). 
 The physiological benefits of DNA lesions as topoisomerase poisons, if any, 
are unclear. However, it is notable that topoisomerase I and topoisomerase II 
both appear to play roles in fragmenting genomic DNA during apoptosis (125, 
127-129). It has been suggested that the apoptotic activities of topoisomerases are 
enhanced (or perhaps triggered) by DNA lesions that are generated following the 
release of oxygen radicals from permeable mitochondria in apoptotic cells (125, 
127-129). 
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Topoisomerase II and Leukemia 
 In addition to its role as an essential cellular protein and target for anticancer 
drugs, clinical studies suggest that topoisomerase II initiates DNA strand breaks 
that can generate chromosomal translocations that trigger specific types of 
leukemia (see Figure 4). For example, ~2-3% of patients treated with regimens 
that include etoposide ultimately develop acute myelocytic leukemia (14, 24-26). 
Recently, correlations between the rising use of mitoxantrone to treat breast 
cancer and the development of secondary leukemias also have been noted (130, 
131). The common feature in ~50% of these leukemias is the presence of 
translocations within an 8.3 kb breakpoint cluster region in the MLL (mixed 
lineage leukemia) gene at chromosome band 11q23 (13, 14, 24-26) (Figure 7). 
 The basis for the development of topoisomerase II-initiated leukemias has 
not been elucidated, but it appears to be related to the function of the protein 
product of the MLL gene. MLL is the human homolog of the Drosophila trithorax 
and yeast Set1 proteins, and is a histone methyltransferase that is involved in 
transcriptional regulation in hematopoietic cells (26, 132-135). Accumulating 
evidence suggests that the fusion of the MLL protein with other cellular partner 
proteins alters enzyme function and affects the differentiation of pluripotent 
hematopoietic stem cells or committed myeloid or lymphoid stem cells by 
deregulating the expression of HOX genes (26, 132, 133, 135, 136). 
 Infant acute lymphoblastic leukemias and some benzene-induced leukemias 
also display translocations involving chromosomal band 11q23 (137). 
Epidemiological and biochemical studies have established potential links 
between these malignancies and topoisomerase II. For example, the maternal 
consumption (during pregnancy) of foods that are high in genistein or other 
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Figure 7. Diagram of the MLL gene locus and breakpoint cluster region. The 
MLL gene is located on chromosome band 11q23 and encodes a protein that is 
>400 kDa in size.  Translocations and other aberrations involving this gene 
have been observed in patients with specific leukemia and have been linked to 
the activity of type II topoisomerases. The coding region contains an 8.3 kb 
breakpoint cluster region (bcr, boxed in red) flanked by BamHI sites (B). 
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naturally occurring topoisomerase II poisons increases the risk of developing 
infant acute lymphoblastic leukemias ~10–fold (18, 20-23). In addition, 
individuals with chronic exposure to benzene display an increasingly higher risk 
for leukemias with 11q23 chromosomal translocations if they are heterozygous or 
homozygous for the C609T polymorphism of the NAD(P)H:quinone 
oxidoreductase 1 (NQO1) (138-142). NQO1 is the enzyme that reduces 
benzoquinone to the less reactive hydroquinone (138-140, 142) (Figure 8). As 
discussed above, benzoquinone is a highly active topoisomerase II poison. 
 Although the involvement of topoisomerase II-mediated DNA cleavage in 
the development of leukemias with MLL translocations is widely accepted, the 
role of the enzyme-associated DNA strand breaks in triggering the chromosomal 
aberrations is controversial. Two hypotheses have been proposed (see Figure 4). 
The first postulates that the breaks induced by topoisomerase II play a direct role 
in the translocation process. In this case, the enzyme cleaves within the MLL gene 
and following processing and recombination/repair; the breaks are reattached to 
other sites in the genome (presumably that also were cleaved by the type II 
enzyme). Supporting this hypothesis, all MLL (and partner) chromosomal 
breakpoints identified in patient samples, including those with secondary and 
infant leukemias, are located in close proximity to in vitro sites of topoisomerase 
II-mediated DNA cleavage (143-145). Furthermore, leukemias with 11q23 
chromosomal translocations are only observed in patients treated with 
topoisomerase II poisons, and are not seen following other anticancer therapies. 
This is despite the fact that radiation, DNA alkylation and crosslinking agents,  
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Figure 8. Metabolism of benzene to benzoquinone. Benzene is metabolized 
to benzene oxide in the liver by cytochrome P450 2E1 and converted to phenol 
by a nonenzymatic rearrangement. Phenol is converted to hydroquinone by a 
subsequent round of cytochrome P450 metabolism and non-enzymatic 
rearrangement. The now water soluble hydroquinone diffuses to the bone 
marrow and is metabolised, to benzoquinone by endogenous 
myeloperoxidase (MPO). Benzoquinone is converted back to hydroquinone by 
NAD(P)H:quinone oxidoreductase 1 (NQO1). Other metabolic and clearance 
pathways exist, but were omitted for simplicity. Adapted from (1). 
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and drugs such as bleomycin that chemically cleave DNA all generate 
chromosomal breaks and induce apoptotic pathways. 
 The second hypothesis states that the breaks induced by topoisomerase II 
play an indirect role in the translocation process. In this case, enzyme-mediated 
DNA cleavage induces apoptosis, which initiates chromosomal fragmentation 
(146). Occasionally (by processes that have yet to be described), apoptosis aborts 
and nuclease-generated breaks within the MLL gene are processed and 
reattached to other sites in the genome (147). Supporting this theory, a major site 
of apoptotic cleavage is located in the breakpoint cluster region of the MLL gene 
(147-150). Moreover, translocations involving 11q23 can be induced in cultured 
human cells by agents that trigger apoptosis, but do not target topoisomerase II 
(147-150). The discrepancy between patients and cellular studies regarding the 
requirement for topoisomerase II poisons to induce leukemic translocations is 
notable. The apoptotic model reconciles this discrepancy by further postulating 
that the inhibition of topoisomerase II function following treatment with poisons 
alters chromatin structure and that these alterations, coupled with nuclease 
action, are required for the translocation event in patients (150). 
 It is likely that the process that translates topoisomerase II-mediated DNA 
cleavage into 11q23 chromosomal translocations is highly complex and 
multifaceted. Both (or neither) of the above hypotheses may contribute to the 
process.  
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Scope of the Dissertation 
 Type II topoisomerases are necessary for proper chromosome structure and 
segregation (43, 50, 53, 57, 58). In addition to their essential functions, 
topoisomerase II has been a successful target for anticancer agents for almost 
four decades (10, 104, 105, 151). Topoisomerase II-targeted agents exploit the 
natural catalytic cycle of the enzyme to generate double-stranded DNA breaks 
(10, 16, 95, 152-154). These breaks in the genetic material, if present at high 
enough levels, induce programmed cell death pathways (11-14, 16, 17). However, 
insufficient generation of topoisomerase II-mediated DNA scission can lead to 
repair of the damage and can ultimately generate translocations, deletions and 
sister chromatid exchanges (11-14, 16, 17). Significant clinical evidence has linked 
topoisomerase II-targeted cancer chemotherapy regimens with the development 
of leukemias featuring 11q23 translocations (13, 14, 24-26). Exposure to benzene 
(which is metabolized to benzoquinone) also has been linked with the 
development of these leukemias (139-142).  
 Aside from the ability of benzoquinone to induce leukemia, other toxic 
quinone metabolites display genotoxic activity. However, this damage occurs 
primarily in the liver. Exposure to polychlorinated biphenyls (PCBs) and 
acetaminophen (metabolized to quinone and quinone imine compounds, 
respectively) induces chromosomal aberrations in this organ (33-36).  
 It is unclear how quinone and quinone imine metabolites induce DNA 
damage in the liver. However, the damage induced by these agents is consistent 
with the actions of topoisomerase II poisons. Furthermore, the exact role of the 
DNA breaks generated by exposure to clinical and environmental topoisomerase 
II poisons in the induction of leukemias is unclear. Therefore, the goals of this 
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dissertation are to 1) further characterize quinones as topoisomerase II poisons; 
2) examine the molecular interactions between the anticancer agent etoposide 
and topoisomerase IIα; and 3) explore the ability of topoisomerase II-targeted 
agents to induce aberrations in the MLL gene in cultured human cells. 
 Chapter I of this dissertation reviews both type I and type II topoisomerases, 
as well as the role of each enzyme in treating and/or initiating human cancers. 
Chapter II describes the materials and methods utilized in the studies presented 
in Chapters III-VII.  
 Chapter III of this dissertation characterizes the reactive metabolite of 
acetaminophen, N-acetyl p-benzoquinone imine (NAPQI), as a topoisomerase II 
poison. Results indicate that NAPQI has the ability to induce double-stranded 
DNA breaks by inhibiting topoisomerase II-mediated ligation of cleaved nucleic 
acid molecules. Aside from enhancing enzyme-mediated DNA scission, NAPQI 
inhibits both the cleavage and relaxation activities of the enzyme when incubated 
in the absence of DNA. The amount of compound necessary to induce half the 
maximal inhibition of cleaved DNA substrate achieved was ~10–fold higher than 
that necessary to inhibit 50 percent of strand passage activity. This suggests a 
dual activity of this agent against the enzyme. Finally, the parent compound 
acetaminophen did not abrogate etoposide activity in vitro or in cultured human 
cells. The results of this study are published (155). 
 Chapter IV of this dissertation describes hydroquinone and quinone-based 
metabolites of PCBs as topoisomerase-poisons. All quinone-based PCB 
metabolites examined displayed significant activity as topoisomerase II poisons. 
These agents require covalent adduction to topoisomerase II and inhibited DNA 
ligation by the enzyme. The PCB hydroquinone, however, exhibited little activity 
 26 
to enhance topoisomerase II-mediated double-stranded DNA breaks. Like 
NAPQI, these agents also inhibited the enzyme in the absence of DNA. A series 
of binding experiments suggest that these agents are capable of blocking the N-
terminal gate of the protein by crosslinking the protomer subunits of 
topoisomerase II. This crosslinking activity appears to contribute to part of the 
activity of these agents against the enzyme. The results of this study are 
published (156). 
 Chapter V of this dissertation further explores the mechanism by which 
quinones act as topoisomerase II poisons. Quinones require adduction to 
function as topoisomerase II poisons. Therefore, sites of quinone adduction were 
mapped using mass spectrometry. Four cysteine residues were identified as sites 
of quinone adduction; cys170, cys392, cys405 and cys455. Mutations (C->A) were 
made at each position and the resulting enzymes were purified. Substitution of 
either cys 392 or cys405 reduced quinone sensitivity by ~50%. Simultaneous 
mutation of these residues did not confer further resistance to quinones. 
Topoisomerase II mutants carrying cys->ala mutations at residues 392 or 405 
displayed faster rates of ligation in the presence of benzoquione. Furthermore, 
mutation of cys455 to ala generated a mutant enzyme that was 1.5– to 2–fold 
hypersensitive to quinones. This mutant displayed higher levels of clamp closed 
form of the enzyme in the presence of benzoquione. Taken together, these results 
suggest at least a dual activity of quinones against topoisomerase II. They adduct 
to cys 392 and cys405 to inhibit ligation and block the N-terminal protein gate 
increasing the concentration to DNA in the active sites of the enzyme. The results 
of this study are published or submitted (157, 158). 
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 Chapter VI of this dissertation further examines the interactions between 
etoposide and topoisomerase II. Consistent with previous studies, the A–ring of 
the drug appears to be necessary for drug binding while the E–ring, appears to 
play a functional role in enhancing enzyme-mediated DNA scission. Addition of 
bulk at the 4’ position of this ring significantly decreased binding of the resultant 
agent indicating that the E–ring rests in a confined pocket within the protein. 
Removal of the glycosidic moiety of etoposide has only minor effects on DNA 
cleavage that are not due to a decrease in drug enzyme-binding. Instead, results 
suggest that the glycosidic moiety of etoposide may interact with DNA in the 
enzyme-drug-DNA ternary complex. The results of this study have not yet been 
published. 
 Chapter VII of this dissertation studied the ability of two characterized 
topoisomerase II poisons to induce MLL aberrations in cultured human cells. 
Treatment of cells with either of these agents increase levels of topoisomerase II 
covalent DNA complexes and permanent double-stranded DNA breaks. 
Analysis of the MLL bcr revealed several aberrations of a 1.8 kb XbaI fragment 
that contains a translocation “hotspot” after exposure to etoposide or 
benzoquinone. Furthermore, inhibition of apoptosis decreased but did not 
eliminate these translocations. These data suggest that multiple pathways 
contribute to MLL gene aberrations that can lead to leukemias. Furthermore, this 
system can be used to analyze the role of type II topoisomerases in generating 
11q23 translocations as well as the specific repair machinery involved. Finally, 
concluding remarks for this dissertation are found in Chapter VIII.  
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CHAPTER II 
 
METHODS 
 
Materials 
 Human topoisomerase IIα, top2αC170A, top2αC392A, top2αC405A, 
top2αC455A and top2αC392/405A were expressed in Saccharomyces cerevisiae 
(159) and purified as described previously (160, 161). Negatively supercoiled 
pBR322 DNA was prepared using a Plasmid Mega Kit (Qiagen) as described by 
the manufacturer. Human topoisomerase I was a gift from Dr. Mary Ann Bjornsti 
(St. Jude Children’s Research Hospital). Mass spectrometry grade trypsin and 
chymotrypsin were obtained from Fisher and Princeton Separations, 
respectively. Restriction enzymes, phosphatase, T4 DNA ligase, and T4 
polynucleotide kinase were from New England Biolabs. [γ-32P]ATP and genistein 
were obtained from ICN, etoposide, NAPQI, acetaminophen, benzoquinone, 
hydroquinone and camptothecin were from Sigma, TOP-53 was a gift from Taiho 
Pharmaceuticals, amsacrine was a gift from Bristol-Myers Squibb, and CP-
115,953 was a gift from Pfizer Global Research. 2-(2-Chloro-phenyl)-
[1,4]benzoquinone (2’Cl-2,5pQ), 2-(3-chloro-phenyl)-[1,4]benzoquinone (3’Cl-
2,5pQ), 2-(4-chloro-phenyl)-[1,4]benzoquinone (4’Cl-2,5pQ), 2-(3,5-dichloro-
phenyl)-[1,4]benzoquinone (3’,5’Cl-2,5pQ), 3-(4-Chloro-phenyl)-
[1,2]benzoquinone (4’Cl-2,3oQ), 4-(4-chloro-phenyl)-[1,2]benzoquinone (4’Cl-
3,4oQ), and 4'-Chloro-biphenyl-2,5-diol (4’Cl-2,5HQ) were the generous gifts of 
Dr. Hans J. Lehmler, University of Iowa. DEPT, EPT and DDEPT were the 
generous gifts of Dr. Norma Dunlap, Middle Tennessee State University. 
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Hydroxyphenyl-etoposide and Phenyl-etoposide were the generous gifts of 
David B. Berkowitz, University of Nebraska. Z-VAD-fmk was purchased from 
Axxora and was dissolved as a 15 mM stock in DMSO and stored at -70 oC. 
Etoposide, camptothecin, genistein, TOP-53, and amsacrine, were stored at 4 oC 
as 10 or 20 mM stock solutions in 100% DMSO. NAPQI and acetaminophen were 
prepared as 20 mM stock solutions in 100% DMSO and water, respectively, and 
used fresh for all experiments. The quinolone CP-115,953 was dissolved as 40 
mM solution in 0.1 N NaOH, and stored at -20 °C. Immediately prior to use, the 
quinolone was diluted to 8 mM with 10 mM Tris, pH 7.9. All other chemicals 
were analytical reagent grade. 
 
Procedures 
  
 Synthesis of PCB metabolites.  
 2’Cl-2,5pQ, 3’Cl-2,5pQ, 4’Cl-2,5pQ, 3’,5’Cl-2,5pQ, 4’Cl-2,5HQ, 4’Cl-2,3oQ 
and 4’Cl-3,4oQ were synthesized by coupling of the appropriate chloroaniline 
with benzoquinone as described by Amaro et al. (162). 4’Cl-2,5HQ was generated 
by reducing 4’Cl-2,5pQ with sodium dithionite (163). 4’Cl-2,3oQ and 4’Cl-3,4oQ 
were generated by oxidizing the corresponding diol PCB derivatives with 
silver(I) oxide (162, 164). The [1,2]benzoquinones were used within 48 hours after 
their synthesis to minimize decomposition. In all cases, spectroscopic data were 
in agreement with proposed structures. Furthermore, the purity of all 
compounds was >98% as determined by gas chromatography 
([1,4]benzoquinone) or gas chromatography-mass spectrometry (diols). The only 
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exception were the two [1,2]benzoquinones, which were characterized with 1H 
nuclear magnetic resonance spectroscopy and used without further purification. 
 
 Adduction of Topoisomerase IIα by Quinones.  
 To determine sites of quinone adduction on human topoisomerase IIα, 135 
nm enzyme was incubated in a total of 300 µL of cleavage buffer (10 mM Tris-
HCl, pH 7.9, 100 mM KCl, 5 mM MgCl2, 0.1 mM NaEDTA, and 2.5% glycerol) in 
the presence of 250 µM plumbagin for 10 min at 37 ˚C. Reactions were quenched 
with 20 µL of 45 mM DTT. Samples were applied to 30,000 NMWL filter columns 
(Millipore), washed with 10% methanol in 25 mM ammonium bicarbonate, and 
resuspended in 25 µL of 25 mM ammonium bicarbonate. DTT (2.5 µL of 45 mM) 
was added, and the protein was incubated for 15 min at 50 ˚C. Iodoacetamide 
(2.5 µL of 100 mM) was added and the sample was incubated at room 
temperature in the absence of light for 15 min. Additional DTT (2.5 µL of 45 mM) 
was added to quench the iodoacetamide, and the protein was incubated for 15 
min at 50 ˚C. Samples were washed with 10% methanol in 25 mM ammonium 
bicarbonate and resuspended in 25 µL of 25 mM ammonium bicarbonate. 
Trypsin (0.1 µg) was added and samples were incubated for 16 h at 37 ˚C to 
digest the protein. Alternatively, chymotrypsin (0.1 µg) was added and samples 
were incubated for 6 h at room temperature. Peptides were eluted from the 
column, dried and reconstituted in 0.1% formic acid for mass spectral analysis. 
 Residues in topoisomerase IIα that were adducted by quinone were 
identified by mass spectral analysis of the tryptic or chymotryptic peptides. The 
LC-MS/MS analyses were performed on a ThermoFinnigan LTQ linear ion trap 
mass spectrometer equipped with a ThermoFinnigan Surveyor LC pump and 
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autosampler, NanoSpray source (Thermo Electron), and Xcalibur 1.4 instrument 
control and data analysis software. HPLC separation of the tryptic peptides was 
achieved using a 100 µm x 11 cm C-18 capillary column (Monitor C18, 5 micron, 
100 angstrom, Column Engineering) at a flow rate of 0.7 µL min-1. Solvent A was 
H2O with 0.1% formic acid and solvent B was acetonitrile containing 0.1% formic 
acid. The gradient program was: 0–3 min, linear gradient from 0–5% B; 3–5 min, 
5% B; 5–50 min, linear gradient to 50% B; 50–52 min, linear gradient to 80% B; 52–
55 min, linear gradient to 90% B; 55–56 min, 90% B in solvent A. MS/MS scans 
were acquired using an isolation width of 2 m/z, an activation time of 30 ms, an 
activation Q of 0.250, and 30% normalized collision energy using 1 microscan 
and ion time of 100 for each MS/MS scan. The mass-spectrometer was tuned 
prior to analysis using the synthetic peptide TpepK (AVAGKAGAR). Some 
parameters may have varied slightly from experiment to experiment, but 
typically the tune parameters were as follows: spray voltage of 2.0 KV, capillary 
temperature of 160 ºC, capillary voltage of 60 V, and tube lens of 130 V. Tandem 
MS analysis was performed using data-dependent scanning in which one full MS 
spectrum, using a full mass range of 400–2000 amu, was followed by 3 MS/MS 
spectra. Wild-type and modified peptides were identified using the SEQUEST 
algorithm (165), and the SEQUEST Browser software (Thermo Electron, San Jose, 
CA) using the human subset of the NCBI database. In addition, lists of theoretical 
or Sequest identified unmodified peptides were created and each peptide was 
run through P-Mod software to check for possible chemical modifications (166). 
The candidate modifications found by software were verified by visual 
inspection of corresponding spectra. 
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 Generation of Mutant Human Topoisomerase IIα Proteins.  
 Mutations in the topoisomerase IIα PCR substrate were generated by cloning 
a SalI-KpnI fragment of YEpWob6 (167) that encoded the N-terminus of the 
human enzyme into pUC18. Site-directed mutagenesis was performed using the 
QuickChange II PCR system (Stratagene). The sequence of the forward and 
reverse primers used to generate the C170A mutation were 
GGAGCCAAATTGGCTAACATATTCAGTACCAAATTTACTGTGG and 
GAATATGTTAGCCAATTTGGCTCCATAGCCATTTCGACCACC, respectively. 
The sequence of the forward and reverse primers used to generate the C392A 
mutation were CTTTACAACCCAAGAGCTTTGGATCAACAGCCCAATTG-
AGTG and GATAAATTTTTCACTCAATTGGGCTGTTGATCCAAAGCTCT-
TGG, respectively. The sequence of the forward and reverse primers used to 
generate the C405A mutation were CAAAGCTGCCATTGGCGCTG-
GTATTGTAGAAAGCATAC and CAGTTTAGTATGCTTTCTACAATACCAGC-
GCCAATGGCAGC, respectively. The sequence of the forward and reverse 
primers used to generate the C455A mutation were 
CAGGGGGCCGAAACTCCACTGAGGCTACGCTTATCC and CCCTCAGTCA-
GGATAAGCGTAGCCTCAGTGGAGTTTCGGCCC, respectively. The 
mutagenized codons are underlined. To generate the C392/405A double 
mutation, sequential rounds of PCR were performed using the primers to 
generate the C392A and C405A mutations as above. Mutations were verified by 
sequencing and SalI-KpnI fragments were cloned back into YEpWob6. Mutant 
human topoisomerase IIα enzymes were purified as described above. 
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 Plasmid DNA Cleavage.  
 DNA cleavage reactions were carried out using the procedure of Fortune 
and Osheroff (168). Assay mixtures contained 135 nM topoisomerase IIα, and 10 
nM negatively supercoiled pBR322 DNA in a total of 20 µL of cleavage buffer (10 
mM Tris-HCl, pH 7.9, 100 mM KCl, 5 mM MgCl2, 0.1 mM NaEDTA, and 2.5% 
glycerol) that contained 0 to 200 µM etoposide, DEPT, EPT, DDEPT, NAPQI, 
acetaminophen, PCB metabolite, plumbagin, or benzoquinone; or 50 µM 
genistein or amsacrine; or 5 µM CP-115,953. DNA cleavage was initiated by the 
addition of enzyme and mixtures were incubated for 6 min at 37 °C to establish 
DNA cleavage-religation equilibria. Enzyme-DNA cleavage intermediates were 
trapped by adding 2 µL of 5% SDS and 1 µL of 375 mM EDTA, pH 8.0. Proteinase 
K was added (2 µL of 0.8 mg/mL) and reactions were incubated for 30 min at 45 
°C to digest the topoisomerase IIα. Samples were mixed with 2 µL of agarose 
loading buffer (60% sucrose in 10 mM Tris-HCl, pH 7.9, 0.5% bromophenol blue, 
and 0.5% xylene cyanol FF), heated for 15 min at 45 °C, and subjected to 
electrophoresis in 1% agarose gels in TAE buffer (40 mM Tris-acetate, pH 8.3, 2 
mM EDTA) that contained 0.5 µg/mL ethidium bromide. DNA cleavage was 
monitored by the conversion of negatively supercoiled plasmids to linear 
molecules. DNA bands were visualized by ultraviolet light and quantified using 
an Alpha Innotech digital imaging system. 
 In order to determine whether DNA cleavage by topoisomerase IIα was 
reversible, EDTA was added prior to treatment with SDS. To examine whether 
cleavage was protein-linked, proteinase K treatment was omitted. In reactions 
that tested whether PCB metabolite activity was affected by DTT, reactions 
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contained a final DTT concentration of 500 µM that was added either before or 
after cleavage complex formation and processed as above. 
 To analyze the effects of quinones on topoisomerase IIα in the absence of 
DNA, 100 µM etoposide, NAPQI, acetaminophen, PCB metabolite, or 
benzoquinone was incubated with the enzyme for 0 to 3 min at 37 °C in 15 µL of 
cleavage buffer. Cleavage reactions were initiated by adding negatively 
supercoiled pBR322 DNA in 5 µL of cleavage buffer. The concentrations of 
enzyme, DNA, and the agent in the final reaction mixtures were 135 nM, 10 nM, 
and 100 µM, respectively. Topoisomerase IIα DNA cleavage-religation equilibria 
were established and processed as described above. 
 
 Site-specific DNA Cleavage.  
 DNA sites cleaved by human topoisomerase IIα were determined by a 
modification of the procedure of O’Reilly and Kreuzer (169). A linear 4330 bp 
fragment (HindIII/EcoRI) of pBR322 plasmid DNA singly labeled with 32P on the 
5’-terminus of the HindIII site was used as the cleavage substrate. Reaction 
mixtures contained 0.35 nM DNA substrate and 60 nM topoisomerase IIα in 50 
µL of cleavage buffer with 1 mM ATP. Assays were carried out in the absence of 
compound, or in the presence of 12.5 or 25 µM etoposide, 25 µM benzoquinone 
or PCB metabolite or 50 µM DEPT or 100 µM NAPQI or 250 µM EPT or DDEPT 
or 0–500 µM plumbagin. Reactions were initiated by the addition of the enzyme 
and were incubated for 10 min at 37 °C. Cleavage intermediates were trapped by 
adding 5 µL of 5% SDS followed by 5 µL of 250 mM NaEDTA, pH 8.0. 
Topoisomerase IIα was digested with proteinase K (5 µL of 0.8 mg/mL) for 30 
min at 45 °C. Reaction products were precipitated twice in ethanol, dried, and 
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resuspended in 40% formamide, 8.4 mM EDTA, 0.02% bromophenol blue, and 
0.02% xylene cyanole FF. Samples were subjected to electrophoresis in a 6% 
sequencing gel. The gel was then fixed in 10% methanol/10% acetic acid for 5 
min, dried, and DNA cleavage products were analyzed on a Bio-Rad Molecular 
Imager FX. 
 
 DNA Religation.  
 DNA religation mediated by topoisomerase IIα was monitored according to 
the procedure of Byl et al. (170). Topoisomerase IIα DNA cleavage/religation 
equilibria were established as described above in the absence of compound, or in 
the presence of 100 µM etoposide, PCB metabolite, etoposide, benzoquinone, 
NAPQI, DEPT, EPT, or DDEPT. Religation was initiated by shifting reaction 
mixtures from 37 °C to 0 °C, and reactions were stopped at time points up to 40 s 
by the addition of 2 µL of 5% SDS followed by 1 µL of 375 mM NaEDTA, pH 8.0. 
Samples were processed and analyzed as described above for topoisomerase IIα 
plasmid DNA cleavage reactions. 
 
 DNA Ligation.  
 22 and 25-base oligonucleotides corresponding to residues 80–121 and 122–
126 of pBR322 and its 47-mer complement were prepared on an Applied 
Biosystems DNA synthesizer. The sequences of the two top and single bottom 
strands were 5’-CCGTGTATGAAATCTAACAATG-3’ 5’-CGCTCATCGTCA-
TCCTCGGCACCGT-3’ and 5’-ACGGTGCCGAGGATGACGATGAGCGCA-
TTGTTAGATTTCATACACGG-3’, respectively. The 25-mer oligonucleotides 
were 5’-activated with p-nitrophenol according to Bromberg et al. (171). Single-
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stranded 22-mer oligonucleotides were labeled on their 5’-termini with 
[32P]phosphate and purified as described (172). Equimolar amounts of 
complementary oligonucleotides were annealed by incubating at 70 °C for 10 
min and cooling to 25 °C. 
 DNA ligation reactions were carried out according to Bromberg et al. (171). 
Assays contained 200 nM wild-type human type IIα topoisomerase, 0–100 µM 
etoposide, DEPT, EPT, or DDEPT and 10 nM activated nicked oligonucleotide in 
a total of 20 µl of 10 mM Tris-HCl, pH 7.9, 135 mM KCl, 7.5 mM CaCl2, 0.1 mM 
EDTA, and 2.5% glycerol. Reaction mixtures were incubated at 37 °C for 48 
hours. Cleavage intermediates were trapped by adding 2 µL of 5% SDS followed 
by 1 µL of 375 mM NaEDTA, pH 8.0. Topoisomerase IIα was digested with 
proteinase K (2 µL of 0.8 mg/mL) for 30 min at 45 °C. Reaction products were 
treated as described above and subjected to electrophoresis in a 14% sequencing 
gel. The gel was then fixed in 10% methanol/10% acetic acid for 5 min, dried, 
and DNA cleavage products were analyzed on a Bio-Rad Molecular Imager FX. 
 
 DNA Binding.  
 The binding of topoisomerase IIα to linear DNA substrates was assessed 
using a nitrocellulose filter-binding assay. Either the linearized pBR322 DNA 
substrate described above or a 32P-labeled double-stranded 50-mer 
oligonucleotide that contained a single topoisomerase II cleavage site (173) was 
employed. The oligonucleotide was prepared on an Applied Biosystems DNA 
synthesizer. The sequences of the top and bottom strands were 5’-TTGGTAT-
CTGCGCTCTGCTGAAGCC↓AGTTACCTTCGGAAAAAGAGTTGGT-3’ and 5’-
ACCAACTCTTTTTCCGAAGGT↓AACTGGCTTCAGCAGAGCGCAGATACCA
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A-3’, respectively. Arrows indicate cleavage sites by topoisomerase IIα The 
enzyme was incubated for 0–5 min at 37 °C in 15 µL of DNA binding buffer (10 
mM Tris-HCl, pH 7.9, 30 mM KCl, 0.1 mM NaEDTA, and 2.5% glycerol) that 
contained no compound, PCB metabolite, or etoposide. Binding equilibria were 
initiated by addition of DNA in 5 µL of binding buffer and followed by 
incubation for 6 min at 37 °C. The final concentrations of topoisomerase IIα, 
DNA, and etoposide, PCB metabolite, or benzoquinone in the final reaction 
mixtures were 400 nM, 5 nM, and 100 µM, respectively. Nitrocellulose 
membranes (0.45 µm HA, Millipore) were prepared by incubation in DNA 
binding buffer for 10 min. Samples were applied to the membranes and filtered 
in vacuo. Membranes were washed 3 times with 1 mL of DNA binding buffer, 
dried, and submerged in 8 mL of scintillation fluid (Econo-Safe, Research 
Products International). Radioactivity remaining on the membranes was 
quantified using a Beckman LS 5000 TD Scintillation Counter.  
 Assays that monitored the binding of topoisomerase IIα to negatively 
supercoiled plasmid were carried out according to the procedure of Fortune et al. 
(174). Reaction mixtures contained enzyme and etoposide, PCB metabolite, or 
benzoquinone in 15 µL of binding buffer. Samples were incubated for 5 min at 37 
°C. Binding was initiated by adding DNA in 5 µL of binding buffer and 
incubated at 37 °C for an additional 6 min. The final concentrations of 
topoisomerase IIα, DNA, and PCB metabolite in the final reaction mixtures were 
0–400 nM, 5 nM, and 100 µM, respectively. 2 µL of 60% sucrose in 10 mM Tris-
HCl, pH 7.9 was added to samples and were loaded without further processing 
onto a 1% agarose gel and subjected to electrophoresis in TBE buffer (100 mM 
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Tris-borate, pH 8.3, 2 mM EDTA). Gels were stained for 30 min with 0.5 µg/mL 
ethidium bromide and samples were analyzed as described above. 
 
 Protein Clamp Closing.  
 Filter binding assays were used to analyze the salt-stable closed-clamp of 
topoisomerase IIα (175). Briefly, 5 nM human topoisomerase IIα and 2 nM 
pBR322 were incubated for 5 min at 37 °C in a total of 90 µL of clamp closing 
buffer (50 mM Tris-HCl, pH 8.0, 100 mM KCl, 1 mM EDTA, 8 mM MgCl2). No 
compound, 100 µM PCB metabolite, benzoquinone or 250 µM plumbagin or a 
combination of 100 µM ICRF-193 + 2 mM ATP was added in a total of 10 µL of 
10% DMSO. Mixtures were incubated for an additional 5 min at 37 °C.  
 In some experiments, 4’Cl-2,5pQ was incubated with topoisomerase IIα for 
5 min in the absence of DNA. Following the addition of DNA, samples were 
incubated for an additional 5 min at 37 °C.  
 In all cases, binding mixtures were loaded onto glass fiber filters (Millipore) 
pre-incubated in clamp closing buffer, and filtered in vacuo. Filters were washed 
3 times with clamp closing buffer (low salt wash), followed by 3 washes with 
clamp closing buffer that contained 1 M NaCl (high salt wash), followed by 3 
washes with 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, and 0.5% SDS. DNA was 
precipitated with isopropanol and loaded onto a 1% agarose gel in TAE buffer 
containing 0.5 µg/mL ethidium bromide. DNA was visualized as described 
above. 
 
 
 39 
 Protein Crosslinking.  
 The ability of quinones to crosslink the protomer subunits of human 
topoisomerase IIα was assessed using SDS polyacrylamide gels. Crosslinking 
mixtures contained 135 nM topoisomerase IIα in a total of 60 µL of cleavage 
buffer. The enzyme was incubated for 0–2 min at 37 °C in the presence of 100 µM 
4’Cl-2,5pQ or benzoquinone or for 6 min in the absence of compound or in the 
presence of 100 µM 4’Cl-2,5pQ or 250 µM plumbagin. In dilution experiments, 
80–800 nM topoisomerase IIα was incubated with 100 µM 4’Cl-2,5pQ for 1 min. 
In all cases, reactions were quenched by the addition of 2 µL of 5 mM DTT and 
were incubated at 37 ˚C for an additional 2 min. Samples were precipitated with 
TCA and resuspended in 10 µL of H2O. Laemmli buffer (10 µL, Bio-Rad) was 
added and samples were subject to electrophoresis in a 7.5% denaturing 
acrylamide gel (Bio-Rad) at 200 v for 1 h. The protein was visualized by 
coumassie staining. 
 
 Partial Proteolytic Mapping.  
 To identify peptides crosslinked by PCB metabolites, a modified Cleveland 
mapping protocol was utilized. Briefly, 3 µg of human topoisomerase IIα was 
treated with 100 µM 4’Cl-2,5pQ for 0–2 min at 37 ˚C in 10 µL of cleavage buffer. 
Reactions were quenched with 1 µL of 5 mM DTT. Proteolysis was initiated by 
the addition of 0.4 ng of V8 protease (Pierce) and samples were incubated at 37 
˚C for 30 min. Protease reactions were quenched with 3 µL of 10% SDS followed 
by the addition of 15 µL of Laemmli buffer. Samples were subject to 
electrophoresis in a 4–20% denaturing acrylamide gel (Bio-Rad) at 200 v for 1.5 h. 
Protein was visualized by silver staining (Bio-Rad). 
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 Topoisomerase II-Drug Binding.  
 Competition binding studies were performed using a nitrocellulose filter 
binding technique. Nitrocellulose membranes (0.45 µm HA; Millipore) were 
soaked in yeast binding buffer (10 mM sodium phosphate, pH 7.7, 250 mM KCl, 
0.1 mM NaEDTA, and 5 mM MgCl2) or DNA binding buffer for 10 min. Reaction 
mixtures contained 1.6 µM yeast topoisomerase II or human topoisomerase IIα 
and 20 µM [3H]etoposide, as well as 0–100 µM etoposide, hydroxyphenyl-
etoposide or phenyl-etoposide in a total of 60 µL of binding buffer. Samples were 
incubated for 6 min at 30 °C (yeast) or 37 °C (human) and applied to the 
nitrocellulose membranes in vacuo. Filters were immediately washed three times 
with 1 mL of ice-cold binding buffer, dried, and submerged in 8 mL of 
scintillation fluid (Econo-Safe; Research Products International). Radioactivity 
remaining on membranes was quantified using a Beckman LS 5000 TD 
scintillation counter. The amount of radioactive etoposide remaining on the filter 
in the absence of enzyme was subtracted prior to binding calculations. 
 
 DNA Cleavage Mediated by Topoisomerase IIα in CEM Cells.  
 Human CEM acute lymphoblastic leukemia cells (ATCC) were cultured 
under 5% CO2 at 37 °C in growth media [RPMI 1640 medium (Cellgro by 
Mediatech, Inc.) containing 10% heat-inactivated fetal calf serum (Hyclone) and 2 
mM glutamine (Cellgro by Mediatech, Inc.)]. The In vivo Complex of Enzyme 
(ICE) bioassay (176, 177) (as modified on the TopoGEN, Inc. website) was 
employed to determine the ability of PCB metabolites to induce topoisomerase 
IIα-mediated DNA breaks in CEM cells. Exponentially growing cultures were 
treated with 25 µM PCB metabolite for 6 h, 10 µM benzoquinone for 4 h or 10 µM 
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etoposide, DEPT, EPT, DDEPT or camptothecin for 2 h. Cells (~5 x 106) were 
harvested by centrifugation and lysed by the immediate addition of 3 mL of 1% 
sarkosyl. Following gentle dounce homogenization, cell lysates were layered 
onto a 2 mL cushion of CsCl (1.5 g/mL) and centrifuged in a Beckman NVT 90 
rotor at 80,000 rpm (~500,000 × g) for 5.5 h at 20 °C. DNA pellets were isolated, 
resuspended in 5 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, and blotted onto 
nitrocellulose membranes using a Schleicher and Schuell slot blot apparatus. 
Covalent complexes formed between topoisomerase and DNA were detected 
using polyclonal antibodies directed against human topoisomerase IIα (Kiamaya 
Biochemical Co.) or human topoisomerase I (Biolegend) at a 1:1000 dilution.  
 
 H2AX Phosphoryolation Mediated by Topoisomerase II Poisons. 
 Human CEM acute lymphoblastic leukemia cells (ATCC) were cultured as 
described above. Cells (4 × 106) were seeded in a total of 10 mL of growth media. 
Phosphorylation of H2AX after exposure to topoisomerase II poisons was 
monitored by western blot. Cells were exposed to 25 µM etoposide for 2 h or 10 
µM benzoquinone for 4 h. Cells were harvested and lysed with 50 µL 50 mM 
Tris-HCl, pH 7.9, 100 mM NaCl and 0.5% NP-40. A total of 35 µg of protein from 
cell lysates was loaded from each sample onto a 4-20% SDS-polyacrylamide gel 
(purchased from Sigma) and subjected to electrophoresis. Protein was then 
transferred to an activated PVDF membrane and γ-H2AX levels were determined 
by probing with a monoclonal anti-rabbit antibody directed to the H2AX 
phosphoprotein at a 1:2000 dilution. 
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 Caspase-3 Activation 
 Human CEM acute lymphoblastic leukemia cells were cultured as described 
above. Cells (4 × 106) were seeded in a total of 10 mL of growth media. Cells were 
treated with 15 µM Z-VAD-fmk or DMSO vehicle 2 h prior to treatment with 25 
µM etoposide for 2 h or 10 µM benzoquinone for 4 h, washed in 10 mL of growth 
media without compound. 2 × 106 cells were collected immediately following the 
drug washout and again 6 h later. Cells treated with Z-VAD-fmk prior to 
addition of topoisomerase II poison were maintained in the agent during the 6 h 
recovery period. Caspase-3 activation was determined by using the Apo-Alert 
Caspase-3 Colorimetric Assay kit (Clontech) as described by the manufacturer. 
 
 MLL Gene Aberrations Induced by Topoisomerase II Poisons. 
 Human CEM acute lymphoblastic leukemia cells were cultured as described 
above. Cells (8 × 106) were seeded in a total of 20 mL of growth media. Cells were 
exposed to 25 µM etoposide for 2 h or 10 µM benzoquinone for 4 h. Cells were 
washed in 10 mL of growth media without compound and were resuspended in 
30 mL of growth media and 1 × 106 cells were collected every 24 hours for 5 days. 
An additional 1 × 106 cells cultured in the absence of either agent were also 
collected for comparison. In experiments that analyzed the role of apoptotic 
nucleases in generating MLL aberrations, cells were treated with 15 µM Z-VAD-
fmk 2 h prior to the addition of topoisomerase II poison and throughout the 
recovery period. Cells (1 × 106) were harvested 3 days following exposure to 
either etoposide or benzoquinone. 
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 Genomic DNA from treated and untreated cells was purified using a DNA 
Wizard Genomic DNA Isolation kit (Promega). DNA (5 µg) was digested with 40 
units of XbaI (New England Biolands) in 200 µL of buffer supplied by the 
manufacturer. DNA was ethanol precipitated and ligated with 2000 units of T4 
DNA ligase (New England Biolabs) in 300 µL of buffer supplied by the 
manufacturer to form circular DNA PCR substrates. DNA was ethanol 
precipitated and resuspended in 75 µL of 10 mM Tris-HCl, pH 7.7. Samples were 
further purified by passing the circularized DNA through a TE-100 column 
(Clontech) to remove excess ATP.  
 A modified procedure described by Libura et al. was used to analyze the 
MLL bcr (178). Two rounds of PCR were performed to amplify the 1.8 kb XbaI 
region of the MLL bcr. The forward primers for the first and second round of 
PCR were 5’- TCTACAAGTGCCAGGGGTCT-3’ and 5’-AATAGCATGCTGCCT-
GCACTGCACTCCTAA-3’, respectively. The reverse primers for the first and 
second round of PCR were 5’- CCCGACGTGGATTTTCTTTA-3’ and 5’-GATCG-
TAGGATATGTCCCTTATAAATGACAAACTACTGCTTCC-3’, respectively. 
PCR reactions were carried out using a Long Template PCR kit (Roche Applied 
Biosciences). PCR mixtures for the first round of PCR contained 200 ng of 
circularized DNA (described above), with 125 ng of the appropriate forward and 
reverse primer, 2.5 µL of 10 mM dNTP (Sigma), 3.75 units of long template PCR 
polymerase mix in a total of 50 µL of the supplied “buffer 3”. 2 µL of the first 
round reaction mix was used in lieu of 200 ng of circularized DNA in the second 
round reaction mix. For the first set of PCR the temperature pattern was as 
follows: 35 cycles at 94°C for 30 s, 54°C for 45 s, followed by 68°C extension 
period for 3 min. The extension period was extended by 2 min after the first 10 
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cycles and each 10 cycles thereafter. The second set of PCR the temperature 
pattern was as follows: 35 cycles at 94°C for 30 s, 56°C for 45 s, followed by 68°C 
extension period for 3 min. The extension period was extended by 2 min after the 
first 10 cycles and each 10 cycles thereafter. In both sets of PCR, the final length 
of the extension period for the final 5 cycles was 7 min. 
 Following PCR, 2 µL of agarose loading buffer was added to samples and 
amplified circularized DNA fragments were subject to gel eletrophorese in 1% 
agarose in TAE buffer containing 0.5 µg/mL ethidium bromide. DNA bands 
were visualized by ultraviolet light using an Alpha Innotech digital imaging 
system. 
 
 45 
CHAPTER III 
 
N-ACETYL-p-BENZOQUINONE IMINE, THE TOXIC METABOLITE OF 
ACETAMINOPHEN, IS A TOPOISOMERASE II POISON 
 
 
Introduction 
 Acetaminophen is the most widely used analgesic in the United States and 
the world and is contained in more than one hundred prescription and non-
prescription products (179, 180). Unfortunately, the drug is also the second 
leading cause of toxic drug overdoses in the United States (181, 182) and 
accounts for ~50% of hospital admissions for poisoning in the United Kingdom 
(181, 182). Over 56,000 cases of acetaminophen poisoning were reported in the 
United States in the year 2000, resulting in 100 deaths (181, 182).  
 Acetaminophen is metabolized in the liver (183). Normally, the drug is 
cleared from the body by sulfation or glucuronidation followed by renal 
excretion (179, 184-187). However, if these two processes become overwhelmed 
or if the cytochrome P450 system has been induced by prior insult to the liver 
(such as alcohol ingestion), acetaminophen is converted to NAPQI by CYP2E1 
and to a lesser extent by CYP1A2 and CYP3A4 (179, 184-190) (Figure 9). NAPQI 
is cleared primarily by conjugation to glutathione (179, 184-187).  
 All of the harmful effects of acetaminophen have been attributed to the 
formation of NAPQI (34, 179, 184-187). This reactive metabolite is toxic to cells 
and induces apoptosis and necrosis in cultured cells and in vivo (34, 191). In 
addition, the compound is genotoxic in humans and genotoxic and carcinogenic 
in animals (33, 34). It generates DNA strand breaks, gaps, and other  
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Acetaminophen NAPQI
Figure 9. Stuctures of acetaminophen and NAPQI. 
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chromosomal aberrations, and induces sister chromatid exchange (33, 34). The 
mechanistic basis for the actions of NAPQI is not fully understood. Since the 
compound can alkylate and oxidize proteins, it was initially believed that 
NAPQI toxicity was due to a direct inactivation of cellular enzymes (34, 184, 192). 
More recent studies, however, suggest that toxicity is also facilitated by the 
depletion of cellular glutathione (34, 184, 193). This depletion opens the cell to a 
variety of reactive chemicals (including oxygen radicals), which inactivate 
enzymes and damage the genetic material (34, 193). Finally, since depletion of 
glutathione allows the accumulation of NAPQI in cells, it is once again believed 
that (at least) some of the cytotoxic/genotoxic effects of NAPQI may be caused 
by the direct alkylation and/or oxidation of cellular proteins by the compound 
(34).  
 The specific cellular proteins that are modified by NAPQI following 
acetaminophen metabolism are not well characterized. However, the genotoxic 
effects of NAPQI are consistent with the actions of topoisomerase II-targeted 
drugs. Since the genotoxic events triggered by NAPQI resemble those of 
topoisomerase II poisons, the effects of the compound on human topoisomerase 
IIα were examined.  
 
Results 
 
 NAPQI Increases DNA Cleavage Mediated by Human Topoisomerase IIα.  
 The plasma concentration of acetaminophen in humans following a 
standard drug dose ranges from 50–100 µM (34, 179, 184-187, 194). The average 
plasma concentration in patients who suffer accidental acetaminophen overdose 
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is ~250 µM drug, while that in patients who intentionally overdose is ~950 µM 
drug (181). With these values in mind, the effects of 0–200 µM acetaminophen 
and NAPQI on DNA cleavage mediated by human topoisomerase IIα were 
determined (Figure 10).  
 NAPQI increased levels of topoisomerase II-mediated double-stranded 
DNA breaks in a concentration-dependent manner. The highest relative amount 
of DNA scission was observed at 100 µM NAPQI and was >5–fold higher than 
the no drug control. This cleavage enhancement is as compared to the widely 
used anticancer drug, etoposide, which stimulated enzyme-mediated DNA 
cleavage ~8–fold at a similar concentration. In marked contrast, acetaminophen 
had a marginal effect on the DNA cleavage activity of human topoisomerase IIα. 
These results indicate that metabolism of acetaminophen to NAPQI converts the 
parent compound to a strong topoisomerase II poison. 
 Several controls were carried out to ensure that the DNA cleavage seen in 
Figure 10 was mediated by topoisomerase IIα (Figure 11). First, no linear DNA 
was generated by NAPQI in the absence of enzyme. Second, scission was 
reversed when EDTA was added to the reaction prior to denaturation of 
topoisomerase IIα with SDS. This reversibility is consistent with an enzyme-
mediated reaction. Third, the electrophoretic mobility of the cleaved DNA (i.e., 
linear band) was dramatically retarded in the absence of proteinase K treatment, 
indicating that all of the cleaved plasmid molecules were covalently attached to 
topoisomerase IIα. These findings provide strong evidence that the double-
stranded DNA breaks observed in the presence of NAPQI are generated by 
human topoisomerase IIα. 
 49 
FI
FIII
FII
D
N
A
0  10  25  50 100 150 200
0
2
4
6
8
R
e
la
ti
v
e
 D
N
A
 C
le
a
v
a
g
e
0 50 100 150 200
Drug (µM)
Etoposide
NAPQI
APAP
Figure 10. NAPQI stimulates DNA cleavage mediated by human 
topoisomerase IIα . An ethidium bromide-stained agarose gel of DNA 
cleavage reactions carried out in the presence of 0-200 µM NAPQI is shown at 
top. A lane containing DNA in the absence of enzyme (DNA) is shown as a 
control. The mobilities of negatively supercoiled DNA (form I, FI), nicked 
circular plasmid (form II, FII), and linear molecules (form III, FIII) are 
indicated. Levels of DNA cleavage were quantified and expressed as a fold 
enhancement over reactions that were carried out in the absence of drug. 
Assays mixtures contained NAPQI (closed circles), etoposide (open circles) or 
acetaminophen (APAP, open squares). Error bars represent the standard 
deviation of three independent experiments. 
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Figure 11. DNA cleavage in the presence of NAPQI is mediated by 
topoisomerase IIα . Levels of DNA cleavage were quantified and expressed as 
a fold enhancement over reactions that were carried out in the absence of 
drug. Data for DNA alone (DNA) or with NAPQI (NAPQI) in the absence of 
enzyme are shown. DNA cleavage mediated by human topoisomerase IIa in 
the absence (TII–NAPQI) or presence (TII+NAPQI) of 100 µM NAPQI was 
examined. To determine whether the DNA cleavage observed in the presence 
of NAPQI was protein-linked, proteinase K treatment was omitted (-Pro K). 
Reversibility of reactions containing NAPQI was examined by adding EDTA 
prior to SDS treatment (+EDTA). Error bars represent the standard deviation 
of three independent experiments. 
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 To further examine the effects of NAPQI on DNA scission mediated by the 
human type II enzyme, singly end-labeled linear pBR322 plasmid was used as a 
substrate. This linear DNA allows cleavage to be monitored at the site-specific 
level. As seen in Figure 12, NAPQI increased DNA scission at every site cleaved 
by the enzyme in the absence of drug. It also, induced cleavage at a number of 
additional DNA sites. Levels of cleavage induced by 100 µM NAPQI were 
similar to those observed in reactions that contained 25 µM etoposide. This result 
is consistent with assays that employed negatively supercoiled plasmid substrate 
(see Figure 10). While the DNA sites cleaved by topoisomerase IIα in the 
presence of the two drugs were similar, site utilization differed. A number of 
sequences appeared to be preferentially cleaved when NAPQI was present in 
reactions. 
 Recent reports indicate that agents that are reactive toward protein 
sulhydryl groups increase levels of DNA breaks generated by human 
topoisomerase IIα when they are incubated with the enzyme in the presence of 
DNA (118, 195). A common characteristic of these “alkylating topoisomerase II 
poisons” is that they rapidly inactivate topoisomerase IIα when they are 
incubated with the enzyme in the absence of its DNA substrate (118). Since 
NAPQI is reactive toward protein sulhydryl groups and alkylates a number of 
proteins (34, 192), similar incubation studies were performed (Figure 13). NAPQI 
rapidly inactivated human topoisomerase IIα in the absence of DNA. Within one 
min, the enzyme lost ~90% of its DNA cleavage activity. These results suggest 
that the effects of NAPQI on the human enzyme may be due (at least in part) to a 
covalent modification of the protein.  
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Figure 12. DNA cleavage site utilization of human topoisomerase IIα in the 
presence of NAPQI. An autoradiogram of a polyacrylamide gel is shown. 
DNA cleavage reactions contained no drug (TII), 25 µM etoposide (TII+Etop), 
or 100 µM NAPQI (TII+NAPQI). A DNA control is shown in the far left lane 
(DNA). Data are representative of three independent assays. 
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Figure 13. NAPQI rapidly inactivates human topoisomerase IIα in the 
absence of DNA. Reaction mixtures were incubated in the absence (open 
circles) or presence of 100 µM NAPQI (closed circles) for 0 to 3 min prior to the 
addition of DNA. Levels of DNA cleavage in reaction mixtures that were not 
pre-incubated (i.e., time zero) were set to 100%. Error bars represent the 
standard deviation of three independent experiments. 
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 NAPQI Inhibits DNA Religation Mediated by Human Topoisomerase IIα.  
 Topoisomerase II poisons increase levels of enzyme-mediated DNA breaks 
by two non-mutually exclusive mechanisms. Whereas etoposide appears to act 
primarily by inhibiting the ability of topoisomerase II to religate DNA breaks, 
other poisons such as quinolones appear to act primarily by enhancing the 
forward rate of DNA scission (15, 16, 97, 98, 109, 196). 
 To determine the mechanistic basis for the actions of NAPQI against human 
topoisomerase IIα, the effects of the compound on enzyme-mediated religation 
were examined (Figure 14). The rate of religation in the presence of NAPQI was 
several–fold slower than observed in the absence of drug and approached levels 
of inhibition seen with etoposide (not shown). While the enzyme religated <15% 
of the cleaved DNA in 30 s in reactions that contained 25 µM NAPQI, the t1/2 
value for religation in the absence of drug was ~10 s. On the basis of these values, 
it is proposed that NAPQI increases levels of topoisomerase II-mediated DNA 
breaks primarily by inhibiting the ability of the enzyme to religate DNA. 
 
 NAPQI Inhibits DNA Strand Passage Catalyzed by Human Topoisomerase IIα.  
 A number of well characterized topoisomerase II poisons inhibit the overall 
catalytic activity of the enzyme (197-201). However, in many cases, the ability to 
increase DNA cleavage and inhibit overall catalytic activity require significantly 
different drug concentrations. This finding implies that different drug binding 
sites on topoisomerase II may be responsible for the two events. Therefore, to 
determine the relationship between cleavage enhancement and catalytic 
inhibition for NAPQI, the effects of the drug on topoisomerase II-catalyzed DNA 
relaxation were examined.  
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Figure 14. DNA religation mediated by human topoisomerase IIα is 
inhibited by NAPQI. DNA religation mediated by topoisomerase IIα was examined 
in the absence of drug (open circles), or in the presence of 25 µM NAPQI (closed 
circles). Samples were incubated at 37 ˚C to establish DNA cleavage/religation 
equilibria and were then shifted to 0 ˚C to initiate religation. The amount of DNA 
cleavage observed at equilibrium for each drug was set to 100% at time zero. DNA 
ligation was quantified by the loss of linear cleaved molecules. Points represent the 
average of three independent experiments. 
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 NAPQI was a strong inhibitor of DNA relaxation catalyzed by human 
topoisomerase IIα. When catalytic levels of the enzyme (~5 nM) were employed 
in assays, 50% inhibition was observed at nearly stoichiometric levels of NAPQI 
(~5 nM) (not shown). In order to compare results of catalytic and DNA cleavage 
assays directly, relaxation was carried out using the same concentration of 
topoisomerase IIα that was utilized for DNA scission (~135 nM). Short time 
courses (30 s) and low ATP concentrations (250 µM) were employed in these 
latter experiments so that inhibition could be monitored accurately. As seen in 
Figure 15, 50% inhibition of DNA relaxation at high topoisomerase IIα 
concentrations was observed at ~1.5 µM NAPQI. This drug concentration is as 
compared to the ~15 µM NAPQI that was required to enhance DNA cleavage to 
50% of its maximal value. These results suggest that the inhibition of overall 
catalytic activity and the stimulation of DNA cleavage by NAPQI may be due to 
separate events. 
 
 NAPQI is a Topoisomerase II Poison in Cultured Human Cells.  
 The ICE bioassay was employed to determine whether NAPQI affects levels 
of DNA cleavage mediated by topoisomerase IIα in cultured human CEM cells. 
In this assay, cells are lysed with an ionic detergent, and proteins that are 
covalently attached to genomic DNA are separated from free proteins by 
sedimentation through a CsCl cushion. The pelleted DNA from cultures treated 
with no drug, 50 or 100 µM NAPQI, or 10 µM etoposide (for comparison) was 
blotted and probed with a polyclonal antibody specific for human topoisomerase 
IIα. As seen in Figure 16, levels of topoisomerase IIα that were covalently  
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Figure 15. NAPQI inhibits the overall catalytic activity of topoisomerase IIα . 
DNA relaxation reactions catalyzed by topoisomerase IIα were carried out for 
30 s in the presence of 0-25 µM NAPQI. DNA relaxation was quantified by the 
disappearance of negatively supercoiled DNA substrate. Error bars represent 
the standard deviation of three independent experiments.  The inset shows an 
ethidium bromide-stained agarose gel of DNA relaxation reactions carried out 
in the presence of 0-25 µM NAPQI. A lane containing DNA in the absence of 
enzyme (DNA) is shown as a control. The mobilities of negatively supercoiled 
DNA (form I, FI) and nicked circular plasmid (form II, FII) are indicated. 
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Figure 16. NAPQI enhances human topoisomerase IIα-mediated DNA 
cleavage in treated human CEM cells. The ICE bioassay was used to monitor 
the level of cleavage complexes in cells treated with NAPQI. DNA (10 µg) 
from cultures treated with no drug, 50 or 100 µM NAPQI, or 10 µM etoposide 
was blotted onto a nitrocellulose membrane. Blots were probed with a 
polyclonal antibody directed against human topoisomerase IIα. Results are 
representative of two independent experiments. 
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attached to DNA following treatment with NAPQI increased several–fold over 
the drug-free control.  
 It should be noted that some cleavage-independent topoisomerase IIα-DNA 
crosslinking was observed in vitro in DNA cleavage assays that contained 
NAPQI. Therefore, it is possible that a portion of the covalent topoisomerase IIα-
DNA complex observed in NAPQI-treated CEM cells actually reflects protein-
DNA crosslinking rather than enzyme-mediated DNA scission. However, the 
topoisomerase IIα:DNA base pair ratio (~1:325) used in the in vitro cleavage 
assays was >20 times higher than estimated (~1:7500) for CEM cells (202). When 
in vitro experiments were carried out using topoisomerase IIα:DNA base pair 
ratios that approximated the cellular condition, no significant protein:DNA 
crosslinking was observed (not shown). Therefore, it is likely that NAPQI acts as 
a topoisomerase II poison in cultured human cells. 
 
 Acetaminophen Does Not Compete with Etoposide for Human Topoisomerase IIα. 
  Acetaminophen does not significantly increase enzyme-mediated DNA 
cleavage in vitro (see Figure 10). However, it still is possible that the drug 
interacts with topoisomerase IIα at the same site as anticancer agents such as 
etoposide, but does not induce DNA cleavage. Such is the case for the 
antibacterial quinolone ciprofloxacin. This drug targets prokaryotic type II 
topoisomerases and has little effect on DNA scission mediated by the eukaryotic 
enzyme (198, 203, 204). However, ciprofloxacin competes with etoposide and 
several other anticancer drugs, blocking their ability to increase DNA cleavage 
by topoisomerase II (204).  
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 Considering the wide use of products that contain acetaminophen, it is 
important to know whether this drug alters the efficacy of topoisomerase II-
targeted chemotherapeutic agents. Therefore, two experiments were carried out 
to determine the effects of acetaminophen on the actions of etoposide against 
human topoisomerase IIα. First, an in vitro competition assay was performed. In 
this assay, etoposide (25 µM) was mixed with acetaminophen (0–500 µM) and 
then added to a topoisomerase IIα-DNA complex. Even at a concentration of 500 
µM acetaminophen (which is 3–5 times higher than the upper range of the 
normal non-toxic dose found in blood), no decrease in etoposide-induced DNA 
cleavage was observed (Figure 17). Therefore, if acetaminophen interacts with 
topoisomerase IIα at all, it probably does not interact with the binding site 
utilized by anticancer drugs such as etoposide. 
 Second, ICE bioassays were performed to examine the effects of 
acetaminophen on covalent topoisomerase IIα-DNA complexes in human CEM 
cells. As seen in Figure 17, no increase in complex formation was observed in the 
presence of 150 µM acetaminophen (the upper limit for non-toxic drug doses). 
Furthermore, pre-incubation of cells with 150 µM acetaminophen had no effect 
on levels of topoisomerase IIα-DNA complexes that were induced by 10 µM 
etoposide. Thus, it appears that normal therapeutic doses of acetaminophen do 
not significantly interfere with the actions of etoposide on topoisomerase IIα in 
treated cells. 
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Figure 17. Acetaminophen does not interfere with the ability of etoposide to 
increase DNA cleavage mediated by human topoisomerase IIα in vitro and 
cultured human cells. Left: An ethidium bromide-stained agarose gel of DNA 
cleavage reactions carried out in the presence of 25 µM etoposide and 0-500 
µM acetaminophen is shown. Reactions containing DNA in the absence 
(DNA) or presence of topoisomerase IIα (Topo II), but in the absence of drugs 
are shown as controls. Levels of DNA cleavage were quantified and expressed 
as a fold enhancement over reactions that contained no acetaminophen. Error 
bars represent the standard deviation of three independent experiments. 
Right: The ICE bioassay was used to monitor the level of cleavage complexes 
in cells. DNA (10 µg) from cultures treated with no drug, 150 µM 
acetaminophen, 10 µM etoposide or 150 µM acetaminophen plus 10 µM 
etoposide was blotted onto a nitrocellulose membrane. Blots were probed with 
a polyclonal antibody directed against human topoisomerase IIα. Results are 
typical of two independent experiments. 
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Discussion 
 Although acetaminophen is the most widely used analgesic in the world, it 
causes hepatotoxicity if ingested in doses that are beyond its normal therapeutic 
window (34, 179-182, 184-187). Acetaminophen-induced liver damage also can 
occur if the organ has been compromised by previous insults (185-187, 189, 190). 
All of the harmful effects of acetaminophen have been attributed to its reactive 
metabolite, NAPQI (185-187, 194). This compound induces DNA strand breaks 
and other genotoxic events in a variety of treated cells and also promotes 
apoptosis and necrosis (33, 34, 191). Results of the present study indicate that 
NAPQI is a potent poison of human topoisomerase IIα and induces enzyme-
mediated double-stranded DNA breaks approximately half as well as etoposide, 
a widely prescribed anticancer drug.  
Relationships between the enhanced topoisomerase IIα-mediated DNA 
cleavage and the cytotoxic/genotoxic effects of NAPQI are not known. However, 
exposure of cells to topoisomerase II poisons causes DNA strand breaks and 
many of the other cytotoxic/genotoxic events seen following NAPQI treatment 
(11-17, 109). While NAPQI reacts with a number of proteins in vivo and induces 
oxidative damage in cells (34), the present findings are consistent with a role for 
topoisomerase IIα in mediating the toxicity of this acetaminophen metabolite. 
 It is presumed that NAPQI increases levels of cellular DNA cleavage by 
human topoisomerase IIα by a mechanism that involves the direct interaction of 
the compound with the enzyme-DNA complex. However, NAPQI-treatment also 
generates DNA adducts in cells by inducing oxidative stress (34). Many of these 
adducts enhance topoisomerase II-mediated DNA cleavage, or are converted to 
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abasic sites, which are strong topoisomerase II poisons (119, 120, 122, 161, 205-
208). Therefore, it is possible that some of the increase in enzyme-mediated DNA 
scission that is observed following cellular exposure to NAPQI results from an 
interaction of topoisomerase IIα with drug-induced DNA damage. 
 As determined by experiments carried out in vitro or in cultured human 
cells, acetaminophen does not significantly raise levels of DNA cleavage 
generated by topoisomerase IIα. Furthermore, it does not antagonize the 
poisoning effects of etoposide. Therefore, normal doses of acetaminophen should 
neither cause topoisomerase II-mediated DNA damage, nor decrease the efficacy 
of topoisomerase II-based cancer chemotherapy.  
 Structural changes between acetaminophen and NAPQI (i.e., the loss of two 
hydrogen molecules; see Figure 9) are relatively minor. The primary difference 
between the two compounds is related to their chemical reactivity. While 
hydroquinones (i.e., acetaminophen) are relatively inert toward proteins, 
quinones (i.e., NAPQI) are very reactive toward protein sulfhydryl groups and 
other residues (34). Recent work suggests that thiolation agents enhance 
topoisomerase II-mediated DNA scission (118, 195). Therefore, it is possible that 
NAPQI alkylation of topoisomerase IIα plays a role in stabilizing DNA cleavage 
complexes. 
 In summary, exposure to NAPQI increases levels of DNA cleavage mediated 
by topoisomerase IIα in vitro and in cultured cells. These findings suggest that at 
least some of the cytotoxic/genotoxic effects caused by acetaminophen overdose 
may be mediated by the actions of NAPQI as a topoisomerase II poison. 
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CHAPTER IV 
 
POLYCHLORINATED BIPHENYL QUINONE METABOLITES POISON 
HUMAN TOPOISOMERASE IIα: ALTERING ENZYME FUNCTION BY 
BLOCKING THE N-TERMINAL PROTEIN GATE 
 
 
Introduction 
 Polychlorinated biphenyls (PCBs) represent a class of compounds with two 
aromatic six-member rings that contain from one to ten chlorine atoms (209, 210). 
These chemicals were employed in a variety of large-scale industrial applications 
from the 1930s to the 1970s (209-211). For example, PCBs were used as organic 
diluents, lubricants, and cooling fluids, and were commonly utilized in the 
production of adhesives, paper, pesticides, and flame retardants. One of the 
properties that made PCBs so attractive for industrial purposes was their high 
stability and low biodegradability (209, 211). As a result, however, these 
compounds accumulated in the environment. Due to human health concerns, 
most countries banned the production and use of PCBs in the 1970s (209, 211). 
Three decades later, these compounds remain persistent environmental 
contaminants (209, 211-213). 
  Exposure to PCBs is associated with a broad spectrum of human health 
problems, including neurotoxicity, hepatotoxicity, hypothyroidism, and 
immunodeficiency (209, 211, 214, 215). PCBs are complete carcinogens in rodents 
and display genotoxic activity in vitro and in vivo (35, 36). For example, in 
laboratory studies, these compounds induce chromosomal aberrations and sister 
chromatid exchanges in cultured human lymphocytes (216). Similar 
chromosomal abnormalities have been found in the peripheral lympocytes of 
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workers who were occupationally exposed to PCBs, with longer exposures 
correlating with greater DNA damage (217, 218). Finally, PCBs cause liver cancer 
in mice and rats and are listed by the Environmental Protection Agency as 
probable human carcinogens (209, 215, 219). 
 The underlying basis for the chromosomal damage induced by PCBs is not 
understood. However, it is believed that these compounds do not trigger DNA 
damage directly. Rather, they act through a series of phenolic and quinone-based 
metabolites (162, 220-223). It has been proposed that the generation of reactive 
oxygen species by redox cycling, the depletion of glutathione by adduction, or 
the generation of DNA lesions by oxidation may play a role in chromosome 
damage (162, 220-223). In addition, PCB quinone metabolites form protein 
adducts through cysteine residues in treated cells (223). The specific cellular 
proteins that are modified by these compounds are not well characterized. 
However, the genotoxic effects of PCBs are consistent with the actions of 
topoisomerase II poisons and a previous study found that these compounds 
inhibited enzyme-catalyzed DNA decatenation (223). Since the genotoxic events 
triggered by PCBs resemble those of topoisomerase II poisons, the effects of a 
variety of quinone and hydroquinone PCB metabolites on human topoisomerase 
IIα were examined.  
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Results 
 
 PCB Metabolites Enhance DNA Cleavage Mediated by Human Topoisomerase IIα.  
  The PCB metabolites used in the present study are shown in Figure 18. The 
compounds were either mono- or di-chlorinated, and included a series of p-
quinones and o-quinones, as well as a p-hydroquinone. 
 All of the quinone-based PCB metabolites increased DNA cleavage 
mediated by topoisomerase IIα greater than 4–fold (Figure 19). As seen in the left 
panel, 4’Cl-2,5pQ was equipotent to etoposide and increased cleavage ~8–fold. 
On the basis of titrations from 0–200 µM metabolites (not shown), levels of 
cleavage enhancement plateaued at ~100 µM for all of the quinones examined. In 
contrast to 4’Cl-2,5pQ, which was the most active quinone metabolite, the 
corresponding hydroquinone conger, 4’Cl-2,5HQ, displayed very little activity 
against topoisomerase IIα. No significant increase in DNA scission was observed 
up to 200 µM 4’Cl-2,5HQ (Figure 19, left panel). These results strongly suggest 
that PCB quinones are potent topoisomerase II poisons in vitro, but that PCB 
hydroquinones are far less active against the enzyme.  
 Since 4’Cl-2,5pQ was the most active metabolite, it was used as the “model” 
quinone for control experiments designed to determine whether the enhanced 
DNA cleavage induced by PCB metabolites was mediated by topoisomerase IIα 
(Figure 20). First, no linear DNA was observed in reactions that contained 100 
µM 4’Cl-2,5pQ, but lacked enzyme. Second, the electrophoretic mobility of the 
cleaved DNA (i.e., the linear band) was dramatically reduced in the absence of 
proteinase K treatment, indicating that all of the cleaved plasmid molecules were 
covalently attached to topoisomerase IIα. Third, scission was reversed when  
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Figure 18. Structures of PCB metabolites. 
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Figure 19. PCB metabolites stimulate DNA cleavage mediated by human 
topoisomerase IIα . Levels of DNA cleavage were quantified and expressed as 
a fold enhancement over reactions that were carried out in the absence of 
metabolites. Cleavage titrations are shown in the left panel. Reaction mixtures 
contained 0–200 µM 4’Cl-2,5pQ (open squares), or 4’Cl-2,5HQ (closed 
squares). A parallel titration with etoposide (open circles) is shown as a 
control. Relative DNA cleavage enhancement induced by 100 µM PCB 
metabolites is shown in the right panel. Error bars represent the standard 
deviation of at least three independent experiments. 
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Figure 20. DNA cleavage induced by PCB metabolites is mediated by 
topoisomerase IIα . An ethidium bromide-stained agarose gel of DNA 
cleavage reactions is shown. DNA controls lacking enzyme were in the 
absence (DNA) or presence of 4’Cl-2,5pQ (4’Cl-2,5pQ + DNA). DNA cleavage 
mediated by human topoisomerase IIα in the absence (Topo II) or presence 
(4’Cl-2,5pQ) of 100 µM 4’Cl-2,5pQ was examined. To determine whether the 
DNA cleavage observed in the presence of 4’Cl-2,5pQ was protein-linked, 
proteinase K treatment was omitted (-Pro K). Reversibility of reactions 
containing 4’Cl-2,5pQ was examined by adding EDTA prior to SDS treatment 
(EDTA). The electrophoretic mobilities of negatively supercoiled DNA (form I, 
FI), nicked circular plasmid (form II, FII), and linear molecules (form III, FIII) 
are indicated. Data are representative of two independent assays. 
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EDTA was added to reaction mixtures before cleavage complexes were trapped 
by the addition of SDS. This reversibility is inconsistent with a non-enzymatic 
reaction. Taken together, the above findings provide strong evidence that PCB 
quinones increase DNA cleavage through an enzyme-mediated reaction. 
 Previous studies suggest that quinones alter the activity of topoisomerase 
IIα by covalently modifying the enzyme (1, 118, 223). This is the primary reason 
why quinones are believed to be more active toward the enzyme than 
hydroquinones (117, 223). If protein adduction plays an important role in the 
actions of PCB metabolites, once a quinone has modified topoisomerase IIα, it 
should not be able to dissociate from the enzyme. Therefore, order-of-addition 
experiments were carried out to address the effects of the reducing agent DTT on 
the actions of 4’Cl-2,5pQ (Figure 21). As expected, no enhancement of enzyme-
mediated DNA scission was observed when 100 µM quinone was incubated with 
500 µM DTT prior to its addition to the topoisomerase IIα-DNA complex. 
Conversely, once a cleavage complex was established in the presence of 4’Cl-
2,5pQ, DTT had no effect on the enhancement of DNA scission. In control 
experiments, DTT did not significantly alter levels of DNA cleavage mediated by 
topoisomerase IIα in the absence of the quinone (Figure 21) or in the presence of 
the anticancer drug etoposide (which does not form a covalent protein adduct, 
not shown) (1, 118, 223). These findings indicate that PCB metabolites increase 
DNA strand breaks generated by topoisomerase IIα by forming covalent adducts 
with the enzyme. 
 Quinones can undergo enzyme dependent redox cycling to generate free 
radicals that damage nucleic acids (114, 222). In addition, some biologically 
relevant quinones can form adducts with DNA (30, 114, 220, 224). Since many  
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Figure 21. Effects of reducing agents on the ability of 4’Cl-2,5pQ to enhance 
DNA cleavage mediated by human topoisomerase IIα. A representative 
ethidium bromide-stained agarose gel is shown. The DNA substrate is shown 
as a control in lane 1. Reactions were carried out in the absence (lanes 2-4) or 
presence of 100 µM 4’Cl-2,5pQ (lanes 5-7). Reactions contained no reducing 
agent (-, lanes 1, 2 and 5), 500 µM DTT that was added to reaction mixtures 
after topoisomerase II-DNA cleavage complexes were established (post, lanes 
3 and 6), or 500 µM DTT that was incubated with 4’Cl-2,5pQ prior to the 
addition of the quinone to cleavage reactions (pre, lanes 4 and 7). The 
mobilities of supercoiled (FI), nicked circular (FII), and linear (FIII) DNA 
molecules are as in Figure 20. Results are representative of four independent 
experiments. 
 72 
DNA lesions have been shown to poison human topoisomerase IIα (121, 122, 124, 
126, 161, 207), it is possible that the enhancement of DNA scission by the PCB 
metabolites is due to a modification of the plasmid substrate. To address this 
issue, 100 µM 4’Cl-2,5pQ was incubated with negatively supercoiled pBR322 for 
6 min, but removed by gel filtration prior to the addition of the enzyme. No 
enhancement of DNA cleavage was observed under these conditions (data not 
shown). Thus, modification of DNA does not appear to contribute to the effects 
of PCB metabolites on topoisomerase IIα. 
 To determine the effects of PCB metabolites on the DNA cleavage site 
specificity of topoisomerase IIα, a singly end-labeled fragment of pBR322 was 
used as the substrate. This 4330 bp linear DNA allows cleavage to be monitored 
at specific sites. Four of the quinone metabolites were used for cleavage 
mapping, including both mono- and di-chlorinated p-quinones. All of them 
increased topoisomerase IIα-mediated DNA scission at a number of distinct 
sequences (Figure 22). As determined by visual inspection, the quinones 
displayed DNA cleavage site specificities that were identical to one another, but 
differed significantly from that of etoposide. Furthermore, strong sites of 
cleavage enhancement appeared to correspond to sites cut by topoisomerase IIα 
in the absence of poisons. This finding suggests that PCB quinones may be acting 
distal to the active site of the enzyme, since drugs that act at the scissile bonds 
generally alter cleavage site utilization by topoisomerase II (225). Consistent with 
the global DNA cleavage data, 4’Cl-2,5HQ had little effect on enzyme-mediated 
DNA scission and yielded a cleavage pattern that was similar to that of the 
topoisomerase IIα control (Figure 22).  
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Figure 22. DNA cleavage site utilization by human topoisomerase IIα in the 
presence of PCB metabolites. An autoradiogram of a polyacrylamide gel is 
shown. DNA cleavage reactions contained no compound (Topo II), 12.5 µM 
etoposide, or 25 µM of the indicated PCB. A DNA control is shown in the far 
left lane. Data are representative of at least three independent experiments. 
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 PCB Quinones Inhibit DNA Religation Mediated by Human Topoisomerase IIα. 
 Topoisomerase II poisons increase levels of enzyme-mediated DNA breaks 
by two non-mutually exclusive mechanisms (10, 15, 16, 109). Drugs such as 
etoposide act primarily by inhibiting the ability of topoisomerase IIα to religate 
DNA breaks (97, 226). In contrast, drugs such as quinolones have little effect on 
strand rejoining and appear to act primarily by increasing the forward rate of 
DNA scission (98, 227).  
 To determine the mechanism by which PCB metabolites increase levels of 
topoisomerase II-generated DNA strand breaks, their effects on rates of 
religation mediated by human topoisomerase IIα were assessed (Figure 23). All 
of the PCB quinones examined strongly inhibited the ability of the enzyme to 
reseal cleaved DNA molecules, suggesting that this inhibition is the primary 
mechanism by which these compounds increase levels of topoisomerase II-DNA 
cleavage complexes. Considerably less inhibition was seen for 4’Cl-2,5HQ. 
 
 Exposure of Topoisomerase IIα to PCB Quinones in the Absence of DNA Inhibits 
Enzyme Activity.  
 
 Although quinones act as topoisomerase II poisons when incubated with 
enzyme-DNA complexes, several studies indicate that they are potent inhibitors 
of enzyme activity when incubated with human topoisomerase IIα prior to the 
addition of DNA (1, 118, 155). It is not known whether these two properties of 
quinones share a common basis for action. 
 To determine whether PCB metabolites also display inhibitory properties, 
these compounds were incubated with topoisomerase IIα in the absence of DNA 
and their effects on enzyme-mediated DNA cleavage were characterized. As seen  
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Figure 23. DNA religation mediated by human topoisomerase IIα is 
inhibited by PCB metabolites. Left panel: DNA religation was examined in 
the absence of compound (none, closed circles), or in the presence of 100 µM 
etoposide (open circles), 100 µM 4’Cl-2,5pQ (open squares) or 100 µM 4’Cl-
2,5HQ (closed squares). Right panel: Representative religation data for PCB 
metabolites at 10 s. In all cases, samples were incubated at 37 ˚C to establish 
DNA cleavage/religation equilibria and were then shifted to 0 ˚C to initiate 
religation. Levels of DNA cleavage observed at equilibrium were set to 100% 
at time zero. DNA religation was quantified by the loss of linear cleaved 
molecules. Error bars represent the standard deviation of at least three 
independent experiments.of at least three independent experiments. 
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in Figure 24, exposure of topoisomerase IIα to PCB quinones prior to the addition 
of plasmid rapidly decreased the ability of the enzyme to cleave DNA. Inhibition 
by all of the quinones (at 100 µM) was nearly complete within 30 s. In contrast, 
no inhibition was observed following a 3 min exposure to etoposide. While 
incubation with 4’Cl-2,5HQ decreased DNA cleavage, the rate of inhibition was 
substantially slower than observed with the corresponding quinone. Taken 
together, these results indicate that PCB metabolites, like other quinone-based 
compounds (1, 118, 223) and ICRF-193 (which acts by trapping the N-terminal 
protein clamp of topoisomerase II) (228), are mixed function inhibitors of 
topoisomerase IIα. When incubated with the enzyme-DNA complex, they act as 
topoisomerase II poisons; when incubated with the enzyme in the absence of a 
nucleic acid substrate, they block topoisomerase II function. 
 
 Exposure of Topoisomerase IIα to PCB Quinones Prior to the Addition of DNA 
Inhibits the Binding of the Enzyme to Circular Plasmid Substrates.  
 
 As a first step toward defining the mechanism by which incubation of PCB 
quinones with topoisomerase IIα in the absence of DNA impairs enzyme activity, 
the effects of these compounds on enzyme-DNA binding was assessed. Initial 
experiments utilized negatively supercoiled circular plasmids as substrates. 
Exposure of topoisomerase IIα to several p-quinones (at 100 µM) sharply 
decreased the formation of non-covalent enzyme-DNA complexes (Figure 25, left 
top panel and bottom summary panel). In contrast, equivalent concentrations of 
etoposide or 4’Cl-2,5HQ had no significant affect on binding. 
 Additional experiments examined the effects of PCB metabolites on the 
binding of topoisomerase IIα to linear plasmids. Similar patterns were observed  
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Figure 24. PCB metabolites rapidly inactivate human topoisomerase IIα in 
the absence of DNA. PCB metabolites were incubated with the enzyme prior 
to the addition of DNA and the effects of these compounds on enzyme activity 
were assessed by DNA cleavage assays. Left panel: Time course for the 
incubation of topoisomerase IIα with no compound (closed circles), 100 µM 
etoposide (open circles), 100 µM 4’Cl-2,5pQ (open squares) or 100 µM 4’Cl-
2,5HQ (closed squares). Right panel: Representative values for PCB 
metabolites at 30 s. Levels of DNA cleavage for reactions in which metabolites 
and DNA were added simultaneously (i.e., time zero) were set to 1.0. Error 
bars represent the standard deviation of at least three independent 
experiments. 
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Figure 25. Substrate-dependent effects of PCB metabolites on 
topoisomerase IIα-DNA binding. Assays employed a negatively supercoiled 
circular plasmid (top left panel), a linear plasmid (top middle panel), or a 
duplex 50-mer oligonucleotide (top right panel) as the substrate. For 
experiments that used the circular plasmid, 0-400 nM enzyme was incubated 
with no compound (none), 100 µM etoposide, or 100 µM PCB metabolite for 5 
min prior to the addition of DNA. For assays that used linear substrates 
(linear plasmid or the 50-mer), 400 nM enzyme was incubated with no 
compound, 100 µM etoposide, or 100 µM PCB metabolite for 0–5 min prior to 
the addition of DNA. The bottom summary panel is a representative graph 
including all three substrates in assays carried out under identical reaction 
conditions (exposure of 400 nM enzyme to compounds for 5 min prior to the 
addition of DNA). Error bars represent the standard deviation of at least three 
independent experiments 
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with the linear substrate; however, the decrease in binding was less dramatic 
(Figure 25, center top panel and bottom summary panel). In general, the 
inhibition observed with linear DNA was ~1/2 that seen with circular substrates.  
 The linear plasmid substrates were >4,300 bp in length. To further 
investigate the differences seen between linear and circular substrates, the effects 
of PCB metabolites on the ability of topoisomerase IIα to bind short DNA 
fragments was examined. The substrate used for these experiments was a duplex 
50-mer that contained a DNA cleavage site for the human enzyme (173). As seen 
in Figure 25 (right top panel and bottom summary panel), exposure of 
topoisomerase IIα to PCB quinones prior to the addition of DNA had no 
substantial effect on the ability of the enzyme to bind the oligonucleotide.  
 In summary, PCB quinones sharply impair the binding of topoisomerase IIα 
to circular DNA substrates, display a smaller effect on the binding to linear 
molecules, and have no effect on the binding to oligonucleotides. These findings 
are not consistent with the idea that quinones adduct an amino acid residue in 
the active site of topoisomerase IIα. Rather, as discussed below, they suggest that 
the compounds may alter enzyme function by affecting the N-terminal gate of 
topoisomerase II.  
 
 4’Cl-2,5pQ Blocks the N-Terminal Protein Gate of Human Topoisomerase IIα.  
 During the catalytic cycle of type II topoisomerases, the “T-helix” (i.e., the 
DNA helix that is “transported” through the transient double-stranded break 
that the enzyme generates in a separate helix) enters the protein through a gate 
that is comprised of the N-terminal domains of the two protomer subunits of the 
enzyme (15, 16, 57, 58, 109). Upon ATP binding, topoisomerase II undergoes a 
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conformational change that closes the N-terminal gate and induces passage of 
the T-helix through the DNA break (15, 16, 57-59, 65, 109). Formation of this N-
terminal clamp does not allow the T-helix to exit the protein through the original 
gate (15, 16, 57-59, 65, 109, 229, 230). Thus, it promotes a unidirectional strand 
passage event (59). In addition, clamp closure does not allow a second T-helix to 
enter the enzyme through the N-terminal gate until the strand passage event is 
completed and the first T-helix has exited topoisomerase II through a C-terminal 
gate (15, 16, 57-59, 109, 229, 230). 
 Closure of the N-terminal gate in the presence of DNA results in the 
formation of a protein clamp that topologically encircles the DNA, forming a 
non-covalent, but salt-stable complex with circular nucleic acids (65, 229). If the 
gate is closed prior to the addition of DNA, circular nucleic acids are prevented 
from entering the active site of topoisomerase II (229). Linear DNA molecules, 
however, are still able to access the active site by feeding directly through the 
central annulet of the enzyme (65, 229). As discussed above, treatment of 
topoisomerase IIα with PCB quinones prior to the addition of DNA inhibits the 
binding of circular plasmid, but has a distinctly lesser effect with linear plasmid 
or oligonucleotide substrates. Since this finding is consistent with an effect on the 
N-terminal clamp, the ability of 4’Cl-2,5pQ and 4’Cl-2,5HQ to induce clamp 
closure was examined.  
 In order to assess clamp closing, topoisomerase IIα was incubated with 
negatively supercoiled plasmid and the mixture was applied to a glass fiber 
filter. In the absence of a stable protein clamp, circular DNA (which does not 
bind to glass fibers) passes through the filter in the flow through, low salt (LS), or 
high salt (HS) washes. Alternatively, DNA trapped by stable protein clamps is 
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eluted from the filter only after denaturation of the enzyme with SDS (Figure 26, 
inset). 
 Previously, stable clamps have been observed for wild-type human 
topoisomerase IIα only in the presence of a non-hydrolyzable ATP analog or in 
the presence of ICRF-193 and ATP (65, 229, 230). Similar results were seen in the 
present study (Figure 26, left panel). Less than 3% of the circular plasmid 
substrate formed a salt-stable complex with the enzyme in the absence of an ATP 
analog, while ~10% did so in the presence of 100 µM ICRF-193 and ATP. 
Remarkably, when 100 µM 4’Cl-2,5pQ was incubated with a mixture of 
topoisomerase IIα and DNA, even in absence of ATP, ~20% of the initial plasmid 
substrate formed a salt-stable non-covalent complex with the enzyme (left panel). 
In a set of parallel experiments, ~8% of the plasmid formed a salt-stable complex 
following incubation with 100 µM 4’Cl-2,5HQ. Finally, incubation of 
topoisomerase IIα with 100 µM 4’Cl-2,5pQ prior to the addition of DNA reduced 
the formation of salt-stable complex by nearly 10–fold (right panel). Taken 
together, the above results strongly suggest that exposure of topoisomerase IIα to 
PCB quinones blocks the N-terminal protein gate even in the absence of a high-
energy cofactor.  
 
 4’Cl-2,5pQ Crosslinks the Subunits of Topoisomerase IIα.  
 Data shown in Figure 21 indicate that PCB quinones alter the activity of 
topoisomerase IIα by covalently adducting the enzyme. Adduction results in the 
formation of a covalent bond between the sulfhydryl (or other amino acid group 
such as an amine) and one of the hydrogenated carbons on the quinone ring (231, 
232).  
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Figure 26. 4’Cl-2,5pQ blocks the N-terminal gate of human topoisomerase 
IIα. Filter binding assays were used to analyze the salt-stable closed-clamp of 
topoisomerase II. Reactions contained no compound (None), 100 µM 4’Cl-
2,5pQ or 100 µM 4’Cl-2,5HQ in the absence of ATP, or 100 µM ICRF-193 + 2 
mM ATP. DNA eluted from filters after sequential low salt (LS), high salt 
(HS), or SDS (SDS) washes was subjected to electrophoresis in an agarose gel. 
Salt-stable non-covalent enzyme-DNA complexes were quantified by the 
amount of plasmid that did not elute until the SDS wash relative to the total 
plasmid eluted in all three washes. Left panel: Compounds were incubated 
with topoisomerase IIα after the addition of plasmid (POST). Right panel: 4’Cl-
2,5pQ was incubated with enzyme prior to the addition of plasmid (PRE). 
Error bars represent the standard deviation of four independent experiments. 
A representative ethidium bromide-stained agarose gel is shown in the inset 
in the left panel. 
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 Quinone compounds are capable of crosslinking proteins in the cell (231, 233, 
234). Previous studies demonstrate that benzoquinone (and derivatives), as well 
as PCB quinones, are capable of adducting to more than one sulfhydryl group 
(223, 231). To this point, a single molecule of 2’Cl-2,5pQ has been shown to 
adduct to three separate glutathione molecules, one at each of the compounds 
electrophilic sites (223) (see Figure 28E). Thus, the PCB quinones shown in Figure 
1 are able to act as protein crosslinking agents.  
 Therefore, three possible mechanisms are consistent with the actions of PCB 
quinones (Figure 27). First, covalent modification of topoisomerase IIα by 
quinones may induce the N-terminal gate to close in a manner that is similar to 
that observed in the presence of ATP (model A). While this model is formally 
possible, it should be noted that clamp closure in the absence of a nucleotide 
cofactor has not been reported (65, 229, 230). Second, quinones may adduct 
residues above the position where the T-segment normally rests prior to strand 
passage and sterically block entrance or exit of the helix (model B). However, 
since there are no reported structures of topoisomerase IIα with an intact, but 
open, N-terminal gate, it is not known whether PCB metabolites or other 
quinones would have enough bulk to act in this fashion. Third, PCB quinones 
may crosslink the two protomers of topoisomerase IIα, thereby blocking the N-
terminal gate of the protein (model C).  
 To help distinguish between these three models, the ability of 4’Cl-2,5pQ to 
crosslink the two subunits of human topoisomerase IIα was assessed (Figure 28A 
and B). Following incubation with the PCB quinone, a distinct new protein band 
appeared with an apparent molecular mass of ~330 kDa. This mass is 
approximately twice that of the protomer molecular mass of topoisomerase IIα  
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Figure 27. Models for how PCB Quinones block the N-terminal gate of 
human topoisomerase IIα. (A) PCB quinones induce natural clamp closure of 
the enzyme as seen with ATP (above).  (B) PCB quinones adduct to positions 
above the T-segment that sterically block entrance or exit of the helix.  (C) PCB 
quinones crosslink the two protomers of human topoisomerase IIα. 
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Figure 28. 4’Cl-2,5pQ crosslinks the protomer subunits of human 
topoisomerase IIα. Panel A shows a coumassie-stained denaturing 
polyacrylamide gel in which 135 nM topoisomerase IIα was treated 100 µM 
4’Cl-2,5pQ for 0–2 min. The mobility of a topoisomerase IIα subunit monomer 
and dimer is indicated as well as the origin of the gel. The gel is representative 
of two independent experiments. Panel B quantifies the loss of the monomeric 
topoisomerase IIα subunit over time as a result of crosslinking by 4’Cl-2,5pQ. 
Data were derived from the gel shown in Panel A and a parallel experiment. 
Error bars represent the standard error of the mean for these two experiments.  
Panel C displays a partial proteolytic map of topoisomerase IIα following 
exposure to 100 µM 4’Cl-2,5pQ over time. A silver-stained polyacrylamide gel 
that is representative of four independent experiments is shown. Arrows 
indicate specific polypeptide bands that diminished following exposure to the 
PCB quinone. Panel D quantifies the formation of SDS-stable dimers when 80–
800 nM topoisomerase IIα was treated with 100 µM 4’Cl-2,5pQ for 1 min.  
Error bars represent the standard deviation of four independent experiments. 
Panel E shows a coumassie-stained denaturing polyacrylamide gel in which 
135 nM topoisomerase IIα was treated with no compound (None), 100 µM 
4’Cl-2,5pQ, or 250 µM plumbagin for 6 min. Structures of both compounds are 
shown with sites of potential protein adduction marked by asterisks. The gel 
is representative of two independent experiments. 
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(170 kDa), suggesting that two subunits of the protein were crosslinked in the 
presence of 4’Cl-2,5pQ. Partial proteolytic mapping experiments demonstrated 
that specific topoisomerase IIα peptides were crosslinked by the quinone (Figure 
28C). These results favor model C. 
 In addition to the dimer band, an apparent high molecular weight protein 
species was observed at the origin at incubation times of 1 min or longer (Figure 
28A). After a 6 min exposure to 100 µM 4’Cl-2,5pQ, most of the enzyme 
remained at the origin (Figure 28E). It is notable that this protein species was 
soluble and did not precipitate upon centrifugation. Consequently, the protein at 
the origin does not appear to be an insoluble aggregate and is believed to 
represent a high molecular species that is too large to effectively enter the gel. 
Thus, it appears that the quinone is able to establish crosslinks between different 
topoisomerase IIα homodimers (i.e., intermolecular crosslinks).  
 If model C is correct, however, 4’Cl-2,5pQ must be able to crosslink the two 
promoter subunits of an individual enzyme homodimer (i.e., intramolecular 
crosslink). Therefore, dilution experiments (from 800 down to 80 nM 
topoisomerase IIα) were carried out to determine whether the 330 kDa band 
resulted from an inter- or intramolecular crosslinking event. If the 330 kDa band 
arose from crosslinking of two separate topoisomerase IIα molecules, it should 
decrease proportionally as the concentration of the protein decreases. 
Conversely, if the band arose from crosslinking two protomers of an individual 
topoisomerase IIα homodimer, its intensity should be independent of protein 
concentration. As seen in Figure 28D, the 330 kDa band did not decrease at lower 
protein concentrations. This finding indicates that the dimer band most likely is 
formed by an intramolecular crosslinking event. Based on these data, we propose 
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that PCB quinones block the N-terminal gate of topoisomerase IIα, at least in 
part, by crosslinking the two protomer subunits of the enzyme. 
 As a control, the effects of plumbagin on topoisomerase IIα were examined 
(Figure 28E). Although similar in size to the PCB metabolites, this compound has 
a quinone ring that contains only a single reactive site (marked by the asterisk in 
the figure). By comparison, 4’Cl-2,5pQ has three potential sites of adduction (also 
marked by asterisks). Even though plumbagin covalently adducts to cysteine 
residues on human topoisomerase IIα (determined by mass spectrometry), it 
displayed very little ability to enhance enzyme-mediated DNA cleavage (118) or 
to inhibit enzyme activity in the absence of nucleic acids (data not shown). 
Following a 6 min incubation with 250 µM plumbagin, no protein dimers or high 
molecular weight species were observed. Hence, as expected for a quinone that 
has only a single site of adduction, plumbagin displays no ability to induce 
protein-protein crosslinks. These findings are not consistent with models A or B, 
which require only a single site of adduction per quinone molecule. Rather, they 
support the importance of protomer-protomer crosslinks, as postulated in model 
C. 
 
 PCB Metabolites Increase Levels of DNA Cleavage Mediated by Topoisomerase IIα 
in Cultured Human Cells.  
 
 Since PCB metabolites act as topoisomerase II poisons in vitro, the ICE 
bioassay was employed to determine whether these compounds increase DNA 
cleavage mediated by topoisomerase IIα in human cells. In this assay, cultured 
CEM leukemia cells were lysed with an ionic detergent, and proteins that were 
covalently attached to genomic DNA were separated from free proteins by 
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sedimentation through a CsCl cushion. The pelleted DNA from cultures treated 
with no compound or 25 µM PCB metabolites for 6 h was blotted and probed 
with a polyclonal antibody directed against human topoisomerase IIα. Results for 
cells treated with 10 µM etoposide for 2 h are shown for comparison. In all cases, 
less than 10% cell death was observed over the course of experiment. As seen in 
Figure 29, levels of topoisomerase IIα that were covalently attached to DNA 
increased 3– to 4–fold following treatment of cells with PCB metabolites (as 
compared to ~7–fold with etoposide). 
 The covalent topoisomerase II-DNA complexes monitored in the ICE 
bioassay are believed to represent cleavage complexes. However, since some 
quinones can induce protein-DNA crosslinks, it is possible that a portion of the 
observed complexes may actually reflect crosslinks rather than cleavage. We do 
not believe that this is the case for the following reasons. First, no protein-DNA 
crosslinking was observed in experiments with purified topoisomerase IIα, even 
under conditions that employed enzyme:base pair ratios (~1:325) that were >20 
times higher than those estimated (~1:7500) for CEM cells (202) and quinone 
concentrations (100 µM) that were 4 times higher than those used in the cellular 
studies (see Figure 20). Second, treatment of CEM cells with 25 µM 4’Cl-2,5pQ 
did not increase levels of covalent topoisomerase I-DNA complexes (Figure 29). 
It is notable that 4’Cl-2,5pQ does not stimulate topoisomerase I-mediated DNA 
cleavage in vitro (data not shown). Since the type I enzyme is intimately 
associated with chromosomal DNA, this latter finding argues against 4’Cl-2,5pQ 
acting as a general protein-DNA crosslinking reagent. On the basis of these two 
control experiments, we conclude that PCB metabolites are topoisomerase II 
poisons in cultured human cells. 
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Figure 29. PCB metabolites increase topoisomerase IIα-mediated DNA 
cleavage in human CEM cells. The ICE bioassay was used to monitor the 
level of cleavage complexes in cells treated with PCB metabolites. DNA (10 
µg) from cultures treated with no compound (None), 25 µM of the indicated 
PCB metabolite for 6 h, or 10 µM etoposide or 10 µM camptothecin (CPT) for 2 
h was blotted onto a nitrocellulose membrane. Blots were probed with a 
polyclonal antibody directed against human topoisomerase IIα (left) or human 
topoisomerase I (right).  Relative DNA cleavage was calculated relative to 
levels of cleavage complexes observed in untreated cells. Error bars represent 
the standard deviation of three independent experiments.  Representative 
immunoblots are shown in the insets. 
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 Although 4’Cl-2,5HQ displayed minimal cleavage enhancing activity in 
vitro, it induced topoisomerase II-mediated DNA scission in CEM cells. 
However, since these leukemic cells display peroxidase activity (235), it is likely 
that the hydroquinone was activated to 4’Cl-2,5pQ within the cell. 
 
Discussion 
 
 Exposure to PCBs induces a variety of chromosomal aberrations in humans 
and treated human cells (209, 211), but the underlying basis for this genomic 
damage has yet to be defined. Multiple pathways are likely to be involved, such 
as oxidative damage due to redox cycling, glutathione depletion, or adduction of 
protein thiols (162, 220-223).  
 Since the genotoxic effects of PCBs are consistent with the actions of 
topoisomerase II poisons and quinones have been shown to enhance DNA 
scission mediated by the type II enzyme (1, 118, 155), we examined the effects of 
several PCB metabolites on the activity of human topoisomerase IIα. Results 
indicate that a variety of PCB quinones, including mono- and di-chlorinated 
compounds and both p- and o-quinones, are potent topoisomerase IIα poisons in 
vitro and in cultured human cells. Furthermore, as demonstrated previously 
with other bioreactive quinones (1, 118, 155), incubation of topoisomerase IIα 
with PCB metabolites in the absence of DNA leads to a rapid loss of enzyme 
activity. 
 While quinones appear to act by covalently adducting topoisomerase IIα (1, 
118, 155), the mechanism by which these compounds alter enzyme activity is not 
understood. Moreover, it is not known whether the same series of events is 
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responsible for both the enhancement of DNA cleavage and the inhibition of 
enzyme activity. Results with PCB metabolites suggest that these two opposing 
actions of quinones may be linked, at least in part, to an effect on the N-terminal 
gate of topoisomerase IIα. Based on the differential ability of the quinone-treated 
enzyme to bind circular and linear forms of DNA, and the generation of salt-
stable non-covalent complexes between topoisomerase IIα and circular plasmids 
in the presence of 4’Cl-2,5pQ, it appears that PCB metabolites block the N-
terminal gate of the protein. 
 The effects of 4’Cl-2,5pQ on topoisomerase IIα are in many respects similar 
to those described for ICRF-193 and related bisdioxopiperazines. These 
compounds alter enzyme function by stabilizing the closed-clamp form of 
topoisomerase II (230, 236, 237). If the clamp is closed in the absence of a nucleic 
acid substrate, DNA cleavage is inhibited because DNA is unable to enter the 
active site of the enzyme (230). Conversely, if the clamp closed after DNA 
binding, levels of cleavage rise modestly (2– to 3–fold) (238). This latter effect is 
presumably due to the increased concentration of non-covalent enzyme-DNA 
complexes. In this regard, cleavage enhancement by 4’Cl-2,5pQ (~8–fold) was 
considerably higher than induced by ICRF-193. However, the PCB quinone also 
was more efficient at trapping a salt-stable complex between topoisomerase IIα 
and supercoiled plasmid. 
 The above similarities notwithstanding, the mechanism by which 4’Cl-2,5pQ 
traps the salt-stable complex is very different than seen with ICRF-193. While 
bisdioxopiperazines act in a strictly non-covalent manner (230), the quinones 
appear to require covalent adduction to the protein (1, 118, 155). Furthermore, 
bisdioxopiperazines stabilize the closed N-terminal protein clamp by inhibiting 
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ATP hydrolysis (228). In contrast, PCB quinones induce a salt-stable enzyme-
DNA complex even in the absence of a nucleotide triphosphate cofactor and 
have only a modest effect on ATP hydrolysis (data not shown). Based on protein 
crosslinking experiments, we propose that PCB quinones block the N-terminal 
gate of topoisomerase IIα by crosslinking the two protomer subunits of the 
enzyme (Figure 27, model C). If this hypothesis is correct, reactive amino acids 
(most likely N-terminal residues) on the two protomers must be in close enough 
proximity in the absence of ATP (<8 Å) to bond to the same quinone molecule. 
Since the N-terminal gate of topoisomerase IIα has to be at least 20 Å across to 
accommodate the T-segment, this proposal implies that the N-terminal domain 
of topoisomerase IIα must be very flexible and dynamic in the absence of ATP.  
 Two complicating points should be noted. First, while exposure to 4’Cl-
2,5pQ resulted in the preferential loss of individual peptides, no specific higher 
molecular mass peptide species were identified (Figure 28C). Rather, a high 
molecular mass smear was observed. This finding suggests that quinone 
crosslinking of the topoisomerase IIα protomers may involve multiple sites of 
adduction rather than unique amino acid residues. Second, under conditions that 
paralleled those employed for DNA cleavage experiments, high molecular mass 
topoisomerase IIα multimers were observed following exposure to PCB quinones 
(Figure 28A and E). This indicates that intermolecular protein-protein 
crosslinking also is taking place. It is not known how (or if) these intermolecular 
events contribute to either the enhancement of enzyme-mediated DNA cleavage 
or the inhibition of enzyme activity by quinones. 
 Finally, although the evidence indicates that blocking the N-terminal protein 
gate plays an important role in the actions of quinones against topoisomerase IIα, 
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additional possibilities cannot be excluded. To this point, quinone-treated 
enzyme binds oligonucleotide substrates, but the adducted protein is not capable 
of cleaving the bound 50-mers (data not shown). Furthermore, levels of clamp 
closing and protein crosslinking are not as great as levels of enzyme inhibition 
under similar conditions. Thus, in the absence of structural data, alternative 
mechanisms must still be considered. 
 In conclusion, PCB metabolites are reactive chemicals that are health 
hazards to humans and are probable carcinogens. The toxic and mutagenic 
effects of these compounds are complex and most likely driven by a variety of 
pathways. Although the ultimate relationship of our findings to the health effects 
of PCBs is not known, the present work suggests that topoisomerase IIα may 
play a role in mediating at least some of the chromosomal damage induced by 
these environmental contaminants. 
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CHAPTER V 
 
QUINONE-INDUCED ENHANCEMENT OF DNA CLEAVAGE BY HUMAN 
TOPOISOMERASE IIα: DUAL ACTIVITY OF QUINONES AGAINST THE 
ENZYME 
 
 
Introduction 
 Topoisomerase II poisons play important roles in both the treatment and the 
development of human cancers. Approximately one-half of all cancer 
chemotherapy regimens contain drugs that target the type II enzyme. However, 
a small number of patients who receive therapy that includes topoisomerase II-
targeted drugs develop secondary leukemias. These drug-related leukemias 
commonly feature aberrations (deletions, duplications, and translocations) in the 
mixed-lineage leukemia (MLL) gene at chromosomal band 11q23 (13, 14, 24, 25, 
239-242). In addition, bioflavonoids, which are beneficial for adult health, are 
believed to increase the risk of infant leukemias that include MLL 
rearrangements when ingested during pregnancy (18, 20-23).  
 Recently, a number of toxic quinone-based metabolites of drugs or 
environmental pollutants have been shown to be potent human topoisomerase II 
poisons (118). These include N-acetyl-p-benzoquinone imine (derived from 
acetaminophen) (155), benzoquinone (derived from benzene) (1, 117), as well as 
several PCB metabolites (156). Exposure to these compounds causes DNA strand 
breaks and other chromosomal aberrations, and has been linked to a variety of 
human health problems, including cancer (19, 35, 243-245).  
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 The quinone-based topoisomerase II poisons differ from “classic” 
topoisomerase II poisons (such as etoposide and bioflavonoids) in two ways. 
First, quinones are mixed-function inhibitors of the type II enzyme: they increase 
DNA scission when added to a topoisomerase II-DNA complex, but inhibit 
scission when incubated with the enzyme prior to the addition of nucleic acids 
(1, 117, 155, 156, 223, 246-249). Second, in contrast to compounds like etoposide 
(which interact with topoisomerase II in a non-covalent manner), quinones act by 
covalently attaching to the protein (1, 117, 118, 155, 156, 223).  
 It is not known how this covalent modification increases levels of cleavage 
complexes and it is possible that quinones affect enzyme activity by more than 
one process. Religation experiments suggest that these compounds function at 
least in part by impairing the ability of topoisomerase II to rejoin cleaved DNA 
termini (1, 117, 155, 156). In addition, quinones block the N-terminal gate of the 
protein, thereby increasing the concentration of DNA associated with 
topoisomerase II by trapping the substrate in a non-covalent complex (156). 
Molecular sizing experiments suggest that quinones block the N-terminal gate by 
crosslinking the two protomer subunits of topoisomerase IIα (156). 
 Because of the human health concerns of quinone-based topoisomerase II 
poisons and their unusual mode of action against the type II enzyme, sites of 
quinone adduction on human topoisomerase IIα were mapped by mass 
spectrometry.  
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Results 
 
 Identification of Cysteine Residues in Human Topoisomerase IIα that are Adducted 
by Quinones.  
 
 In an effort to further dissect the mechanistic basis for the actions of 
quinones as topoisomerase II poisons, amino acid residues in human 
topoisomerase IIα that are covalently modified by these compounds were 
identified by mass spectrometry. Initial attempts utilized benzoquinone as the 
modification agent. Unfortunately, no individual amino acid residues were 
identified in these experiments. This is most likely due to the ability of 
benzoquinone to crosslink multiple residues in the protein (223).  
 To overcome this technical difficulty, plumbagin, which has only a single 
reactive site, was employed (Figure 30). Plumbagin is a topoisomerase II poison, 
however, it is at least 10–fold less potent than benzoquinone (Figure 30). In 
addition, the compound does not effectively block the N-terminal gate of the 
enzyme (Figure 30) and does not crosslink the protomer subunits (156). These 
data support the hypothesis that multiple processes contribute to the increase in 
cleavage complexes by quinone-based topoisomerase II poisons. 
 As determined by LC-MS/MS analysis of tryptic and chymotryptic 
peptides derived from human topoisomerase IIα, four cysteine residues were 
adducted by plumbagin, cys170, cys392, cys405, and cys455. Representative  
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Figure 30. DNA cleavage enhancement by human topoisomerase IIα in the 
presence of plumbagin. Upper Right: The structures of plumbagin and 
benzoquinone are shown. Reactive sites on the compounds are indicated by 
stars. Left: An autoradiogram of a polyacrylamide gel of DNA cleavage 
reactions is shown. Assays contained no compound (None), 12.5 µM 
etoposide, or 25 µM benzoquinone or 100–500 µM plumbagin. A DNA control 
is shown in the far left lane. Data are representative of two independent 
experiments. Lower Right: Results of topoisomerase II protein clamp closing 
assays are shown. The bar graph represents levels of salt-stable bound DNA 
formed when topoisomerase II-DNA complexes were treated with no drug 
(None), 250 µM plumbagin or 100 µM benzoquinone. Error bars represent the 
standard deviation of four independent experiments. 
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spectra are shown in Figure 31. Modeling studies based on the structure of yeast 
topoisomerase II place cys170, cys392 cys405 in the N-terminal domain and 
cys455 in the B’-subdomain of the catalytic core of the enzyme (58, 250) (Figure 
32). As determined in a previous study, all of these residues exist in the protein 
as free sulfhydryls (i.e., not part of a disulfide bridge) with the exception of 
cys455, which is free only10–15% of the time (251). 
 
 DNA Cleavage Mediated by N-terminal Mutant Human Topoisomerase IIα 
Enzymes.  
 
 In order to assess the contributions of the above four cysteine residues to 
the actions of quinones as topoisomerase II poisons, each of the residues was 
individually mutated to an alanine residue and the resulting mutant enzymes 
(top2αC170A, top2αC392A, top2αC405A, and top2αC455A, respectively) were 
purified and characterized. With the exception of top2αC455A, all of the mutant 
enzymes displayed wild-type DNA cleavage activity in the absence of 
topoisomerase II poisons (Figure 33A). Top2αC455A exhibited a cleavage activity 
that was ~50% higher than wild-type (see Figure 39). Since the basal properties of 
this mutant enzyme were altered, it will be discussed later in this chapter.  
 To further analyze the properties of top2αC170A, top2αC392A, and 
top2αC405A, the sensitivity of these mutant enzymes to topoisomerase II poisons 
was determined. Etoposide, a classic topoisomerase II poison, as well as 
benzoquinone and the PCB metabolite 4’Cl-2,5pQ, two quinone-based 
topoisomerase II poisons, were utilized for these experiments. As shown in 
Figure 33B, all displayed wild-type sensitivity to the anticancer drug etoposide. 
In contrast, two of the mutant enzymes, top2αC392A and top2αC405A, were less  
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Figure 31. Plumbagin adducts to cysteine residues of human topoisomerase 
IIα.  Low-energy CID spectra of peptides that contain the adducted a) cys170, 
b) cys392, c) cys405 or d) cys455 residues are shown. Fragment ions are 
labeled according to the accepted nomenclature. b-ions are coded blue, y-ions 
are coded red, and precursor ions are coded green. Asterisks denote b- or y-
ions that contain the adducted cysteine residue. The insets show the sequence 
of the adducted peptides; the asterisk denotes the adducted cysteine residue 
and the black lines denote the identified cleavages. 
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Figure 32. Sites of adduction by plumbagin in human topoisomerase IIα. 
Residues adducted by quinones were identified by mass spectrometry. A 
composite of the crystal structures of the yeast catalytic core and N-terminal 
domain is shown and the locations of the homologous cysteine residues 
adducted in human topoisomerase IIa are indicated by shaded circles. These 
residues were mutated to alanines using mutagenesis PCR to evaluate their 
role in quinone action. Adapted from Refs. (58, 250). 
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Figure 33. DNA cleavage activity of N-terminal mutant human 
topoisomerase IIα enzymes. Panel A: Cleavage activity was assessed using 0–
800 nM topoisomerase IIα in the absence of quinones. Assay mixtures 
contained wild-type enzyme (WT, open squares), top2αC170A (C170A, open 
circles), top2αC392A (C392A, filled squares), top2αC405A (C405A, filled 
circles), or top2αC392/405A (C392/405A, open triangles). Panel B: DNA 
cleavage reactions were carried out in the presence of 0–200 µM etoposide. 
Panel C: DNA cleavage reactions were carried out in the presence of 0–200 µM 
benzoquinone. Panel D: DNA cleavage reactions were carried out in the 
presence of 0–200 µM 4’Cl-2,5pQ. Error bars represent the standard deviation 
of at least three independent experiments. 
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responsive to benzoquinone (Figure 33C) and 4’Cl-2,5pQ (Figure 33D) than was 
wild-type topoisomerase IIα. The decreased sensitivity did not appear to be due 
to a reduced affinity for quinone, because at saturating levels of benzoquinone or 
4’Cl-2,5pQ, levels of DNA cleaved by the mutant enzymes were only one-half of 
those observed with the parental enzyme. 
 The finding that mutation of cys392 or cys405 causes partial resistance 
toward quinones can be explained by two possibilities. For example, one residue 
may be involved in the inhibition of DNA religation while the other may be 
involved in blocking the N-terminal gate. If this were the case, an enzyme that 
carries alanine residues at both positions (top2αC392/405A) should display 
enhanced resistance over either singly-mutated enzyme.  
 Alternatively, adduction of these residues by quinones may enhance 
topoisomerase IIα-mediated DNA cleavage by the same mechanism (religation or 
the N-terminal gate). However, it is necessary to modify both residues in order to 
observe an effect. If this were the case, the doubly-mutated enzyme should 
display a sensitivity to quinones that is similar to that of either singly-mutated 
enzyme.  
 To address this mechanistic issue, top2αC392/405A was generated and 
isolated. Like top2αC392A and top2αC405A, the doubly-mutated enzyme 
exhibited wild-type DNA cleavage activity in the absence (Figure 33A) or 
presence (Figure 33B) of etoposide, but displayed ~one-half of the sensitivity to 
either benzoquinone (Figure 33C) or 4’Cl-2,5pQ (Figure 33D). These findings 
suggest that quinone adduction of cys392 and cys405 enhances topoisomerase 
IIα-mediated DNA cleavage as part of the same process. 
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 Finally, two additional cysteine residues, cys216 and cys300, have been 
shown to exist in the protein as free sulfhydryls (251). Even though they were not 
identified as sites of quinone adduction in the present work, top2αC216A and 
top2αC300A were generated and analyzed. Neither enzyme displayed any 
resistance to benzoquinone or 4’Cl-2,5pQ (not shown).  
 
 Effects of Benzoquinone on DNA Religation Mediated by N-terminal Mutant 
Human Topoisomerase IIα Enzymes. 
  
 To further examine the role of cys392 and cys405 in facilitating the actions 
of quinones against human topoisomerase IIα, the abilities of wild-type enzyme, 
top2αC170A top2αC392A, top2αC405A, and top2αC392/405A to religate cleaved 
DNA in the absence or presence of benzoquinone were determined (Figure 34). 
In the absence of the quinone, all of the enzymes religated DNA to a similar 
extent (~50% ligation was observed in 10 s). However, in the presence of 
benzoquinone, top2αC392A, top2αC405A, and top2αC392/405A exhibited faster 
rates of religation (~40% ligation in 10 s) as compared to either wild-type 
topoisomerase IIα or top2αC170A (~20% ligation in 10 s). These findings support 
the conclusions of the preceding section and strongly suggest that adduction of 
cys392 and cys405 by quinones increases levels of DNA cleavage complexes by 
inhibiting the ability of the enzyme to religate cleaved nucleic acid substrates.  
 
 Ability of Benzoquinone to Block the N-terminal Gate of N-terminal Mutant 
Human Topoisomerase IIα Enzymes.  
 
 As discussed above, quinones that are strong topoisomerase II poisons 
contain multiple electrophilic carbons (i.e., sites of adduction) and block the N- 
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Figure 34. Quinone-resistant mutant human topoisomerase IIα enzymes 
display higher rates of DNA religation in the presence of benzoquinone. 
Left Panel: DNA religation reactions were carried out in the presence of 100 
µM benzoquinone. Assay mixtures contained wild-type enzyme (WT, open 
squares), top2αC170A (C170A, open circles), top2αC392A (C392A, filled 
squares), top2αC405A (C405A, filled circles), or top2αC392/405A (C392/405A, 
open triangles). Samples were incubated at 37 ˚C to establish DNA 
cleavage/religation equilibria. Reactions were shifted to 0 ˚C to initiate 
religation. DNA religation was quantified by the loss of linear cleaved 
molecules. Right Panel: Representative DNA religation data at 10 s is shown. 
DNA cleavage/religation equilibria were established in the presence (filled 
bars) or absence (None, open bars) of benzoquinone. Error bars represent the 
standard deviation of at least three independent experiments. 
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terminal gate of human topoisomerase IIα by crosslinking the two protomers of 
the enzyme (156, 223). This action has no direct effect on the DNA cleavage-
religation equilibrium of the enzyme. However, since it traps the non-covalent 
protein-DNA complex, it increases levels of scission by raising the concentration 
of DNA in the active site of topoisomerase II. Therefore, to determine whether 
any of the cysteine residues identified by mass spectrometry as sites of quinone 
adduction in topoisomerase IIα are involved in blocking the N-terminal gate of 
the enzyme, DNA binding, protein clamp closing, and protomer crosslinking 
experiments were performed. 
 Initial studies examined the ability of quinone-treated enzymes to bind 
circular and linear forms of DNA. As seen in Figure 35, treatment of wild-type 
topoisomerase IIα with benzoquinone prior to the addition of DNA differentially 
affects the ability of the enzyme to bind these DNA substrates. By blocking the 
N-terminal gate of topoisomerase IIα, quinones impair the ability of circular 
DNA to diffuse into the active site in the central annulus of the protein. This 
action decreased levels of circular DNA binding to ~30% of the levels observed 
in the absence of quinone. In contrast, linear forms of DNA, especially short 
oligonucleotides (double-stranded 50-mer), are able to enter the “closed-clamp” 
form of the enzyme and bind to the active site (~80% and 100% binding, 
respectively, as compared to parallel “no quinone” controls). DNA binding 
results for quinone-treated top2αC170A, top2αC392A, top2αC405A, and 
top2αC392/405A were nearly identical to those observed for the wild-type 
enzyme (Figure 35).  
 The second set of experiments utilized a “clamp closing” assay. In these 
experiments, the enzyme was incubated with circular DNA substrates prior to  
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Figure 35. Substrate-dependent effects of benzoquinone on N-terminal 
mutant topoisomerase IIα-DNA binding. Assays employed a negatively 
supercoiled circular plasmid (shaded bars), a linear plasmid (open bars), or a 
duplex 50-mer oligonucleotide (filled bars) as the substrate. Enzymes were 
incubated with 100 µM benzoquinone for 5 min prior to the addition of DNA. 
DNA binding in the absence of benzoquinone was set to 100%. Error bars 
represent the standard deviation of at least three independent experiments. 
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the addition of benzoquinone. Blocking the N-terminal gate traps the circular 
substrate in the central annulus of topoisomerase IIα, generating a non-covalent 
protein-DNA complex that is stable in 1 M NaCl (175). Benzoquinone treatment 
increased the concentration of salt-stable protein-DNA complexes ~4–fold (from 
~4.5% to ~17% of the total DNA) when wild-type topoisomerase IIα was 
employed (Figure 36). Once again, similar results were observed for all of mutant 
enzymes. Levels of salt-stable complexes formed with top2αC392A, top2αC405A, 
and top2αC392/405A were slightly lower (~13–14% of the total DNA) than seen 
with wild-type enzyme in the presence of benzoquinone. However, levels of salt-
stable protein complexes formed with these enzymes also were lower (~3.2–3.6% 
of the total DNA) in the absence of quinone (Figure 36). 
 The third set of experiments examined the ability of benzoquinone to 
crosslink the two protomer subunits of human topoisomerase IIα. Exposure of 
the enzyme to quinones efficiently crosslinks the two protomer subunits of the 
protein homodimer. This event is monitored by gel electrophoresis under 
denaturing conditions and is characterized by the loss of the ~170 kDa protomer 
and the subsequent generation of a new protein species with an apparent 
molecular mass of ~330 kDa. As seen in Figure 37, treatment of wild-type 
topoisomerase IIα as well as the mutant enzymes with benzoquinone resulted in 
a rapid loss of protein monomer. The half-life for protomer crosslinking (~15 s) 
was similar for all of the enzymes examined. To address the possibility that all 
three cysteine residues (cys170, cys392, and cys405) are involved in crosslinking 
with only one being required at any given time, a triple mutant of topoisomerase 
IIα (top2αC170/392/405A) was generated. The half-life for protomer crosslinking  
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Figure 36. Benzoquinone blocks the N-terminal gate of N-terminal mutant 
human topoisomerase IIα enzymes. Filter binding assays were used to 
analyze the salt-stable closed-clamp of topoisomerase II. Enzyme-DNA 
complexes were established and further incubated in the absence (None, open 
bars) or presence (filled bars) of 100 µM benzoquinone. Samples were applied 
to glass fiber filters, DNA was eluted by sequential washes in low salt, high 
salt, and SDS, and eluted samples were subjected to electrophoresis in an 
agarose gel. Salt-stable non-covalent enzyme-DNA complexes were quantified 
by the amount of plasmid that did not elute until the SDS wash relative to the 
total plasmid eluted in all three washes. Error bars represent the standard 
deviation of at least three independent experiments. 
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Figure 37. Benzoquinone crosslinks the protomer subunits of N-terminal 
mutant human topoisomerase IIα enzymes. Assay mixtures contained 135 
nM wild-type enzyme (WT, open squares), top2αC170A (C170A, open circles), 
top2αC392A (C392A, filled squares), top2αC405A (C405A, filled circles), or 
top2αC392/405A (C392/405A, open triangles) that was treated with 100 µM 
benzoquinone for 0–4 min. Samples were subject to electrophoresis in a 
polyacrylamide gel and protein was visualized by coomassie staining. The 
level of 170 kDa enzyme protomer that was present in the absence of 
benzoquinone was set to 1. Error bars represent the standard deviation of at 
least three independent experiments.   
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of this enzyme was similar to that of the double top2αC392/405A mutant (data 
not shown). 
 Taken together, the experiments described above provide strong evidence 
that cys170, cys392, and cys405 are not required for quinones to block the N-
terminal of topoisomerase IIα or crosslink the two protomer subunits of the 
protein. Thus, the adduction of cys392 and cys405 by benzoquinone appears to 
enhance DNA scission mediated by topoisomerase IIα primarily by inhibiting the 
ability of the enzyme to religate cleaved nucleic acid molecules. 
 
 Human Topoisomerase IIα Carrying a Cys455–>Ala Mutation (top2αC455A) is 
Hypersensitive to Quinones.  
 
 The previously characterized Cys–>Ala mutants (top2αC392A, top2αC405A, 
or top2αC392/405A) displayed wild-type DNA cleavage activity in the absence 
of topoisomerase II poisons. In contrast, top2αC455A exhibited a cleavage 
activity with negatively supercoiled plasmid DNA that was ~50% higher than 
that of the wild-type enzyme (Figure 38). Enhanced DNA cleavage was not due 
to an increase in DNA binding by the mutant enzyme. In fact, top2αC455A 
displayed a lower binding affinity for negatively supercoiled DNA than did 
wild-type topoisomerase IIα. In addition, as determined by nitrocellulose filter 
binding experiments the mutant and wild-type enzymes bound similar levels of 
linear plasmid DNA or oligonucleotide (data not shown). 
 To further analyze the properties of top2αC455A, its sensitivity toward 
topoisomerase II poisons was compared to that of wild-type human 
topoisomerase IIα. It should be noted that the data shown in Figure 39 is plotted 
as relative DNA cleavage. Thus, the data account for the enhanced scission  
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Figure 38. DNA cleavage activity of wild-type human topoisomerase IIα and 
top2αC455A. Cleavage activity was assessed using 0–800 nM enzyme. Assay 
mixtures contained wild-type enzyme (WT, open circles) or top2αC455A 
(C455A, closed circles). Error bars represent the standard deviation of at least 
three independent experiments. 
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Figure 39. Effects of quinones and traditional topoisomerase II poisons on 
the DNA cleavage activity of top2αC455A. Assay mixtures contained wild-
type topoisomerase IIα (WT, open circles) or top2αC455A (C455A, closed 
circles). Relative levels of DNA cleavage are shown. For both the wild-type 
and mutant enzymes, the level of DNA cleavage in the absence of 
topoisomerase II poisons was set to 1.0. Panel A: DNA cleavage was assessed 
in the presence of 0–200 µM benzoquinone. Panel B: DNA cleavage was 
assessed in the presence of 0–200 µM 4’Cl-2,5pQ. Panel C: DNA cleavage was 
assessed in the presence of 0–200 µM etoposide. Panel D: DNA cleavage was 
assessed in the presence of 50 µM etoposide, genistein, amsacrine, 
benzoquinone, or 4’Cl-2,5pQ, or 5 µM CP-115,953. Values represent the ratio 
of DNA cleavage generated by top2αC455A divided by that generated by the 
wild-type enzyme. The dotted line represents equal sensitivities for the 
indicated compound by both enzymes. Values below the line indicate 
resistance, while those above the line indicate hypersensitivity. Error bars 
represent the standard deviation of at least three independent experiments. 
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activity of top2αC455A by setting the initial level of DNA cleavage in the absence 
of topoisomerase II poisons to 1.0 for both the mutant and wild-type enzymes. 
 As seen in Figure 39A, B, and D, the mutant enzyme was hypersensitive 
(~1.5– to 2–fold) to two quinone-based topoisomerase II poisons, benzoquinone 
and the PCB quinone 4’Cl-2,5pQ. The enhanced sensitivity did not appear to 
result from an increased affinity for the quinones, because at saturating (i.e., 
plateau) concentrations of benzoquinone or 4’Cl-2,5pQ, levels of DNA cleaved by 
the mutant enzyme were always higher than those observed for the wild-type 
enzyme.  
 To determine whether the enhanced susceptibility of top2αC455A was 
unique to quinones, the sensitivity of the enzyme toward a series of traditional 
(i.e., non-covalent) topoisomerase II poisons was assessed. Drugs from four 
different classes were employed for these experiments, including etoposide (a 
demethylepipodophyllotoxin), genistein (an isoflavone), CP-115,953 (a 
quinolone), and amsacrine (an anilinoacridine). As seen in Figure 39C and D, the 
sensitivity of the mutant enzyme toward these traditional topoisomerase II 
poisons was similar to that of wild-type topoisomerase IIα. Therefore, the 
hypersensitivity of top2αC455A appears to be specific to quinone-based 
topoisomerase II poisons. 
 
 Basis for the Quinone Hypersensitivity of top2αC455A.  
 As discussed above, quinones have two effects on human topoisomerase IIα 
that may contribute to their actions as topoisomerase II poisons: they inhibit the 
ability of the enzyme to ligate cleaved DNA and they block the N-terminal gate 
of the protein. As a first step toward determining the mechanistic basis for the 
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quinone hypersensitivity of top2αC455A, the ability of the enzyme to ligate DNA 
was characterized. In the absence of quinones, the mutant enzyme ligated DNA 
~1/3 slower than did wild-type topoisomerase IIα (Figure 40). This decreased 
ligation rate probably accounts (at least in part) for the higher levels of DNA 
cleavage generated by top2αC455A in the absence of topoisomerase II poisons.  
 Addition of benzoquinone to reaction mixtures decreased the ability of 
top2αC455A to ligate DNA (Figure 40). Levels of ligation mediated by 
top2αC455A dropped ~2.8–fold (from 33.1% to 11.9%) in the presence of the 
quinone. This drop was similar to the 2.5–fold decrease observed for wild-type 
topoisomerase IIα (from 49.0% to 19.3%). Therefore, the heightened sensitivity of 
top2αC455A to quinones does not appear to be related to effects on DNA 
ligation. 
 To further explore the basis for quinone hypersensitivity, the ability of 
benzoquinone to block the N-terminal protein gate of top2αC455A was 
characterized (175) (Figure 41). In the absence of quinone, top2αC455A and wild-
type topoisomerase IIα trapped similar levels of DNA in a salt-stable non-
covalent complex (4.5% vs. 5.6%, respectively). However, in the presence of 
benzoquinone, a dramatic difference was observed. Whereas the level of DNA 
trapped by the wild-type enzyme rose to 16.8%, that trapped by top2αC455A was 
~3 times higher (47.1%). These data strongly suggest that the enhanced ability of 
quinones to block the N-terminal gate of top2αC455A contributes to the 
hypersensitivity of the enzyme toward these topoisomerase II poisons. 
Furthermore, this activity may contribute to enzyme-mediated DNA breaks. 
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Figure 40. DNA ligation mediated by wild-type human topoisomerase IIα  
and top2αC455A in the absence and presence of benzoquinone. Samples 
contained wild-type topoisomerase IIα (WT, open bars) or top2αC455A 
(C455A, closed bars) and were incubated at 37 ˚C to establish DNA 
cleavage/ligation equilibria. Reactions were shifted to 0 ˚C for 10 s, and DNA 
ligation was quantified by the loss of linear cleaved molecules. DNA 
cleavage/ligation equilibria were established in the absence (None) or 
presence (BQ) of 100 µM benzoquinone. Error bars represent the standard 
deviation of at least three independent experiments. 
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Figure 41. Ability of quinones to close the N-terminal gate of wild-type 
human topoisomerase IIα (WT) and top2αC455A (C455A). Filter binding 
assays were used to analyze the salt-stable closed-clamp form of 
topoisomerase II. Enzyme-DNA complexes incubated in the absence (None, 
open bars) or presence (filled bars) of 100 µM benzoquinone. Samples were 
applied to glass fiber filters, eluted by sequential washes in low salt (LS), high 
salt (HS), and SDS, and eluted DNA was subjected to electrophoresis in an 
agarose gel. Representative gels are shown in the inset. Salt-stable non-
covalent enzyme-DNA complexes were monitored by quantifying the amount 
of plasmid in the SDS wash relative to the total plasmid eluted in all three 
washes. Error bars represent the standard deviation of at least three 
independent experiments.  
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Discussion 
 
 A variety of drug-related and environmental quinone-based metabolites are 
potent topoisomerase II poisons. These compounds act by adducting the protein, 
and previous studies suggest that they increase levels of enzyme-DNA cleavage 
complexes by at least two potentially independent mechanisms (1, 117). 
Quinones act directly on the DNA cleavage-religation equilibrium of 
topoisomerase II by inhibiting rates of religation. Alternatively, they block the N-
terminal gate of the protein and thereby raise levels of cleavage complexes by 
increasing the local concentration of DNA in the active site of the enzyme. It is 
not known whether these two effects result from quinone adduction to the same 
amino acid residue(s) in topoisomerase IIα or whether they are mediated by 
modification of separate residues. 
 Although anticancer drugs and other classic topoisomerase II poisons 
function at the active site of the enzyme (10, 15, 16, 95, 96, 252), sites at which 
quinone-based poisons adduct the protein are not known. Therefore, the present 
study identified amino acid residues that are modified by quinones and 
determined their role in the actions of these compounds as topoisomerase II 
poisons. Four cysteine residues were identified by mass spectrometry as sites of 
quinone adduction: cys170, cys392, cys405, and cys455. Mutations (cys–>ala) 
were individually generated at each of these positions. Mutations at cys392 or 
cys405 resulted in enzymes with reduced sensitivity to benzoquinone or 4’Cl-
2,5pQ. Top2αC392A, top2αC405A, and the double mutant top2αC392/405A all 
displayed ~50% resistance to these compounds. Furthermore, top2αC392/405A 
(the only mutant enzyme tested) was ~2– to 4–fold resistant to plumbagin (data 
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not shown). Results of DNA religation and binding studies, together with protein 
clamp closing and crosslinking experiments, strongly suggest that adduction of 
cys392 and cys405 increases levels of topoisomerase IIα-mediated DNA cleavage 
primarily by inhibiting the ability of the enzyme to reseal nucleic acid breaks. 
 Studies with top2αC392A, top2αC405A, and the double mutant 
top2αC392/405A indicate that cys392 and cys405 both are required to observe 
inhibition of DNA religation by quinones. Given the close proximity of these two 
residues (Figure 32), an intriguing possibility is that quinones such as 
benzoquinone act by forming an intra-protomer crosslink between cys392 and 
cys405. This could help explain why mono-adducting quinones, such as 
plumbagin, are weak topoisomerase II poisons. Future structural studies will be 
required to explore this issue. 
 Cys455 also was identified as a site of quinone adduction by mass 
spectrometry. The mutant enzyme was ~1.5– to 2–fold hypersensitive to 
benzoquinone and 4’Cl-2,5pQ, but displayed wild-type sensitivity to traditional 
topoisomerase II poisons. The ability of benzoquinone to inhibit DNA ligation 
mediated by top2αC455A was similar to that of wild-type topoisomerase IIα. 
However, the quinone induced ~3 times more clamp closure with the mutant 
enzyme when compared to wild-type topoisomerase IIα. These findings strongly 
support the hypothesis that quinones increase levels of topoisomerase II-
associated DNA strand breaks, at least in part, by blocking the N-terminal gate of 
the enzyme. 
 Since Cys455 is located in the in the catalytic core of topoisomerase IIα as 
opposed to the N-terminal domain (58, 250), it is unlikely that the residue plays a 
direct role in clamp closure. Why then does the Cys455–>Ala mutation enhance 
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the effects of quinones on the N-terminal gate of topoisomerase II? At least three 
possibilities exist. First, Cys455 may simply represent a “sink” for quinone 
adduction. This would diminish levels of compound available to modify amino 
acid residues involved in clamp closure. Second, adduction of Cys455 may 
attenuate the ability of quinones to block the N-terminal gate of topoisomerase II. 
Therefore, removal of the residue would enhance the actions of quinones on 
clamp closure. Third, the existence of Cys455 as part of a disulfide bridge may 
impede closure of the N-terminal gate. To this point, the majority of Cys455 
exists in a disulfide bridge; at any given time, only 10 to 15% of the residue exists 
as a free sulfhydryl (251). Thus, quinone adduction of Cys455 would enhance the 
ability of other quinone molecules to close the N-terminal gate by preventing the 
disulfide bridge from reforming. Mutation of Cys455–>Ala would prevent the 
formation of the disulfide bridge and enhance clamp closing by mimicking the 
effects of quinone adduction.  
 The first possibility appears to be unlikely. If the sole role of Cys455 in 
quinone action was to draw these compounds away from other residues, levels 
of DNA cleavage mediated by wild-type topoisomerase IIα would eventually 
approach those seen with top2αC455A as quinone concentrations reached 
saturation. As seen in Figure 2, this was not the case. At the present time, it is not 
possible to distinguish between the second and third possibilities (or an even 
more complicated scenario). Further mechanistic and structural studies most 
likely will be required to address this complex issue. 
 In conclusion, quinones are topoisomerase II poisons that act by 
adducting the enzyme. Results of the present study indicate that adduction of 
cys392 and cys405 is important for the actions of quinones and increases levels of 
 120 
enzyme-DNA cleavage complexes primarily by inhibiting DNA religation 
(Figure 34). Furthermore, evidence suggests that quinones also contribute to 
topoisomerase II-mediated DNA scission by blocking the N-terminal protein 
gate. As discussed in previous chapters, this latter effect may inhibit enzyme 
activity in the absence of DNA. Taken together, these data support the 
hypothesis that quinones enhance DNA scission by the enzyme by at least two 
independent mechanisms (Figure 42).  
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Figure 42. Summary of activities of quinones against topoisomerase IIα. 
Quinones adduct to residues cys392 and cys405 to inhibit ligation of the 
cleaved DNA substrate. Quinones also have the ability to close the N-terminal 
protein gate. In the absence of DNA this activity inhibits enzyme activity. 
Conversely, in the presence of DNA, this acitivity enhances DNA scission by 
trapping DNA in the active site of the enzyme. Adapted from Refs. (58, 250). 
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CHAPTER VI 
 
TOPOISOMERASE II-DRUG INTERACTION DOMAINS: IDENTIFICATION OF 
SUBSTITUENTS ON ETOPOSIDE THAT INTERACT WITH THE ENZYME 
 
 
Introduction 
 Podophyllotoxins, derived from the Mayapple or Mandrake root, have been 
used to treat various ailments for over a millennium (253). Although 
podophyllotoxins were used in the treatment of many diseases, the toxicity of 
these agents is a limiting factor. This toxicity prompted the development of 
etoposide among other podophyllotoxin derivatives (105).  
 Etoposide is one of the most successful chemotherapeutic agents used for 
the treatment of human cancers (10, 104, 105, 151). The drug currently is in its 
third decade of clinical use and is front line therapy for a variety of malignancies, 
including leukemias, lymphomas, and several solid tumors (10, 104, 105, 151). 
Until the development of paclitaxel and related compounds, etoposide was the 
most widely prescribed anticancer drug in the world. 
 The cellular target of etoposide is topoisomerase II (10, 104-106, 151). The 
drug acts by inhbiting ligation of topoisomerase II-mediated double-stranded 
breaks (97, 196). Even though the cellular target and mechanism of action of 
etoposide have been known for over 20 years, the interacting domains of the 
drug with its protein target are largely unknown. 
 Several lines of evidence indicate that interactions between topoisomerase II 
and etoposide, as opposed to drug-DNA interactions, are critical for drug 
activity and mediate the entry of etoposide into the ternary enzyme-drug-DNA 
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complex. First, mutation of specific residues in topoisomerase II dramatically 
affects the ability of etoposide to increase levels of enzyme-DNA cleavage 
complexes (10, 15, 109, 160, 254-258). Second, etoposide binds weakly (if at all) to 
DNA in the absence of topoisomerase II (259). Third, the drug binds to yeast 
topoisomerase II and human topoisomerase IIα in the absence of nucleic acids 
and a mutant yeast enzyme (yTop2H1011Y) that is resistant to etoposide displays 
a reduced binding affinity for the agent (260, 261). Fourth, etoposide displays a 
similar kinetic affinity for topoisomerase II-DNA cleavage complexes formed at 
sites with markedly different levels of scission enhancement (262). Finally, DNA 
breaks accumulate more rapidly when etoposide is incubated with 
topoisomerase II prior to the addition of DNA (as compared to the opposite 
order of addition) (262). 
 Hundreds of etoposide derivatives have been analyzed in an effort to 
establish structure-activity relationships within this drug class (263-272). Despite 
the importance of protein-drug interactions, none of these studies have identified 
any of the substituents on etoposide that interact with topoisomerase II. 
However, a recent study from our laboratory utilized saturation transfer 
difference [1H]-nuclear magnetic resonance (STD [1H]-NMR) spectroscopy (273-
277) and protein-drug competition binding assays to define the groups on the 
drug that associate with the type II enzyme. As shown in Figure 43, substituents 
on the A–, B–, and E–rings of etoposide interact with yeast topoisomerase II and 
human topoisomerase IIα. More specifically, NOE signals were observed for the 
geminal protons of the A–ring (6.0 ppm), the H5 and H8 protons of the B–ring 
(7.0 and 6.6 ppm, respectively), as well as the H2’ and H6’ protons (6.4 ppm) and 
the 3’– and 5’–methoxyl protons of the pendent E–ring (3.8 ppm). In contrast, no  
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Figure 43. Summary of etoposide substituents that interact with type II 
topoisomerases. Protons that interact with the enzyme are shown in red, those 
that do not are shown in green. Hydroxyl protons that were obscured by the 
water peak and could not be visualized are indicated in black. The shaded 
region on etoposide, including portions of the A–, B– and E–rings, is proposed 
to interact with topoisomerase II in the binary drug-enzyme complex. 
Adapted from Ref. (278). 
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significant NOE signals arising from the C–ring, the D–ring, or the C4 glycosidic 
moiety were observed, suggesting that there is limited or no contact between 
these portions of etoposide and the enzyme in the binary complex (278).  
 In order to further characterize the contributions of the A– and E– rings and 
glycosidic moiety of etoposide to drug function several podophyllotoxin  
derivatives were employed. Results indicate that the geminal protons of the A–
ring of etoposide bind to topoisomerase II and are necessary for drug-protein 
interactions. In addition, the glycosidic moiety has minor contributions in vitro 
and is dispensable for efficient drug activity. The E–ring appears to play a 
functional role, but additional bulk at the 4’ position hinders drug-enzyme 
binding. 
 
Results 
 Previously, the interacting hydrogens of etoposide with the yeast type II 
enzyme were mapped using STD-NMR (278). geminal protons of the A–ring, the 
H5 and H8 protons of the B–ring, as well as the H2’ and H6’ protons and the 3’– 
and 5’–methoxyl protons of the pendent E–ring. To verify the ability of the STD-
NMR technique to predict interacting drug domains, a variety of 
podophyllotoxin derivatives were tested for their ability to poison topoisomerase 
II (See Figures 44 and 46). 
 
 E–ring Substituents Mediate Drug Activity.  
 A previous study in our lab examined the ability two etoposide derivatives, 
hydroxyphenyl-etoposide and phenyl-etoposide, to act as topoisomerase II 
poisons (278). Removal of the 3’- and 5’-methoxyl groups from the E–ring of 
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etoposide (hydroxyphenyl-etoposide; Figure 44) decreased drug activity ~60% 
(278). Further removal of the 4’-hydroxyl group (phenyl-etoposide; see Figure 
44), decreased drug activity to nearly baseline (278). However, despite the loss of 
these critical substituents, the pendant E–rings of the agents still maintain a close 
association with topoisomerase II in the binary complex (278). The results of this 
study suggests that while the 3’– and 5’–methoxyl groups and the 4’-hydroxyl of 
the E–ring are important for drug function, are not required for drug binding.  
 Therefore, the current study employed nitrocellulose filter binding 
competition assays to further define the contribution of these groups to drug 
binding. As seen in Figure 45, the ability of hydroxyphenyl-etoposide and 
phenyl-etoposide to compete with [3H]etoposide for binding to yeast 
topoisomerase II was similar to that of etoposide. On the basis of these results, 
we conclude that the 3’– and 5’– methoxyl groups and the 4’–hydroxyl of the 
etoposide E–ring play critical functional roles for drug action, but do not mediate 
binding of the drug to the type II enzyme. 
 
 The Glycosydic Moiety of Etoposide Does not Contribute to Drug-induced DNA 
Cleavage Mediated by Human Topoisomerase IIα.  
 
 It has long been known that the glycosidic moiety of etoposide plays 
important physiological roles (10, 104, 105, 151). The presence of this group keeps 
etoposide from interacting with tubulin. Beyond these physiological functions, it 
is not clear whether the glycosidic moiety of etoposide plays any direct role in 
enhancing topoisomerase II-mediated DNA cleavage. To this point, no contacts  
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Figure 44. Structure of Etoposide and E–ring etoposide derivatives. 
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Figure 45. Binding of etoposide and derivatives to yeast topoisomerase II. 
Reaction mixtures contained 20 µM [3H]etoposide and 0–100 µM etoposide 
(open squares), hydroxyphenyl-etoposide (closed squares), or phenyl-
etoposide (open circles). Levels of [3H]etoposide binding to yeast 
topoisomerase II observed in the absence of competitor drug were set to 1. 
Error bars represent the standard deviation of three independent experiments. 
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were observed between topoisomerase II and any glycosidic protons (278). 
However, the hydroxyls of this moiety were unable to be monitored. It is notable 
that substitution of the glycosidic moiety with a flexible and charged amino-alkyl 
side chain, as in TOP-53, significantly enhanced drug-enzyme binding and drug 
activity against topoisomerase II (278). Furthermore, contacts were observed 
between the enzyme and every observable proton of this side chain in the binary 
complex.  
 In order to determine the functional relevance of the sugar moiety of 
etoposide, the activity of 4’-Demthylepipodophyllotoxin (DEPT) was 
characterized. As seen in figure 46, DEPT has all of the same components of 
etoposide but lacks the sugar moiety linked to the C-ring. The ability of 4’-DEPT 
to induce topoisomerase IIα-mediated DNA cleavage was assessed using DNA 
cleavage assays. As seen in Figure 47, left panel, 4’-DEPT also increased levels of 
enzyme-mediated double stranded DNA breaks similar, although slightly lower, 
to those induced by etoposide. Consistent with previous NMR results, it appears 
that the sugar moiety so not significantly contribute to the activity of etoposide. 
 
 Intact A– and E–ring Moieties are Necessary to Efficiently Induce Topoisomerase 
IIα-Mediated DNA Cleavage. 
  
 A previous study indicated that the A-ring was important for drug binding 
to topoisomerase II and the E–ring was involved in drug function (278). Thus, 
two additional podophyllotoxin derivatives were utilized in this study (see 
Figure 46). Epipodophyllotoxin (EPT) has a 4’-methoxy group present on the E–
ring of the molecule to examine the sensitivity of drug function to additional  
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Figure 47. DEPT stimulates DNA cleavage mediated by human 
topoisomerase IIα . Levels of DNA cleavage were quantified and expressed as 
a fold enhancement over reactions that were carried out in the absence of 
podophyllotoxin derivatives. Reaction mixtures contained 0–200 µM etoposide 
(open squares), DEPT (closed squares), EPT (open circles), or DDEPT (closed 
circles). Right Error bars represent the standard deviation of at least three 
independent experiments. 
Figure 46. Structure of etoposide and podophyllotoxin derivatives. 
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Figure 47. Effect of podophyllotoxin derivatives on DNA cleavage mediated 
by human topoisomerase IIα . Levels of DNA cleavage were quantified and 
expressed as a fold enhancement over reactions that were carried out in the 
absence of podophyllotoxin derivatives. Reaction mixtures contained 0–200 
µM etoposide (open squares), DEPT (closed squares), EPT (open circles), or 
DDEPT (closed circles). Right Error bars represent the standard deviation of at 
least three independent experiments. 
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bulk at the 4’ position. A–ring 4’-Demethylepipodophyllotoxin diol, (DDEPT) 
contained an A–ring that was opened to remove the interacting geminal protons. 
 As a first step to determine the effects of the above modifications, the ability 
EPT and DDEPT to induce topoisomerase II-mediated DNA cleavage was 
assessed. Neither EPT nor DDEPT were able to efficiently stimulate single- or 
double-stranded DNA breaks mediated by the enzyme (figure 47). These data 
suggest that the geminal protons of the A–ring are essential for etoposide 
function and the addition of bulk at the 4’ position greatly decreases drug 
efficiency.  
 
 The A– and E–Rings of Etoposide are Important in Inhibiting DNA Ligation 
Mediated by Human Topoisomerase IIα.  
 
 It has been established that the primary mode of action of etoposide is the 
inhibition of topoisomerase II-induced ligation of the cleaved DNA substrate (10, 
97, 196). Therefore, the ability of the podophyllotoxin derivatives to inhibit DNA 
ligation was assessed. Since there was a difference observed in the ability of 
etoposide and the derivatives to induce single- and double-stranded DNA breaks 
(Figure 47), enzyme-mediated ligation of both types of breaks was monitored.  
 Ligation of double-stranded DNA breaks was monitored using a plasmid-
based system. Consistent with previous DNA cleavage experiments, etoposide 
and DEPT inhibited similar amounts of topoisomerase II-mediated ligation 
(Figure 48). EPT and DDEPT were unable to inhibit DNA ligation of cleaved 
nucleic acids.  
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Figure 48. DNA ligation mediated by human topoisomerase IIα in the 
presence of podophyllotoxin derivatives. Left panel: DNA ligation of 
plasmid was examined in the absence of compound (No drug, open triangles), 
or in the presence of 100 µM etoposide (open squares), DEPT (closed squares), 
EPT (open circles), or  DDEPT (closed circles). DNA religation was quantified 
by the loss of linear cleaved molecules. Right panel: DNA ligation of a nicked 
oligonucleotide substrate was examined in the presence of 0-100 µM etoposide 
(open squares), DEPT (closed squares), EPT (open circles), or  DDEPT (closed 
circles). DNA religation was quantified by the loss of nicked DNA substrates. 
Error bars represent the standard deviation of at least three independent 
experiments. 
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 In order to assess the ability of the podophyllotoxin derivatives to inhibit 
enzyme-mediated DNA ligation, a nicked oligonucleotide was utilized (171). 
Again, consistent with cleavage data, 4’-DEPT displayed the ability to inhibit 
topoisomerase II-mediated ligation but to a lesser extent than etoposide (Figure 
48). In contrast, both EPT and DDEPT displayed a limited ability to inhibit 
ligation of a DNA nick despite being unable to induce double-stranded breaks by 
topoisomerase II.  
 
 Specific Alterations of the A– and E–rings of Etoposide Impair Drug Binding to 
Human Topoisomerase IIα.  
 
 In previous NMR experiments, protons of the A– B– and E– rings of 
etoposide were in intimate association with the enzyme (278). However, removal 
of essential components of the E–ring impaired drug function without disrupting 
binding to topoisomerase II (278) (See Figure 45). In order to assess whether 
components of the A–ring are necessary for drug binding and the effect of 
additional bulk at the 4’ position of the E–ring on drug-enzyme interactions, the 
ability of the podophyllotoxin derivatives bind to human topoisomerase IIα was 
assessed.  
 As seen in figure 49, removal of the sugar moiety of etoposide did not affect 
drug binding of the resulting compound (DEPT). However, addition of bulk on 
the E–ring (EPT) greatly reduced the ability of the agent to bind to its enzyme 
target. Furthermore, opening of the A–ring of etoposide also greatly inhibited 
drug binding. These data suggest that the A–ring of etoposide makes necessary 
interactions with topoisomerase II, while the E–ring of the drug potentially rests 
in a space-restricted pocket within the enzyme. The data also indicate that the  
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Figure 49. Binding of etoposide and podophyllotoxin derivatives to human 
topoisomerase IIα . Competition nitrocellulose filter binding assays were 
utilized. Reaction mixtures contained 20 µM [3H]etoposide and 0–100 µM 
etoposide (open squares), DEPT (closed squares), EPT (open circles) or DDEPT 
(closed circles). Levels of [3H]etoposide binding to human topoisomerase IIα 
observed in the absence of competitor drug were set to 1. Error bars represent 
the standard deviation of three independent experiments. 
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minor contributions of the glycosidic moiety to cleavage do not involve drug 
binding to topoisomerase IIα. 
 
 Loss of the Glycosidic Moiety Slightly Alters Cleavage Site Utilization of 
Topoisomerase IIα.  
 
 One property of etoposide is that this agent possesses cleavage-site 
sequence specificity when incubated in the presence of topoisomerase IIα and a 
DNA substrate (106, 225). This indicates that some portion of the molecule 
interacts with DNA in the ternary complex. The loss of the sugar moiety at the 
C4 position of etoposide slightly impairs the ability of the resulting compound to 
induce cleavage by topoisomerase II, but does not alter the ability of the agent to 
bind to the enzyme. This data confirms previous NMR results that the glycosidic 
moiety does not interact with the enzyme in the binary complex. However, it is 
possible that the A– and E–ring substituents as well as the glycosidic moiety 
influence cleavage site utilization by the enzyme. Therefore, to determine 
whether the glycosidic moiety of etoposide influences cleavage site utilization of 
topoisomerase II, cleavage assays utilizing a 32P singly-end labeled DNA 
substrate were performed.  
 Since Etoposide induced far more single strand breaks than any of the 
podophyllotoxin derivatives, a smaller concentration of etoposide was used in 
this assay. Shown in Figure 50, there were modest differences in site utilization 
between etoposide and the podophyllotoxin derivatives. Based on visual 
inspection, DEPT enhanced cleavage mainly at sites preferred by etoposide, 
however, some minor differences in site utilization were observed. The results 
suggest that the sugar moiety of etoposide may play a small role in influencing  
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Figure 50. DNA cleavage site utilization by human topoisomerase IIα in the 
presence of podophyllotoxin derivatives. An autoradiogram of a 
polyacrylamide gel is shown. DNA cleavage reactions contained no 
compound (Topo II), 25 µM etoposide, 50 µM DEPT, or 250 µM EPT or 
DDEPT. A DNA control is shown in the far left lane. Data are representative of 
at least three independent experiments. 
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the site utilization of topoisomerase IIα possibly by altering the binding 
geometry of the drug-enzyme complex. 
 
 Cleavage Mediated by Topoisomerase IIα in Cultured Human Cells in the Presence 
of Podophyllotoxin Derivatives.  
 
 It has long been known that the glycosidic moiety of etoposide plays 
important physiological roles (10, 104, 105, 151). The presence of this group keeps 
etoposide from interacting with tubulin (10, 104, 105, 151). Beyond these 
physiological functions, it is not clear whether the glycosidic moiety of etoposide 
plays any direct role in enhancing topoisomerase II-mediated DNA cleavage. 
Therefore, the ability of podophyllotoxins lacking the glycosidic moiety of 
etoposide to raise cellular levels of topoisomerase II cleavage complexes was 
determined. Consistent with cleavage data, DEPT increased the amount of 
topoisomerase II covalently bound to DNA while EPT and DDEPT were 
ineffective (Figure 51). The results indicate that the loss of the glycosidic moiety 
does not significantly alter their inherent ability of the podophyllotoxin 
derivatives to induce topoisomerase II-mediated breaks in the genetic material.  
 
Discussion 
 Although etoposide is one of the most widely prescribed drugs used for the 
treatment of human cancers (10, 104, 105, 151), the specific ring substituents that 
mediate its interactions with topoisomerase II have been difficult to define. It has 
long been known that the glycosidic moiety of etoposide plays important 
physiological roles, including inhibiting the drug from interacting with tubulin. 
The recent use of STD [1H]-NMR has enabled drug-enzyme interactions to be 
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Etoposide (10 µM)
No Drug
DEPT (10 µM)
EPT (50 µM)
DDEPT (50 µM)
Figure 51. DEPT enhances human topoisomerase IIα-mediated DNA 
cleavage in treated human CEM cells. The ICE bioassay was used to monitor 
the level of cleavage complexes in cells treated with podophyllotoxin 
derivatives. DNA (10 µg) from cultures treated with no drug, 10 µM etoposide 
or DEPT or 50 µM EPT or DDEPT was blotted onto a nitrocellulose membrane. 
Blots were probed with a polyclonal antibody directed against human 
topoisomerase IIα. Results are representative of three independent 
experiments. 
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characterized at the proton level (278). Results indicate that protons on the A–
ring, B–ring, and pendent E–ring are in close contact with yeast topoisomerase II 
and human topoisomerase IIα in the binary enzyme-ligand complex. These 
findings are summarized in Figure 43, which highlights hydrogens that interact 
with topoisomerase II in red and those for which no interactions were observed 
in green. 
 Although no interactions were observed between topoisomerase II and the 
protons of the etoposide glycosidic moiety, it is possible that this moiety may 
influence the cleavage activity of the enzyme. In fact, removal of the sugar group 
had modest effects on topoisomerase II-induced DNA cleavage activity induced 
by the agent. DEPT and etoposide only differed in their ability to induce single-
stranded nucleic acid breaks, with etoposide inducing far more of these breaks. 
This may be due to a decreased ability of DEPT to inhibit ligation of nicked DNA 
substrates. In topoisomerase II-binding assays, removal of the sugar group did 
not alter the ability of etoposide to bind to the enzyme. However, interactions of 
DEPT with the topoisomerase II-DNA-drug ternary complex, in comparison to 
etoposide, were altered as determined by changes in DNA cleavage site 
utilization.  
 Based on previous NMR data, further alterations were made to DEPT to 
assess the functional importance of the A– and E–rings. Removal of the 
interacting geminal protons of the A–ring greatly reduced the ability of the 
resulting agent (DDEPT) to enhance DNA cleavage mediated by topoisomerase 
II (see Figure 47). Loss of E–ring substituents did not alter drug affinity for the 
enzyme but greatly impaired the ability of the compound to increase DNA 
breaks generated by topoisomerase II (see Figure 45) (278). Additionally, 
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addition of bulk at the 4’ position of the E–ring also greatly dimished the activity 
of the agent (EPT, see Figure 47). Lack of activity by either of these agents was 
due to a reduced affinity for the enzyme (see Figure 49). 
 Removal of the glycosidic moiety of etoposide did not greatly alter the 
ability of the drug (DEPT) to induce double-stranded DNA breaks (see Figure 47, 
left panel). Thus, the role of this moiety appears to primarily be physiological 
and not necessary for activity. Several lines of evidence suggest that the 
glycosidic moiety prevents etoposide-tubulin binding allowing the drug to be 
available to target type II topoisomerases in the cell (10, 104, 105, 151). As 
determined by cellular experiments, removal of the glycosidic moiety of 
etoposide did not alter the activity of DEPT in cellular systems (see Figure 51). 
Therefore, it appears that the presence of this group reduces the inhibition of 
tubulin polymerization instead of increasing molecules of etoposide available to 
target topoisomerase II. 
 In conclusion, consistent with previous NMR results, the A–ring is 
necessary for drug binding. Although the E–ring substituents have been 
attributed to drug function, the presence of additional bulk at the 4’ position of 
the E–ring greatly diminished drug binding. This finding indicates that the E–
ring of etoposide rests in a pocket too small to accommodate additional bulk. 
Furthermore, the glycosidic moiety plays a limited role in enhancing 
topoisomerase II-mediated breaks in the genetic material by interacting with the 
DNA in the ternary complex (Figure 52). However, further structural studies will 
be necessary to address with possibility. 
 Finally, previous NMR results determined that substituents of the A– and 
E–ring, the A–ring are necessary for drug binding. Consistent with this data, 
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disruption of substituents necessary for binding abrogates drug activity. Thus, 
the STD-NMR has the ability analyze the molecular interactions of drugs with 
their protein targets. This finding indicates that the E–ring of etoposide rests in a 
pocket too small to accommodate additional bulk. Furthermore, the glycosidic 
moiety plays a limited role in enhancing topoisomerase II-mediated breaks in the 
genetic material by interacting with the DNA in the ternary complex (Figure 52). 
However, further structural studies will be necessary to address with possibility. 
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Figure 52. Summary of functional domains of etoposide. 
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CHAPTER VII 
 
GENERATION OF ABERRATIONS IN THE MLL GENE RESULTING FROM 
CELLULAR EXPOSURE TO TOPOISOMERASE II POISONS 
 
 
Introduction 
 Type II topoisomerases are essential enzymes that are necessary for proper 
chromosome maintenance (15, 41, 43, 50, 51, 53, 57). These enzymes also are the 
targets of a variety of successful anticancer chemotherapy agents (10, 104, 105, 
151). In addition to its role as an essential cellular protein and target for 
anticancer drugs, mounting evidence suggests topoisomerase II initiates 
chromosomal translocations that lead to specific types of leukemia (see Figure 4). 
Approximately 2-3% of patients treated with regimens that include etoposide 
ultimately develop acute myelocytic leukemia (14, 24-26). Approximately one-
half of these leukemias posses translocations within an 8.3 kb breakpoint cluster 
region in the MLL (mixed lineage leukemia) gene at chromosome band 11q23 (13, 
14, 24-26). These leukemias with MLL translocations are seen following exposure 
to other anticancer drugs. 
 In addition these leukemias induced by topoisomerase II-targeted drugs, 
exposure to environmental topoisomerase II poisons has been associated with 
the development of leukemias that display translocations involving 
chromosomal band 11q23 (137). Consumption of foods that are high in 
bioflavanoids (such as genistein, see Figure 6) by pregnant mothers during 
gestation increases the risk of developing specific infant leukemias by an order of 
magnitude (18, 20-23). Furthermore, individuals with chronic exposure to 
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benzene display a higher risk for leukemias with 11q23 chromosomal 
translocations. Benzene is not believed to induce DNA strand breaks directly, 
instead the compound induces DNA breaks through a series of phenolic and 
quinone-based metabolites. Additionally, individuals that are heterozygous or 
homozygous for the C609T polymorphism of the NAD(P)H:quinone 
oxidoreductase 1 (NQO1, the enzyme that reduces benzoquinone to the less 
reactive hydroquinone, Figure 8) (138-142). As described above, benzoquinone is 
a highly active topoisomerase II poison. 
 The involvement of topoisomerase II-mediated DNA cleavage in the 
initiation of leukemias with MLL translocations is widely accepted. However, the 
specific role of the enzyme-associated DNA strand breaks in triggering the 
chromosomal aberrations is controversial. Two potential mechanisms have been 
suggested (see Figure 4). The first postulates that the breaks induced by 
topoisomerase II play a direct role in the translocation process. In this case, 
processing of enzyme-generated breaks in the MLL gene by cellular repair 
proteins would generate the 11q23 aberration. Supporting this hypothesis, all 
MLL (and partner) chromosomal breakpoints identified in patient samples, 
including those with secondary and infant leukemias, are located in close 
proximity to, and in some cases precisely at, in vitro sites of topoisomerase II-
mediated DNA cleavage (143-145). Furthermore, leukemias with 11q23 
chromosomal translocations are only observed in patients treated with 
topoisomerase II poisons (14, 24, 279, 280), and are not seen following other 
anticancer therapies. This is despite the use of other cancer chemotherapeutic 
agents generate chromosomal breaks and induce apoptotic pathways. 
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 The second possibility is that the breaks induced by topoisomerase II play an 
indirect role in the translocation process. In this case the role of topoisomerase II-
mediated DNA cleavage would trigger apoptosis, which generates chromosomal 
breaks in the MLL gene by activated apoptotic nucleases (146). Experimental 
evidence suggests that apoptosis induced by topoisomerase II poisons sometimes 
aborts (by processes that have yet to be described). Nuclease-generated breaks 
within the MLL gene are repaired (147), sometimes resulting in the formation of 
chromosomal translocations. Sequencing studies suggest that a major site of 
apoptotic cleavage is located in the bcr of the MLL gene (147-150). Moreover, 
translocations involving 11q23 can be induced in cultured human cells by agents 
that trigger apoptosis, but do not target topoisomerase II (147-150). To reconcile 
the patient data with the apoptotic model, it is proposed that the inhibition of 
topoisomerase II alters chromatin structure. This alteration, coupled with 
nuclease action, is required for the translocation event in patients (150). 
 It is likely that the process that translates topoisomerase II-mediated DNA 
cleavage into 11q23 chromosomal translocations is highly complex and 
multifaceted. Both (or neither) of the above hypotheses may contribute to the 
process. Therefore, the ability of topoisomerase II poisons to induce MLL 
aberrations in various cellular backgrounds was examined. 
 
Results 
 The human MLL gene is located at chromosome band 11q23. The protein 
product of this gene is an important regulator of the HOX genes and is necessary 
for proper hemopoetic development (26, 132-135). A common feature (~50%) of 
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topoisomerase II-induced leukemias is aberrations in the MLL gene at 
chromosomal band 11q23 (13, 14, 24-26). This chromosomal break typically 
occurs in the intronic region upstream of the ninth exon within the bcr (26) 
(Figure 53).  
 The basis for the development of topoisomerase II-initiated leukemias has 
not been elucidated, but it appears to be related to disrupting the natural 
function of the MLL gene. MLL is the human homolog of the Drosophila trithorax 
and yeast Set1 proteins, and is a histone methyltransferase that is involved in 
transcriptional regulation in hematopoietic cells (26, 132-135). Thus, 
translocations in this region alter the differentiation of pluripotent hematopoietic 
stem cells or committed myeloid or lymphoid stem cells. 
  
 Etoposide and Benzoquinone Increase Levels of Topoisomerase IIα-DNA Complexes 
and Double-Stranded DNA Breaks. 
 It has long been known that topoisomerase II poisons increase levels of 
cleavage complexes in cells. As shown in Figure 54, treatment of cultured human 
CEM cells with either etoposide or benzoquinone enhances levels of 
topoisomerase II that is covalently attached to DNA.  
 The variant of histone H2A, H2AX, is rapidly phosphorylated on ser139 
following the generation of double-stranded DNA breaks (281, 282). Using this 
protein as a marker, the ability of agents to induce DNA breaks can be examined 
by observing levels of the H2AX phosphoprotein (γ-H2AX). As determined by 
monitoring γ-H2AX, treatment of cells with etoposide or benzoquinone induces 
permanent double-stranded nucleic acid breaks in cells (Figure 54). 
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Figure 53. Diagram of the MLL break point cluster region (bcr) of 
chromosomal band 11q23. The MLL bcr is an 8.3 kb BamHI fragment 
composed of exonic and intronic sequences spanning exon 5 through exon 11. 
Arrows indicate clinically observed MLL translocation sites found in patients 
with leukemia. The red arrows indicate the translocation “hotspot” of this 
gene locus. Asterisks indicate approximate sites of XbaI cleavage. Adapted 
from Ref. (26). 
* * 
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 Generation of MLL Aberrations in Cultured Human Cells Following Treatment with 
Topoisomerase II-targeted Agents. 
 
 A 8.3kb region of the open reading frame of the gene is where most of the 
clinically significant translocations in MLL are observed (26). This region spans 
the 5th through 11th exons and is termed the breakpoint cluster region (bcr) (See 
Figures 7 and 53). Since the vast majority of clinically observed breaks in the bcr 
occur in a region upstream of exon 9, a PCR based system was developed to 
analyze this clinically significant region of the MLL gene (178). 
 Flanking the translocation “hotspot” 3’ of exon 9 are XbaI sites with 1.8 kb 
of DNA separating the two sites (see Figure 53) (178). Therefore, this region was 
analyzed in the current study. Human CEM leukemia cells were treated with 
etoposide (25 µM for 2 h) or benzoquinone (10 µM for 4 h). After removal of the 
agents, genomic DNA was isolated from treated cells over the course of a 5 day 
recovery period in the absence of agent (Figure 55). For comparison, DNA from 
untreated CEM cells was also isolated. DNA was digested with XbaI and 
fragments were circularized. The 1.8 kb MLL fragment was amplified by 
sequential rounds of PCR were performed using primers specific for this region. 
By circularizing the genomic DNA, amplification of the bcr region is possible 
regardless of the presence of an unknown translocation partner.  
 After exposure to etoposide or benzoquinone, the analyzed region of the 
MLL bcr displayed several differences in distance between the two XbaI sites. 
Most of the fragments amplified were smaller in size (~500 to 1700 bases) than 
that of the wild-type (1800 bases) (Figure 56). Smaller fragments sizes are 
indicative of deletions, but could also be a result of a translocation that shortens  
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Figure 54. Etoposide and benzoquinone increase covalent topoisomerase II-
DNA complexes and permanent double stranded breaks in cells. Cultured 
CEM leukemia cells were treated with no compound (none), etoposide (25 µM for 
2hr) or benzoquinone (10 µM for 4 h) Left: DNA (10 µg) from cells was blotted onto 
nitrocellulose filters. Levels of topoisomerase IIα cleavage complexes were 
determined by use of a monoclonal antibody directed toward topoisomerase IIα. Right: 
Protein (35 µg) from cell lysates was subject to SDS-PAGE and transferred to 
activated PVDF membrane. Levels of γ-H2AX were determined by use of a 
monoclonal antibody directed toward the H2AX phosphoprotein. Data are 
representative of two independent experiments. 
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Figure 55. Method for generating substrates for PCR of the MLL bcr. DNA 
from treated cells was isolated, digested with XbaI, and subjected to ligation to 
circularize the DNA. The 1.8 kb XbaI region of the MLL gene is indicated in red. 
Primers were designed to bind to the known MLL sequence to avoid problems with 
amplifying the sequence of an unknown translocation partner. The “x” indicates newly 
generated XbaI sites in the circular PCR substrates. 
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  1       2       3      4       5 
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Etoposide 
Benzoquinone 
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Figure 56. Etoposide and benzoquinone induce aberrations in a 1.8 kb XbaI 
fragment of the MLL bcr. Cultured CEM leukemia cells were treated etoposide (25 
µM for 2hr, top gel) or benzoquinone (10 µM for 4 h, bottom gel). Circular DNA 
substrates were prepared as described previously. Cells (1×106) were harvested every 
24 h following treatment for a total of 5 days. Cells incubated in the absence of agent 
are shown for comparison on the far left (none). The 1.8 kb wild-type fragment is 
indicated. Data are representative of two independent experiments. 
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the length between the XbaI cleavage sites. Senquencing studies will be required 
to determine the nature of these aberrations. 
 It is interesting to note that over time, cells treated with benzoquinone 
appear to recover most of the wild-type 1.8 kb XbaI fragment of the MLL bcr 
(Figure 56). This recovery is not observed for cells treated with etoposide. This 
difference in recovery may be the result of a difference in the amount of damage 
induced by each agent or by the activation of alternate repair pathways. 
 
 Multiple Pathways Contribute to Alterations in the MLL bcr. 
 As previously mentioned, the precise mechanism that generates 11q23 
alterations following exposure to topoisomerase II poisons is unknown. 
Although these agents induce double-stranded breaks in the genetic material, it 
has also been suggested that the activation of apoptotic nucleases generates 
strand breaks that ultimately lead to MLL aberrations. Therefore, the ability of 
topoisomerase II-mediated breaks to induce changes in the 1.8 kb XbaI fragment 
of the MLL bcr was examined in the presence and absence of activated apoptotic 
cascades. 
 During activation of the apoptotic pathway, proteases called caspases are 
activated in a cascade-like fashion by cleaving at specific sites in the primary 
sequence of their substrates. During mitochondrial apoptosis caspase-9 is 
activated by the apopotosome, which in turn activates caspase-3 (283). Activated 
caspase-3 cleaves and inactivates proteins necessary for genomic maintenance as 
well as suppressors of apoptotic nucleases (Figure 57) (284). These proteins 
include DNA-pk (necessary for DNA repair) and the inhibitor of caspase 
activated DNAse (inhibits DNA cleavage by caspase activated DNAse). The 
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Figure 57. Initiation of apoptosis in human cells. Conditions that generate 
substantial DNA damage or cellular hypoxia cause the release of cytochrome c from 
the mitochondria. Cytochrome c activates caspase-9 which, in turn, activates caspase-3 
(from pro-caspase-3). Upon activation, caspase-3 cleaves and inactivates a variety of 
cellular proteins including inhibitor of caspase activated DNase (ICAD) and DNA-PK. 
Inactivation of these proteins allows for chromatin fragmentation as well as the 
inhibition of protein sythesis. Several cellular proteins that inhibit apoptotic 
signaling also are shown (Bcl-2:Bax and XIAP). Adapted from Ref. (148). 
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inactivation of these protein, among others, promotes typical DNA 
fragmentation during apoptosis.  
 The protein-based inhibitor Z-VAD-fmk, upon cleavage by caspases, 
inhibits further activity by these enzymes effectively preventing apoptosis (285). 
Shown in Figure 58, treatment of cells with Z-VAD-fmk prior to the addition of 
etoposide or benzoquinone efficiently inhibited the activity of caspase-3, 
indicating efficient inhibition of the apoptotic cascade. 
 Analysis of cells treated with both Z-VAD-fmk and either etoposide or 
benzoquinone displayed lower levels of aberrations in the 1.8 kb XbaI fragment 
of the MLL bcr (Figure 59). However, inhibition of apoptosis did not eliminate 
the generation of alterations. These data suggest that the apoptotic machinery is 
involved in producing aberrations in the MLL gene. However, the presence of 
MLL alterations in the absence of activated caspases suggests that topoisomerase 
II-mediated DNA cleavage also plays a direct role in the generation of MLL 
aberrations. It should be noted that the analysis of cells treated with etoposide 
was obscured by the high level of alterations observed. Sequencing experiments 
will require fewer, more defined, genetic changes.  
 
Discussion 
Exposure to clinical and environmental topoisomerase II poisons has been 
linked to the development of leukemias harboring translocations at chromosomal 
band 11q23 (14, 24-26, 137, 286). The role of topoisomerase II-mediated DNA 
breaks in generating 11q23 aberrations is unclear. Current evidence suggests that 
at least two pathways contribute to the formation of these translocations.  
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Figure 58. Z-VAD-fmk inhibits apoptosis induced by etoposide or 
benzoquinone. Cultured CEM leukemia cells were treated with 15 µM Z-VAD-fmk 
or DMSO vehicle 2hr prior to the addition of etoposide (25 µM for 2hr) or 
benzoquinone (10 µM for 4 hr). Cells were harvested following treatment (0 hr, filled 
bars) or allowed to recover in the absence of drug for 6 hr (open bars). Caspase-3 
activation was expressed as a fold enhancement over cells cultured in the absence of 
compound. Error bars represent the standard error of the mean for two independent 
experiments. 
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None Etopo Etopo + Z-VAD BQ 
BQ + 
Z-VAD 
WT MLL bcr 
Figure 59. Inhibition of apoptosis does not block topoisomerase II-mediated 
MLL aberrations. Cultured CEM leukemia cells were treated etoposide (25 µM for 
2hr, top gel) or benzoquinone (10 µM for 4 hr, bottom gel) in the presence or absence 
of 15 µM Z-VAD-fmk. Circular DNA substrates were prepared as described 
previously. Cells (1×106) were harvested 3 days following treatment with 
topoisomerase II poison. Cells treated with Z-VAD-fmk prior to the addition of poison 
were maintained in 15 µM of the agent throughout the recovery period. Cells 
incubated in the absence of agent are shown for comparison on the far left (none). The 
1.8 kb wild-type fragment is indicated.  
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Due to the discrepancy in the mechanism behind the formation of 11q23 
translocations, a cell based system was utilized to examine the roles of type II 
topoisomerases and apoptotic nucleases in generating these breaks in the 
presence of topoisomerase II poisons (178). A large number of clinically 
significant translocations occur at a specific site upstream of exon 9 (26). Thus a 
1.8 kb XbaI fragment encompassing this site was analyzed. 
Etoposide and benzoquinone increase cellular concentrations of 
topoisomerase II cleavage complexes as verified by the ICE bioassay (see Figure 
54). Additionally, both compounds raised levels of permanent double-stranded 
breaks in CEM cells determined by examining levels of H2AX phosphorylation. 
Following a short treatment of CEM cells with etoposide or benzoquinone, 
significant alterations were observed in the monitored region of the MLL bcr over 
a 5 day recovery period (see Figure 56). After treatment with benzoquinone, as 
opposed to etoposide, cells more efficiently and accurately repaired the MLL bcr. 
This suggests either the two agents induced differential levels of enzyme-
induced cleavage or alternate repair pathways were activated. 
The contributions of DNA strand breaks produced by topoisomerase II 
and apoptotic nucleases in generating MLL gene aberrations is unclear. 
Therefore, the ability of etoposide and benzoquinone to induce these alterations 
in the absence of apoptotic nuclease activation was determined. Treatment of 
cells with Z-VAD-fmk prior to the administration of either compound reduced 
levels of caspase-3 activation to those observed in the absence of a topoisomerase 
II poison (see Figure 58). In the absence of apoptotic nuclease activation, the 
amount of aberrations in the 1.8 kb XbaI fragment of the MLL bcr were dimished 
but not absent (see Figure 59). These data indicate that the apoptotic machinery, 
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in this cell-based system, is involved in the generation of MLL alterations. 
However, the inability of Z-VAD-fmk to fully diminish these aberrations 
indicates that DNA damage generated by topoisomerase II activity directly 
contributes to the formation of alterations in chromosomal band 11q23. 
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CHAPTER VIII 
 
CONCLUSIONS 
 
 Topoisomerase II is an essential enzyme that regulates DNA topology in 
cells (43, 50, 51, 53, 57, 58). This enzyme has been a very successful target for the 
chemotherapeutic treatment of human cancers. For example, etoposide has been 
in clinical use for almost 4 decades and was the most widely described cancer 
chemotherapy agents used until the development of taxols (10, 104, 105, 151). 
This agent kills cells by increasing levels of II topoisomerase II-mediated double-
stranded breaks (15, 41, 43, 50, 51, 53, 57, 97, 196). Despite the wide clinical use of 
etoposide, the functional portions of the molecule that have yet to be fully 
determined. 
 Despite the effectiveness of topoisomerase II-targeted agents in the clinic, 
treatment with these agents has been linked to the development of specific type 
of leukemias, displaying 11q23 translocations (14, 24-26). Furthermore, leukemias 
with 11q23 aberrations have also been observed following the exposure to 
benzene (30, 32, 287-289). Benzene itself is not believed to generate the DNA 
breaks leading to these translocations. Instead evidence suggests that a variety of 
phenolic and quinone metabolites, most notably benzoquione, cause this damage 
in the bone marrow (30, 32, 289). Recently benzoquinone was shown to act as a 
strong topoisomerase II poison in vitro and in cultured human cells (1). 
 Aside from benzoquinone activity in the bone marrow, several other 
quinone and quinone imine metabolites of drugs and environmental toxins 
demonstrate teratogenic activity in the liver (33-36). The basis for this activity is 
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not known. However, the DNA damage induced by these agents is suggestive of 
the actions of topoisomerase II poisons. Furthermore, the mechanism behind 
leukemias that arise following exposure to clinical and environmental toxins is 
unclear. These areas of discrepancy were the basis of this dissertation. 
 
Overall Conclusions 
 A number of conclusions can be drawn from the results presented in this 
dissertation. First, both NAPQI and a variety of PCB quinones are topoisomerase 
II poisons in vitro and in cultured human cells (see Figures 10-12, 16, 19, 22, and 
29). However, when incubate with topoisomerase II in the absence DNA, of these 
agents rapidly inhibited the ability of the enzyme to cleave and relax negatively 
supercoiled DNA plasmids (see Figures 13, 15, and 24). Also, PCB quinones 
appear to require adduction to the enzyme to function (see Figure 21). Evidence 
suggests that these agents have multiple activities against the enzyme.
 Second, due to the ability of quinones to adduct to proteins, sites of 
adduction on topoisomerase IIα were determined (see Figures 31 and 32). Of the 
four sites identified (cysteines 170, 392, 405 and 455), mutation of cys392 and/or 
cys405 to alanine reduced the sensitivities of the resulting mutant enzymes to 
quinones by ~50% (see Figures 33C and D). As a mechanism of quinine 
resistance, these enzymes display rates of DNA ligation that are ~2–fold faster 
than that of the wild-type enzyme in the presence of benzoquinone (see Figure 
34). Alternatively, a cys455->ala mutation of topoisomerase IIα confers 
hypersensitivity to quinones (see Figures 39A, B, and D). This mutant enzyme 
was ~3–fold more sensitive to N-terminal clamp closure, when compared with 
the wild-type enzyme, in the presence of benzquione (see Figure 41). Studies 
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with these cys->ala topoisomerase IIα mutants demonstrate that quinones 
enhance enzyme-induced DNA cleavage by at least two independent 
mechanisms; adduction to cysteine residues 392 and 405 to inhibit topoisomerase 
II-mediated DNA ligation and closure of the N-terminal protein gate that traps 
DNA in the active site of the enzyme (see Figure 42). 
 Third, consistent with previous NMR experiments, disruption of the A– or 
E–rings of etoposide significantly alter drug activity (see Figures 46-50). The data 
also indicate that the glycosidic moiety, believed to primarily play physiological 
roles, plays minor roles in enhancing topoisomerase II-mediated DNA scission 
(see Figures 46-51). Furthermore, removal of the glycosidic moiety of etoposide 
did not alter the ability of the resulting compound to induce topoisomerase II-
mediated DNA breaks in cells relative to in vitro experiments (see Figure 51). 
 Finally, both etoposide and benzoquinone induce aberrations in the MLL bcr 
in cultured human cells. A 1.8 kb XbaI fragment of the MLL bcr, containing the 
observed clinical translocation hotspot (26), was analyzed using a ligase 
mediated PCR technique (178). Following treatment of human CEM cells with 
etoposide or benzoquinone, significant aberrations were observed in this region 
(see Figure 56). Furthermore, cells treated with benzoquione appeared to recover 
the wild-type 1.8 kb fragment over time. Cells treated with etoposide did not 
display a similar ability to recover. Treatment of cells with Z-VAD (and inhibitor 
of apoptosis), aberrations in the 1.8 kb XbaI fragment of the MLL bcr were 
reduced but still present (see Figure 59). These data indicate that apoptotic 
nucleases play a limited role in generating aberrations in the MLL gene locus. 
Furthermore, these data suggest that DNA breaks mediated by topoisomerase II 
directly contribute to alterations in the MLL bcr. 
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Ramifications 
  The results described in this dissertation lead to further knowledge of the 
mechanism of topoisomerase II poisons as chemotherapeutic and carcinogenic 
agents. Previous results indicate that rodent exposure to either acetaminophen or 
PCBs generates chromosomal aberrations including sister chromatid exchanges, 
translocations and deletions as well as cancers of the liver (33-36). This work 
establishes a causal link between metabolites of acetaminophen (NAPQI) and 
PCBs (PCB quinones) and topoisomerase II in the generation of chromosomal 
aberrations. NAPQI and PCB quinones are topoisomerase II poisons. 
Furthermore, acetaminophen, the parent compound of NAPQI, did not 
antagonize etoposide function in purified systems or in cultured human cells (see 
Figure 17). This indicates that the co-administration of acetaminophen with 
etoposide will not reduce the clinical efficiency of the topoisomerase II poison.  
 Prior to this study the mechanism of quinone action was largely unknown. 
This work established a basic mechanism for quinone action against the type II 
enzyme. Mass spectrometry and mutation studies indicate that quinones 
enhance topoisomerase II-mediated DNA cleavage by at least two independent 
activities. First, quinone adduction to cysteine residues 392 and 405 inhibits 
ligation of cleaved DNA molecules by the enzyme. Second, quinones close the N-
terminal gate of topoisomerase II by crosslinking the two protomer subunits 
together. 
 The work described in chapter VI of study described the activity of several 
podophyllotoxin derivatives. It is important to note that these derivatives were 
designed based on data obtained in a previous experiment (278). These results 
verify the saturation transfer difference NMR technique as a sufficient 
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determinant of interacting portions drugs with their enzyme target. Finally, these 
studies suggest that modifications of etoposide designed to increase efficiency, 
availability or reduce toxic side effects should focus on the glycosidic moiety at 
the C4 position. 
 The work in chapter VII describes a cell-based system used to analyze the 
ability to topoisomerase II poisons to induce aberrations in the MLL gene at 
chromosomal band 11q23. Results suggest that multiple pathways are 
responsible for the induction of MLL translocations. Furthermore, this system 
provides a powerful tool to further analyze the relative contributions of several 
cellular activities (i.e. topoisomerases, apoptotic nucleases, repair machinery, etc.) 
in the generation of 11q23 translocations that lead to human leukemias. 
 One simplified model that this work suggests is that quinones adduct to 
topoisomerase II to induce DNA strand breaks that lead to the development of 
leukemias. If this were the case then increasing the relative amount of cellular 
sulfhydryls available (free cysteine and glutathione) may decrease the amount of 
quinone available to act as a topoisomerase II poison. In laboratory animals, 
ingestion of whey protein increase levels of glutathione in the liver (290-292). 
Furthermore, ingestion of whey protein decreased oxidative damaged to the liver 
and kidneys following a burn injury. (292). Thus, individuals who have been 
exposed to quinone precursors can ingest increased amounts of whey protein. 
This would increase cellular levels of free cysteine and glutathione available to 
neutralize quinones and thus limit their mutagenic activities. 
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Future Directions 
 As described in chapter V, several residues on topoisomerase IIα were 
identified as sites of quinone adduction. Mutation of these sites revealed several 
mechanistic properties of quinones as topoisomerase II poisons. One point of 
interest of the lab would be to determine whether the activity of these agents 
against topoisomerase IIβ is similar, at the molecular level, to that of 
topoisomerase IIα. Furthermore, the yeast enzyme, which is partially resistant to 
stimulation of DNA cleavage by these agents (118) could be used to further 
define the role of blocking the N-terminal gate of the protein. This enzyme is 
lacking a cysteine residue that is homologous to the cys405 residue in human 
topoisomerase IIα. Thus, determining the ability of quinones to inactivate and 
crosslink the two protomer subunits and close the N-terminal clamp of the yeast 
enzyme could further establish a role for the crosslinking activity of quinones in 
inactivating topoisomerase II as well as enhancing enzyme-mediated DNA 
cleavage. 
  Mutation of residue cys455 to ala generated a mutant enzyme that displayed 
elevated DNA cleavage activity and was hypersensitive to quinones. Cys455 is 
unique among other cysteine residues identified as sites of quinone adduction as 
it exists, at least some of the time, in a disulfide bond with cysteine residue 427 
(251). Current studies are underway to examine the importance of this disulfide 
to quinone activity. Two possibilities exist; 1) the lack of the ability of residue 455 
to form a disulfide bond with residue 427 enhances the ability of quinones to 
block the N-terminal gate of the protein 2) quinone adduction to residue inhibits 
the ability of quinones to close the N-terminal clamp. To delineate between these 
 166 
two possibilites a top2αC427A will be generated and tested for sensitivity to 
quinones. 
 Chapter VI further examined the interactions between etoposide and 
topoisomerase IIα. Results from this study demonstrate that the A–ring of the 
molecule is necessary for drug binding and that drug activity is sensitive to 
alterations in the E–ring. Previous NMR experiments examined the interacting 
protons of etoposide with yeast topoisomerase II and human topoisomerase IIα 
in the absence of DNA. However, topoisomerase II-targeted agents appear to 
have a base preference at sites of drug induced cleavage (106, 225). This indicates 
that some portion of the molecule probably interacts with DNA in the drug-
enzyme-nucleic acid ternary complex. Therefore, it is of the interest of the lab to 
examine whether topoisomerase II poisons have the ability to interact with DNA 
in the ternary complex. Data indicate that protons of the D–ring and glycosidic 
moiety do not interact with the enzyme, however, this does not exclude them 
from interacting with DNA in the cleavage complex. Future STD-NMR studies 
analyzing the enzyme-drug-DNA complex are planned to determine whether 
portions of the molecule interact with DNA in the ternary complex. Furthermore, 
current studies are focusing on characterizing the activity of etoposide and 
podophyllotoxins with D–ring modifications to determine the functional 
importance of this moiety. 
 STD-NMR is an effective technique to dissect the molecular interactions 
between drugs and their targets. Therefore, future STD-NMR studies will 
examine the interacting groups a variety of topoisomerase II-targeted agents. 
This is further facilitate the development of topoisomerase II poisons for 
anticancer treatments. 
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 The final data chapter in this dissertation described a PCR-based system to 
analyze MLL aberrations following treatment of cultured cells with 
topoisomerase II poisons. This system is a powerful to analyze the factors that 
contribute to translocations at chromosomal band 11q23. The types of aberrations 
(deletions or translocations) that are induced by topoisomerase II and apoptotic 
nucleases can be addressed by sequencing observed aberrations following 
treatment of cells with topoisomerase II poisons. To accomplish this goal, several 
experiments would need to be carried in a variety of cellular backgrounds (i.e., in 
the absence of type II topoisomerases or apoptotic nucleases). Therefore, siRNA 
knockdowns of both topoisomerase IIα and topoisomerase IIβ are currently being 
optimized. 
 Initial results using the PCR-based system indicate that treatment of cells 
with benzoquinone induces a repair pattern that is different than that of cells 
treated with etoposide. Therefore, it is of interest to determine if the repair 
machinery involved in repair of benzoquinone enhanced topoisomerase II-
mediated double-stranded DNA breaks is different from the machinery that 
repairs DNA breaks induced in the presence of etoposide. To accomplish this 
aim, levels of MLL aberrations induced by etoposide will have to be reduced to 
levels observed in the presence of benzoquinone. If etoposide-induced damage 
appears to have a different repair pattern when compared to cells treated with 
benzoquinone, knockdowns of necessary repair proteins can be accomplished 
using siRNA. This will allow the contributions of specific DNA repair pathways 
in the repair of topoisomerase II-mediated DNA cleavage in the presence of 
various agents that target the enzyme to be determined. 
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